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CHAPTER I 
 
 
THE COMPLEXITY OF COINFECTION: 
 A Literature Review of the History, Pathogenesis, and Therapeutic Options in Influenza 
Pneumonia with Secondary Bacterial Infections 
 
1. Pandemic Coinfection: A History of Influenza Pandemics and Secondary Bacterial 
Pneumonia  
Beginning in 1918, as World War I was coming to a close, an influenza pandemic 
occurred resulting in an estimated 50 million deaths worldwide [1-4]. The pandemic had killed 
well over double the number of people who had died due to World War I. Termed the “Spanish 
Flu”, this pandemic resulted in excessive mortality well beyond the expected seasonal influenza 
and targeted young, otherwise healthy adults with a swiftly deadly disease course [1, 5]. Based 
on preserved lung tissue sections and analysis of thousands of autopsies, over 95% of these 
deaths were due to bacterial superinfections,  primarily with pneumococcal pneumonia [5, 6]. In 
addition, over 70% were also bacteremic [6] and widespread pulmonary thrombi were noted on 
postmortem histopathology and examination [7]. Since 1918, several influenza pandemics have 
occurred. The “Asian Flu” pandemic (1957-1958) caused by the H2N2 virus affected primarily 
the young and elderly, resulting in an estimated 1.1 million excess deaths [8]. In 1968, the Hong  
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Kong Flu hit the world in two waves – the first causing excessive mortality in North America, and 
the second wave affecting Europe, Asia and Africa much worse than the first, coinciding with a 
drift in the neuraminidase antigen between 1968 and 1970 [9]. More recently, in 2009, the triple 
reassortment H1N1 virus, termed the “Swine Flu”, had killed roughly 285,400 people worldwide 
by its completion in 2010 [2, 5]. Throughout all these pandemics, bacterial coinfections 
continued to play key role in lethality, making it crucial to consider these bacterial co-pathogens 
when planning for a pandemic [10, 11].  
In an extensive review of influenza and bacterial coinfections from the 20th century, 
several more common pathogens were identified including Streptococcus pneumoniae (S. 
pneumoniae), Haemophilus influenzae, Staphylococcus spp. (in particular S. aureus), and other 
Streptococcus spp. [12]. Beyond the threat of high rates co-infections in pandemics, bacterial-
superinfections also contribute to about 65,000 deaths by seasonal influenza virus infections 
every year in the United States [2, 12], although the rates of bacterial coinfections were found 
to be considerably higher during a pandemic than during the seasonal influenza period – of 
those bacterial coinfections, 41% were identified as S. pneumoniae, followed by 25% 
Staphylococcus spp., 16% other Streptococcus spp., and about 13% H. influenzae. [12]. During 
the 1957 pandemic outbreak S. aureus was identified as most predominant bacteria in 
superinfections [13]. By the following pandemic in the late 1960’s, S. pneumoniae had again 
emerged as the predominant bacterial co-pathogen. Although coinfections are more frequently 
seen in pandemic outbreaks, they are also well documented in seasonal outbreaks. An 
estimated 28% of all seasonal influenza deaths are co-infected [14], and S. pneumoniae 
continues to be the most common single pathogen identified in 16.6% of co-infected cases [12]. 
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1.2. The association of S. pneumoniae in secondary bacterial complications following influenza.  
S. pneumoniae, also termed pneumococcus, is a gram-positive diplococci that commonly 
colonize the upper respiratory tract of 20-50% of healthy children and 8-30% of healthy adults 
[15]. Although generally asymptomatic when colonizing the nasopharynx, pneumococcus is also 
the most frequently seen bacterial agent in bacterial meningitis, otitis media, sepsis and all 
community-acquired pneumonia [15] and is correlated with an increase in intensive care unit 
hospitalizations and death [2].  Pneumococcal disease is difficult to classify because of the 
diverse nature of its various strains and serotypes which affect disease outcomes, coinfection 
models and transmission [16]. Pneumococci can express one of over 90 capsule types which 
greatly alters their pathogenicity, and makes development of effective vaccines and therapies 
difficult [16-18]. Diagnosis is also quite difficult, as many of the bacterial pathogens seen in 
coinfection, S. pneumoniae in particular, regularly colonizes the nasopharynx [1]. As the 
predominant co-pathogen in influenza coinfection, this mini review will focus on the proposed 
contributors to the pathogenesis of the synergistic coinfection of S. pneumoniae with influenza, 
as well as several therapeutic options being considered at this time.  
 
2.  Virus, bacterial and host factors contribute to the lethal synergism in Streptococcus 
pneumoniae superinfections. 
2.1 Virus-induced epithelial injury.   
It has been shown that mice exposed to influenza have hyperinflammatory responses 
with increased bacterial burdens and decreased pulmonary clearance of S. pneumoniae 
following coinfection compared to controls [19]. Although the exact mechanisms behind the 
4 
 
lethal synergism seen with coinfection remain unclear, numerous possible pathways and their 
associated pathology have been identified to establish the connection. Researchers have 
discovered that a complex network of viral, bacterial, host and environmental factors all 
intertwine to create the lethal synergism seen with influenza and secondary bacterial infections. 
This section will break down and summarize much of that research to more fully elucidate this 
complex system. 
2.1a. Pulmonary Epithelial Barrier Damage 
 Influenza infection cause extensive alveolar epithelial damage and surfactant disruption 
resulting in obstruction of small airways by sloughed cells, mucus and other debris [15, 20]. 
These pathologic changes help the invading bacteria to adhere and colonize in the respiratory 
tract. [21, 22] . The damage to the respiratory epithelium also leads to exposure of the 
underlying basement membrane and progenitor epithelial cells, resulting in an inability of the 
respiratory epithelium to repair itself and re-proliferate [23]. In addition, viral neuraminidase 
induces this exposure of bacterial adherence receptors and works in conjunction with bacterial 
neuraminidase to upregulate the viral infection and worsen this process [24]. As epithelial 
damage is worsened, a rise in lethality, likely due to bacteremia, is appreciated [23, 25]. 
Influenza has been shown to cause a long-lasting dysfunction of the alveolar-capillary barrier 
which can last for weeks after initial infection [26]. Exposure of the basement membrane and 
fibrin also increase bacterial adherence [4]. Further stimulation of angiopoietin-4 by influenza 
virus acts to worsen this barrier damage and promotes further inflammation and bacteremia 
[27]. Pandemic viral infections inflict high cytotoxicity on the alveolar epithelium, which could 
possibly cause increased bacterial superinfections and associated mortalities [2, 23]. In addition, 
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influenza infection also causes a decrease in mucociliary clearance and coordination, resulting in 
failure of removal of bacteria prior to the adherence to the damaged surfaces in the lung [15]. 
2.1b. Receptor Exposure and Bacterial Adherence 
 Sialylated mucins act as decoy receptors for the bacteria [1, 3, 4, 28]. The desialylation by 
influenza viral neuraminidase helps in bacterial adherence to epithelial cells. Damage of 
epithelial cells also expose glycans on their surface, thus enhancing pneumococcal adherence 
[28].  A variety of proteins are altered and displayed on epithelial cells following influenza virus 
infections, such as platelet activating factor receptor (PAFr), that promote bacterial adherence 
and disease [1, 29].  Despite this upregulation of PAFr, pneumococcal adhesion resulting in 
pneumonia and bacteremia is possible without PAFr, further highlighting the complexity of this 
disease [29]. Pneumococci also have a variety of virulence factors that allow adherence to these 
newly exposed receptors on damaged epithelium, laminin and fibrin, including pneumococcal 
surface protein A (PsaP) and pneumococcal serine-rich repeat protein (PsrP) [17]. PsaP is a 
lipoprotein pneumococcal antigen that aids in adherence to nasopharyngeal epithelial cells via 
E-cadherin, while PsrP is a lung-specific adherin [30]. 
2.2. Influenza virus-related factors.  
The influenza virus is from the family Orthomyxoviridae, and there are four genera 
within this family currently recognized that are distinguishable based on their antigenic 
differences between nucleoproteins and matrix proteins: Influenza A, B, C, and D, the first two 
of which are most often associated with significant human disease. The influenza virus contains 
a segmented, single-stranded RNA genome which encodes for eight proteins: polymerase PB2, 
polymerase PB1, polymerase PA, hemagglutinin (HA), nucleoprotein, neuraminidase (NA), 
matrix proteins M1 and M2, and nonstructural proteins. Influenza A viruses are further divided 
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into subtypes based on their HA and NA serotypes.  Hemagglutinin is responsible for viral 
recognition and binding to respiratory epithelial cells and subsequent entry, whereas 
neuraminidase, via the same sialic acid molecules, acts to aid in viral exit from the cell. As noted 
previously, both influenza virus and S. pneumoniae have neuraminidases which contribute to 
upregulating inflammation, infection and promoting colonization of bacteria in the lower 
respiratory tract [24]. Another viral protein, PB1-F2, has also been shown to enhance 
inflammation during coinfection through proapoptotic effects and mitochondrial dysregulation 
[31].  
2.3.  S. pneumoniae related factors.  
S. pneumoniae produces several virulent factors that can potentially contribute to the 
lethal synergism in coinfections. Currently, there are over 90 serotypes of pneumococcal capsule 
recognized and these serotypes have various levels of pathogenicity. The serotypes with the 
highest rates of lethality include serotype 3, 6A/B, 9N, and 19F [17]. All these more lethal 
serotypes, as well as many others, also contain a critical virulence factor, pneumolysin. 
Pneumolysin can form pores in the membranes of cells to cause lysis and activate the innate 
response after recognition by toll-like receptors, in particular TLR4, and also trigger 
inflammation independent of TLR recognition [32-34]. Pneumococcal serine-rich repeat protein 
(PsrP) is an adhesion and another virulence factor which aids in bacterial binding to the alveolar 
epithelium and participates in the formation of biofilms and bacterial aggregation [35-37]. 
Bacterial pili, although not expressed in all strains, allow bacteria to bind to epithelial cells and 
survive in the lungs while promoting lung injury and inflammation through a TNF-dependent 
inflammatory response [35]. S. pneumoniae is also known to use molecular mimcry to degrade 
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platelet activating factor and disable neutrophils through a shared phosphorylcholine moiety 
between PAF and the bacterial cell wall [38]. 
2.4. Host-related factors: The innate immune response  
Several studies have highlighted exaggerated immune responses in contributing to the 
synergism during bacterial co-infection. Among innate immune cells, high neutrophil influx has 
been linked with increased immunopathology in bacterial superinfections following influenza 
[19, 39]. Excessive, Mac-1 dependent [40], neutrophil accumulation that persists beyond 12 
hours post bacterial infection results in a greater bacterial burden and worsened disease [41]. 
Neutrophils are short lived and terminally differentiated cells, primarily involved in phagocytic 
clearance of the bacteria. The ingested bacteria are destroyed through the generation of potent 
oxidants after activation of the NADPH oxidase complex (respiratory burst) or by lytic enzymes 
and antimicrobial peptides within the phagolysosome. After bacterial coinfection, neutrophil 
numbers become excessive within hours, but macrophages and dendritic cells do not share the 
same disproportionate increase [42]. Myeloperoxidase measurements do not increase at the 
same rate as the neutrophil quantity, suggesting that these rapidly recruited neutrophils will not 
have the same antibacterial function that the initial responders did [42]. Functional impairment 
of neutrophils is seen through several capacities.  
Phagocytosis has been shown to be decreased in both neutrophils and macrophages 
following influenza infection [39, 42] and several pathways to this reduction have been 
evaluated including resistance to phagocytic granule components [43], and the downregulation 
of the MARCO receptor due to interferon production [4, 44, 45].  While some report that 
neutrophils and macrophages also have a marked decrease in reactive oxygen species following 
coinfection [45], others report that coinfection leads to increases in respiratory burst and 
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hydrogen peroxide production as well as increased neutrophil apoptosis, and decreased 
neutrophil survival [46]. TRAIL+ monocytes in coinfection are apoptosis inducing cells that cause 
significant lung damage as well [47]. Apoptosis of various cell types also appears to be affected 
by bacterial coinfection after influenza. Monocytes express a TNF-related apoptosis-inducing 
ligand (TRAIL) that can be blocked through CCR2 blockage and result in decreased bacterial load 
and protection if administered prior to coinfection [47]. In vitro, influenza virus has been shown 
to accelerate neutrophil apoptosis by enhancing Fas expression and activating caspase, 
decreasing neutrophil survival [46]. The significant neutrophil influx triggered by various viral 
and bacterial toxins such as PB1-F2 in a coinfection results in a cytokine storm and can lead to a 
severely damaging hyperinflammatory response which can be seen histopathologically as 
excessive neutrophilia, sloughing epithelium, hemorrhage, obstructed airways, pleuritic and 
large areas of lung consolidation [42]. Even the cellular response of natural killer cells to 
influenza infection is weakened, contributing to further risk of coinfection [48]. Innate cells can 
kill pathogens through oxidative burst, which creates toxic reactive oxygen species through 
NADPH oxidase complex or myeloperoxidase. Neutrophil killing of S. pneumoniae, however, 
does not appear to be dependent on NADPH –oxidase generation of reactive oxygen species, 
but does require neutrophil elastase and cathepsin G [49]. Gram positive bacteria such as S. 
pneumoniae can have a bacterial superoxide dismutase that can protect the pathogen from 
these toxic reactive oxygen species [43]. 
Neutrophils can potentially cause worsened inflammatory disease through the release 
of neutrophil extracellular traps (NETs). Brinkmann et al. was one of the first to describe the 
release of neutrophil extracellular traps, or NETs, as a form of microbial killing [50]. In response 
to inflammation, neutrophils are stimulated to release intracellular components through a 
process called NETosis. Over the last 15 years, NETOsis emerged as a programmed cell death 
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mechanism separate from apoptosis and necrosis. Morphologically, activated neutrophils 
involved in phagocytosis were shown to start the NETosis process by losing their nuclear 
lobulation as well as losing euchromatin and heterochromatin separation [51]. Next, 
membranes begin separating – first the nuclear membranes will separate and rearrange into 
vesicles and then the granular membranes also break down, resulting in a mixing of cytoplasmic, 
nuclear and granular components. Finally, the cell membrane disintegrates and the NETs are 
released [51, 52].  NETs not only bind gram-negative and gram-positive bacteria, but have been 
shown to bind fungi and viruses as well [50, 53, 54]. Through release of NETs, neutrophils are 
able to continue fighting infection even after their own cell death [see Figure 2.1].  
We have previously shown that excessive neutrophils and NETs contribute to alveolar-
capillary damage after influenza challenge in mice. NETs formation is dependent on redox 
enzyme activities [55]. NETs were first identified as a process of cell death that released DNA, 
histones and granular proteins such as elastase and myeloperoxidase to entrap and kill 
pathogens [50]. Since the initial identification of NETs, they have also been shown to be 
detrimental to the host – particularly through histones which induce endothelial and epithelial 
cell damage and worsened disease [56]. Further, using Pneumococcal superinfection following 
influenza, an extensive accumulation of NETs was recognized, especially in the damaged areas of 
the lungs, indicating their potential role in tissue injury. Moreover, NETs released during 
pneumococcal superinfection did not show any bactericidal or fungicidal activities. [57, 58]. Our 
recent studies have shown that NETs generation is dependent on the Pneumococcal capsule 
thickness and varies with the different serotype infections. The increase in thickness of the 
capsule results in enhanced tissue damage and lung pathology [18]. NETs have been identified in 
various inflammatory disease models other than pneumococcal pulmonary coinfection such as 
coinfection of otitis media and sepsis [59, 60]. Although the complete pathway for NETs 
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induction has yet to be discovered, S. pneumoniae has been shown to induce NETs through an 
enzyme called α-enolasae [61]. Paradoxically, a pneumococcal endonuclease, EndA, has been 
identified as an important virulence factor through its ability to degrade NETs and diminish their 
bactericidal response [62]. As with many other areas of the complex pathogenesis of 
coinfection, it appears that NETs too must be balanced between positive effects and those that 
are detrimental to the host. 
 
2.4a. What is NETosis?  
 
Figure 2.1 Neutrophil Extracellular Traps (NETs). This diagram summarizes the process of 
NETosis. Once neutrophils are activated and reactive oxygen species produced, chromatin and 
cellular membranes begin to break down so that NETs can be released. The release of this 
primarily nuclear material contains several key, toxic ingredients, including histones, neutrophil 
elastase, and myeloperoxidase which act to “trap” and kill pathogens in their sticky NETs. 
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The complete process of neutrophil activation leading to NETs formation and release is 
still being discovered. NETs release can be triggered by a variety of inflammatory mediators and 
proteins such as circulating histones, interleukin-8 (IL-8), bacterial enzymes (ie, α-enolase of 
Streptococcus pneumoniae), thick bacterial capsules, antibodies (possibly through the 
complement cascade), and viral PAMPs [18, 54, 58, 59, 61]. The most widely researched 
pathway of NETosis is NADPH oxidase 2 (NOX2) dependent where NOX2 generates reactive 
oxygen species (ROS) which are necessary for disintegration of the nuclear membrane during 
NETosis [51, 63]. A second mechanism has also been described that is NOX2 independent. This 
mechanism of NETosis relies on mitochondrial ROS and is triggered through rapid activation 
using calcium of a potassium channel, the SK3 channel [64, 65]. This novel mechanism was seen 
in response to Staphylococcus aureus infection and results in NETs release and entrapment 
without neutrophil lysis and death – it is rapid, oxidant independent, and aids in limiting 
bacterial dissemination [65]. It has also been suggested that NETosis is dependent on platelet-
neutrophil interaction. In a model of sepsis, platelet TLR4 had to bind a ligand (such as 
lipopolysaccharide) to then bind neutrophils and trigger NETs formation in the hepatic sinusoids 
and pulmonary capillaries, where the small diameter of the vessels allowed the NETs to be more 
effective at trapping [66, 67]. Platelets are activated by a high bacterial loads with LPS 
concentrations 100 times greater than that which activates neutrophils – therefore, platelets 
likely play an even more critical role in high bacterial load situations where NETs are released as 
a final defense [63]. Once the neutrophils are activated and ROS produced, the chromatin and 
cellular membranes will break down so that the NETs can be released [52]. Chromatin 
decondensation requires histone hypercitrillunation of the arginine residues on H3 and H4 by 
peptidylarginine deiminase 4 (PAD4) [68-70]. PAD4 deficient mice cannot form NETs [71], and 
PAD4 inhibitors limit NETs formation as well [72]. In addition, it has been shown that both 
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neutrophil elastase and myeloperoxidase (MPO) regulate this process as well with elastase 
translocating to the nucleus to degrade histones in a synergistic fashion with MPO [73]. 
Released NETs contain DNA, nuclear proteins and neutrophil granules associated toxic 
proteins, which have been identified for their antibacterial and anti-fungal effects. However, 
NETs-mediated host tissue damage has been linked in several clinical and diseases conditions.  
Histone proteins are one of the major protein components in NETs. Histones are necessary for 
DNA condensation and help form the nucleosome structure by binding their positive charges to 
the negatively charged DNA – this results in the superhelical DNA being wound around four pairs 
of core histones to mold the structure of the chromatin [74]. Histones can also undergo post-
translational modifications, such as methylation, which can regulate gene transcription and aid 
in the passage of epigenetic information through cell divisions as well [74]. Aside from their 
intracellular roles, the extracellular advantages and disadvantages of histones are crucial to 
understanding the effects of NETosis and will be described later. In addition to histones, NETs 
also release granular proteins such as neutrophil elastase and myeloperoxidase. These enzymes 
are not only effective microbial killers, but indiscriminately damage the host as well. 
Antimicrobial activities of NETs.  
Before discussing the deleterious effects of NETosis, it is important to recognize its role 
in microbial trapping and death. Scientists have known about the important role of the 
neutrophil as a first responder to microbial infection since the late 19th century [75]. Since then, 
scientists have discovered that circulating neutrophils are called to areas of injury or insult 
through cytokines and that these neutrophils are activated once they reach the site of infection. 
The activation results in phagocytosis of the microorganism where reactive oxygen species and 
antimicrobial peptides and enzymes can kill these infectious agents. This influx of neutrophils 
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has been shown to reduce progression to severe disease in many cases and is necessary to 
innate immunity [76]. Antimicrobial killing by neutrophils is not limited to phagocytosis. NETs 
also contain high numbers of antimicrobial molecules. During sepsis, LPS can bind platelet TLR4 
receptors which in turn interact with and activate neutrophils to form NETs. These NETs are 
effective bacterial trappers within small diameter vessels such as pulmonary capillaries [66]. 
With seemingly effective bacterial killing performed by NETs, it’s not surprising that bacteria 
have developed methods to evade killing. Many bacteria are trapped by NETs, but not actually 
killed. This trapping still allows the infection spread to be limited, but S. pneumoniae has been 
shown to evade NETs killing through expression of a DNase called endonuclease (EndA). This 
enzyme allows the bacteria not degrade the NET and escape [62, 77], and is required for full 
virulence of S. pneumoniae during pneumonia [62]. 
NETs capture and kill many microbes beyond bacteria. NETs have been shown to 
capture and kill both yeast and hyphal forms of Candida albicans [53]. In addition, viral-induced 
NETs also are important in the innate immune response to a variety of viruses, such as Influenza 
A Virus – interestingly, NETs induced by bacterial infection appear to be quite effective at 
trapping and neutralizing viruses, but those NETs induced by viral infections do not have the 
same effect on bacteria [54]. Not only do NETs trap virions, but they can directly neutralize them 
through defensins and MPO as well – virions removed from NETs have decreased ability to 
infect target cells [54]. 
The direct antimicrobial effects of histones within and outside of NETs have long been 
described and span various diverse microbes from bacteria and viruses to fungi and parasites as 
well. Methods of microbial killing are dependent on the type of histone and the pathogen. There 
are four core histones (H2A, H2B, H3, H4) and a linker histone (H1) that assist in nucleosome 
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formation. Although similar in structure, these five histones can further be divided into lysine-
rich (H1, H2A, H2B) and arginine-rich (H3, H4) proteins [74, 78].  These different histones display 
different antimicrobial properties. The effects of arginine-rich histones have been compared 
with lysine-rich on bacterial outer membrane protease T (OmpT) gene-expressing Escherichia 
coli and found to have different modes of antimicrobial action with the lysine-rich penetrating 
the cellular membrane and the arginine-rich remaining on the cell surface to cause a blebbing 
similar to that of other antimicrobial peptides [78, 79]. Histones not only bind to form the core 
of the nucleosome within the cellular nucleus, but can convey antimicrobial properties outside 
of the nucleus. Within the cytosol, histones can bind lipid droplets and then disassociate to kill 
bacteria in a Drosophila and possibly a murine model [80].  More importantly, extracellular 
histones, such as those released with NETs, have antibacterial properties as well. 
Besides antibacterial effects, NETs released-histones are also described for their 
antiviral effects. The arginine-rich histones (H3, H4) released in NETs have particularly potent 
ability to neutralize H3N2 and seasonal H1N1 influenza viral strains in vitro, although did not 
show any effect on the pandemic H1N1 strain [81]. The method of viral neutralization is still 
unclear, but the arginine-rich composition of these histones likely contributes to their innate 
immune effects. In addition to histones, NETs also release antimicrobial peptides and enzymes 
such as myeloperoxidase and elastase. Myeloperoxidase (MPO) converts hydrogen peroxidase 
to hypochlorous acid to defend the host against pathogens. Neutrophil elastase is also a 
proteinase that acts as an effective microbial killer. 
How is NETosis a detriment to the host during infection? 
Although NETosis may have shown positive effects in fighting infection, recent studies 
have emerged which indicate that these traps may play a larger role in facilitating disease than 
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fighting it. One of the biggest problems encountered with NETs release is their inability to 
identify friend versus foe when responding to infection. In models of sepsis, NETs have been 
shown to be significant players in the pathogenesis and severity of disease. Levels of NETs in the 
blood of septic patients correlates with organ dysfunction and disease severity, and, in an 
experimental setting, this damage is attenuated by degrading NETs with rhDNase in 
combination with antibiotic therapy [60]. In a dual infection murine model of pneumonia, NETs 
released during the primary influenza infection did not protect against secondary pneumococcal 
infection, but instead appeared to be associated with a synergistically worsened disease state as 
compared with influenza and bacterial infections alone [57]. Even within the middle ear, an 
antibody-induced NETs release was shown to create biofilms of pneumococcal bacteria 
secondary to influenza infection [59]. 
NETs are also identified in lung tissue and bronchoalveolar lavage fluid in a murine acute 
lung injury model and are present in higher numbers at areas of more severe damage [55, 56]. 
The sheer influx of neutrophils is shown to be associated with subsequent respiratory epithelial 
damage secondary to viral disease and others [82]. Specifically, NETs release is associated with a 
dose-dependent cytotoxicity to the alveolar epithelial cells. In addition, neutrophils and their 
release of NETs through platelet interaction have been shown to induce significant endothelial 
damage in vitro as well as hepatotoxicity [66]. 
Circulating histones including those associated with NETosis have been implicated in a 
variety of disease processes [56-58, 67, 74, 81, 83-89]. Not only are they known to damage 
cellular membranes due to their basic charge when unbound and outside the nucleus, but they 
also create a form of “sterile” inflammation through TLR2/4 activation of a variety of cell types 
eliciting a DAMP-like immunostimulatory effect [87]. In a study performed by Abrams et al. 
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assessing the role of circulating histones due to nonthoracic blunt trauma, high levels of 
histones were significantly associated with the incidence of subsequent acute lung injury and 
multiple organ failure [58].  More specifically, this lung injury was found to be mostly related to 
histone-induced endothelial damage and activation of coagulation. In addition, extracellular 
histones have been identified as important mediators in sepsis, directly related to significant 
endothelial damage, organ failure and death [88]. But how do these histones cause this 
damage? The charge differences between histones and DNA may contribute to more than just 
nucleosome structure – this charge difference allows extracellular histones bind to 
phospholipids in the cell membranes, and increase cellular permeability and a calcium influx 
which in turn triggers apoptosis leading to cell death [58]. Histone release with NETs, as well as 
myeloperoxidase release with NETs, have both been shown to result in dose-dependent alveolar 
epithelial cytotoxicity – if histones or myeloperoxidase are blocked, this cytotoxicity is 
diminished. Interestingly, the same effect is not seen with elastase inhibitors suggesting that this 
epithelial damage is more associated with histone and MPO release during NETosis [56]. 
Significant endothelial and epithelial damage is also evident secondary to histone cytotoxicity 
released during NETosis in severe glomerulonephritis [87]. Extracellular histones have been 
identified as cytotoxic toward endothelium in numerous studies, resulting in increased vascular 
permeability, hemorrhage, and thrombosis. The levels of histones also correlate with organ 
dysfunction and damage in a model of sepsis [88]. Perhaps most importantly for this project, 
histones have been shown to be crucial mediators of the damage caused in influenza 
pneumonia [83]. 
Microvascular and deep vein thrombosis further exacerbate disease associated with 
NETs release. Microvascular thrombosis has been hypothesized to occur due to platelet 
activation by extracellular histones. Thrombin formation is dose-dependently enhanced by 
17 
 
histones and dependent on histone-activation of platelets through platelet TLR2 and TLR4 [67]. 
This in turn can activate platelets resulting in excessive thrombi formation, especially in disease 
states such as sepsis [63]. It is also suggested that formation of microthrombi secondary to 
alterations in the microcirculation by NETs, can prevent necessary immune cells from reaching 
sites of infection [63]. NETs are also a key component of the scaffold of deep vein thrombi and 
PAD4 deficient mice (which cannot citrullinate histones prior to NETs release) have significantly 
lower incidences of thrombosis than wild type [70].  
In my particular model, why do I believe NETs to be more detrimental than helpful in ridding 
of the infection? 
Hirose, et al. looked at critically ill patients and evaluated levels of citrillunated H3 and 
NETs in their bloodstream to try and garner an idea of the role of NETs in the dissemination of 
inflammatory disease. During this study, they noted that the presence of bacteria within the 
tracheal aspirate at the time of intubation was a significant factor associated with the presence 
of NETs and Cit-H3, and then make a jump to conclude that NETs might play a pivotal role in 
innate defense [86]. Although the positive values of NETs in innate immunity are well-described, 
I tend to partially disagree with this assessment. Recent studies evaluating the detrimental 
effects of NETosis on the host during the innate immune response are becoming more 
numerous and show a significant link between NET release and tissue damage resulting in 
worsened disease severity. Although I have outlined many of these studies already, I will 
highlight a few again that relate closely to my model of dual infection and may help explain why 
I believe that NETs are an ideal potential target for therapy when planning combination 
therapies to treat dual infection pneumonia.  
18 
 
The infection model I used involves sublethal influenza infection administered 
intranasally to mice followed by a low dose of Streptococcus pneumoniae administered 
intranasally three day later. Although neither the influenza nor the bacterial infective doses are 
considered lethal on their own, this particular model has shown that the dual infection of these 
two results in a synergistically worsened and lethal disease course with the development of 
severe ARDS and bacteremia. Histopathology of the pulmonary tissue shows marked endothelial 
and epithelial damage resulting in vascular permeability that would most certainly aid in the 
dissemination of bacteria. In addition, markers of NETs (cit-H3/cit-H4) are clearly identified from 
samples taken from these infected mice. The severity of damage appears in conjunction with 
the neutrophil influx approximately three days after influenza infection and worsens drastically 
over the subsequent 72 hours. 
In a recent study using an acid aspiration-induced model of ARDS, extracellular histones 
were shown to have an inflammatory role with significant stimulation of systemic inflammation 
and pulmonary collateral damage, while blockage of these histones alleviated these signs [89]. 
Although the model for ARDS we are using is different, our preliminary results support these 
findings with increased damage and inflammation being related to the presence of NETs and 
extracellular histones. Our preliminary findings are also consistent with those identified by 
Moorthy et al. (2013) – in this study NETs were not only shown to result in enhanced lung 
pathology, but were also shown to have limited to no bactericidal effects [57]. Significant 
damage to the alveolar-capillary barrier was identified in this model as well. In addition, 
preliminary studies have confirmed that administration of histones directly to a virally infected 
mouse worsen disease pathology contradicting claims that histones act as anti-viral defense. I 
look forward to further discovering the workings of dual infection pathogenesis and will be 
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interested to further assess the capabilities of blocking NETosis as a therapy when considering 
combination therapies to treat ARDS. 
2.5. Toll-like Receptors and their Contribution to Immunopathology and Interferon Signaling 
Toll-like receptors are an important part of the innate immune response and recognize 
conserved patterns in a variety of pathogens. Upon recognition, these receptors trigger a series 
of events resulting in activation of the innate immune response through production of various 
pro-inflammatory chemokines, cytokines, interferons and recruitment of those innate 
responders such as the neutrophils and macrophages [90]. In particular, these TLRs can 
recognize cellular wall components of gram-positive organisms, such as those in S. pneumoniae 
[91] as well as pneumolysin, which stimulates IL-6 and TNF-α after interacting with TLR4 [32]. 
Influenza virus-induced desensitization of lung epithelial cells to bacterial TLR ligands can last 
months after the initial viral infection, creating an environment for increased susceptibility to 
bacterial infection for a long time after clearing influenza [92]. Influenza induces expression of 
toll-like receptors, such as TLR3 which acts to recognize RNA and DNA of pathogens after 
phagocytosis, and this not only sensitizes cells to secondary infection with pneumococcal 
pneumonia, but also decreases bacterial clearance and increases type I interferons, which have 
been shown to negatively affect survival in a murine model [93, 94]. Upregulation of this TLR3 
expression results in increased IL-12p70, which also plays a key role in coinfection [93]. In 
addition to impairment of phagocytosis, production of interferons after recognition of 
pathogens by TLRs plays a large role in pathogenesis of coinfection as well. Type I and II 
interferons are produced following recognition of viral nucleic acids by toll-like receptors (TLRs) 
[1]. The induction of type I interferon during a primary nonlethal influenza infection was shown 
to be sufficient to promote lethality with coinfection of S. pneumoniae [95]. IFN-1 targets 
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granulocytes in the bone marrow and prevents efficient recruitment to inflammatory sites [96]. 
Stimulation of type 1 interferons in coinfection also impairs macrophage recruitment due to 
decreased levels of CCL2, which promotes bacterial colonization [97]. In addition, mice deficient 
in type I interferon receptor signaling have improved survival and bacterial clearance [98]. With 
interferon signaling increase, an impaired production of the neutrophil attractants CXCL1 and 
CXCL2 was noted following coinfection. This may explain some of the impaired neutrophil 
response to the early phase of coinfection [98]. Pneumolysin, a cytolytic toxin of S. pneumoniae, 
induces substantial inflammation through activation of TLR4 [32]. TLR2 is also an important 
mediator of the damage associated with pneumococcal pneumonia [99].  As discussed, the 
innate immune response is necessary early in the disease course, but can result in worsened 
pathology if the response remains elevated for too long. 
Induction of adaptive immune response is also a critical determinant on the outcome of 
the diseases in bacterial superinfections. One mechanism by which type I interferon release in 
response to influenza infection results in worsened bacterial superinfection is through the 
suppression of γδ T cell production of interleukin-17 (IL-17) [95]. γδ T cells in the lung act as 
specialized innate responders and normally produce the majority of IL-17 in response to a 
variety of viral and bacterial infections [95, 100, 101] which can suppress the effects of bacterial 
superinfection. If type I interferon signaling is upregulated and IL-17 production suppressed 
through decreased γδ T cell function, bacterial colonization in the lungs is increased causing in 
deteriorated pathology and disease [95]. Influenza has been shown to induce expression of 
indolamine 2,3-dioxygenase which alters the inflammatory response and promotes IL-10 
susceptibility to S. pneumoniae [24, 102]. Pulmonary interferon-γ produced by T-cells can not 
only suppress phagocytosis, but also concurrently use this mechanism and others to inhibit 
bacterial clearance [44]. Coinfection has also been shown to result in a significant reduction in 
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the virus-specific CD8+ T-cell response within the sites of pulmonary inflammation [103]. B cells 
are also affected and lethal coinfection reduces the B cells’ response to influenza [104, 105]. 
Identifying the pathways most involved in this synergism and filling in the gaps with the 
pathology of the disease will not only improve our general knowledge in all coinfections, but, 
more importantly help identify therapeutic targets to improve clinical outcome in those 
affected. 
 
Figure 2.2 Overview of the complexity of coinfection. The lethal synergism seen with 
secondary bacterial infections and influenza pneumonia is created by a network of viral, 
bacterial, host and environment factors. A few of these factors are summarized in the above 
figure. (A) The virus damages and exposes attachment sites for bacteria which migrate from the 
upper to lower respiratory tracts and adhere (B). This adherence and continued host, viral and 
bacterial factors damage the epithelial and endothelial pulmonary barriers, promoting 
bacteremia and worsened disease (C). In addition, functional changes and PMN interactions via 
TLRs with pathogen components alter innate and adaptive immune functions and continue to 
add to the lethal synergism. 
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3. Current Prospective Therapeutics for bacterial superinfections. 
 Antivirals, antibiotics and supportive care have been the mainstay of treatment for 
influenza coinfections for quite some time. Many of the cases which end up hospitalized 
will result in ARDS which is often a precursor to sepsis. ARDS and sepsis are severe 
diseases with high rates of mortality. In addition, well documented resistance to both 
antiviral medications and antibiotics are being reported, making common options less 
effective than once believed. Another treatment difficulty is evident with pandemic 
outbreaks – pandemics primarily cause the most illness and death in developing 
countries where vaccines and antivirals are both too costly and have poor accessibility 
for those who most need it [11]. Due to these challenges, it is prudent to consider other 
treatment options that can both stand alone and act in combination with already 
available therapies to improve outcome in both seasonal and pandemic influenza 
outbreaks. 
3.1. Antivirals, Antibiotics and Combination Therapies 
Due to the complex nature of coinfection, a wide variety of therapeutic options and 
combinations of therapy are being evaluated for efficacy in a dual infection model of influenza A 
virus with subsequent pneumococcal infection. Combination therapies suggest the best results 
at this time, with one element of the combination being anti-viral therapy. Anti-virals are a 
mainstay of treatment and many are looking for alternatives to oseltamivir and inhaled 
zanamivir due to increasing concern for resistance to this medication [106]. Peramivir is another 
neuraminidase inhibitor that reduced mortality in coinfected mice better than oseltamivir by 
inhibiting viral replication resulting in improved bacterial clearance and survival [107]. Although 
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oseltamivir has shown effectiveness to both viral and bacterial neuraminidase, peramivir only 
seems to inhibit viral neuraminidase, and must be administered intravenously [107, 108]. 
Another neuraminidase inhibiting compound, artocarpin, was shown to have a bactericidal 
effect in vitro, reducing pneumococcal viability by a factor of over 1000, and reduced biofilm 
formation [108]. Historically, amantadine and rimantadine have been used as antiviral therapy, 
but these medications are only affective toward influenza A, not B, and have significant (>99%) 
resistance recorded for several strains of Influenza A, including circulating H3N2 and the 2009 
H1N1. For these obvious reasons, these medications are no longer recommended for use as 
antiviral therapy. There is increasing concern that similar resistance could develop with 
neuraminidase inhibitors, although levels of resistance this severe have yet to be documented.  
A second component to combination therapy of coinfection is antibiotic therapy. 
Several classes of antibiotics have been evaluated. Although β-lactams were initially considered 
a mainstay of treatment for pneumococcal pneumonia, it has been shown well over the last 
decade that standalone therapies are no longer ideal and that combinations with macrolides 
and fluoroquinolones are more effective, especially in light of emerging antibiotic resistance 
[109-111].  Macrolides such as azithromycin and clarithromycin are bacteriostatic and work by 
binding the 50S ribosomal subunit, thereby inhibiting protein synthesis. In addition to their 
antimicrobial effects, macrolides also have an immunomodulatory effect, which poses an 
additional benefit in combatting superinfections. Azithromycin in particular has been shown to 
improve survival in a mouse model of influenza and pneumococcal dual infection with almost 
double the survival rate than ampicillin (92% versus 56%) as well as improved outcomes over 
clindamycin [112]. Combination ampicillin and azithromycin for treatment of pneumococcal 
pneumonia not only decreases lung inflammation, but also decreases pulmonary vascular 
permeability and increases bacterial clearance, limiting the chances of septicemia [113]. A lower 
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number of inflammatory cells and proinflammatory cytokines are seen with macrolide 
treatment than standalone β-lactams as well as less severe lung histopathology – as this 
antibiotic is bacteriostatic, the reduction in an otherwise exacerbated inflammatory response 
seen with β-lactam therapy may be due to lessening in bacterial lysis [99, 112]. Another study 
comparing the effects of moxifloxacin, a bactericidal drug, with azithromycin in a murine model 
of acute bacterial rhinosinusitis supports this as the azithromycin treatment resulted in rapid 
bacterial clearance and reduced inflammation compared with the relatively limited effect of 
moxifloxacin [114]. Further evaluation of the potential negative effects of azithromycin in 
human disease is still needed, but a 2015 study evaluating cardiotoxicity of azithromycin in 
community-acquired pneumonia (CAP) showed that the QT prolongation suggested to be an 
adverse effect of therapy was not associated with treatment, but instead with the disease of 
pneumonia, regardless of the therapy administered [115]. 
3.2. Anti-Inflammatories 
 The use of corticosteroids in treatment of bacterial infections is always a hot topic and one 
heavily debated. On the one hand, some argue that the use of an immune inhibitor in 
combination with an antibiotic to reduce the bacterial burden can more effectively control the 
exaggerated inflammatory response seen in coinfection and that the use of steroids should 
improve survival rates. In a murine model, this seems to hold true – a susceptible murine model 
for the 2009 H1N1 pandemic showed that dexamethasone significantly improved survival rate 
and acute lung injury [116]. A reduction in the proinflammatory cytokine storm, and improved 
clinical outcomes was associated with combination treatment of dexamethasone and 
azithromycin in mice [42]. However, what is most concerning with corticosteroids was 
highlighted in a retrospective cohort study from 2011 in which the early use of glucocorticoids 
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was significantly linked with the development of more severe disease versus patients who did 
not receive the drug in pandemic H1N1 [117]. The in vivo benefits in human disease, particularly 
in a pandemic setting, are clearly still up for debate. 
 Toll-like receptor agonists and antagonists are a relatively new area showing promise as a 
potential combination therapeutic for pneumococcal coinfection. Special attention has been 
given to TLR2, which has been shown to mediate the extensive tissue damage, lung necrosis and 
mortality seen after bactericidal treatment of pneumococcal pneumonia in a murine coinfection 
model [99]. This mediation was independent of TLR4 or the pneumococcal virulence factor, 
pneumolysin. TLR2 also plays a role in transmission of disease, likely with a multitude of other 
factors – when a TLR2 agonist (Pam3Cys) was administered in a murine model of coinfection, 
contact transmission was diminished as well as inflammation and bacterial shedding [90]. A 
TLR2 agonist was again seen to reduce the severity of pneumococcal infection post-influenza in 
a murine model by decreasing bacterial loads and pro-inflammatory cytokines, subsequently 
leading to decreased vascular permeability and reduced bacteremia [118]. Macrophage-
activating lipopeptide 2 (MALP-2) is a TLR2/6 agonist that, when administered prior to 
pneumococcal coinfection, increases proinflammatory cytokine and chemokine release and 
enhances neutrophil recruitment without creating excessive inflammation, so also reduces 
bacterial loads and improves survival [119]. Like TLR2 agonists, TLR5, or flagellin, agonists also 
act as immunostimulants. Given in combination with an antibiotic, flagellin will decrease 
bacterial load and boost antibiotic activity by stimulating CXCL1 to recruit neutrophils and 
reduce bacteremia [120]. TLR3 also participates in the immunostimulatory response when 
stimulated by pneumococcal RNA. TLR3 acts through TRIF to secrete IL-12. In a coinfection, 
influenza virus upregulates TLR3 in dendritic cells, which helps prime the cells for recognition of 
pneumococcal disease [93]. In another study, a TLR4 agonist, UT12, showed promise in 
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improving clinical outcome and disease in a murine coinfection model after hastening the 
macrophage recruitment response [121]. Modulating TLRs is an interesting approach to 
understanding the pathogenesis of coinfection and, with further evaluation, may provide some 
promising combination therapies to attempt. The timing of therapy and its clinical relevance 
should still be carefully considered, as this therapy is effective when administered after 
influenza infection, but prior to secondary infection. 
 The role of γδ T cells in interferon signaling and IL-17 production is also being explored as a 
therapeutic for bacterial superinfections. Since superinfected mice inhibit IL-17, resulting in 
worsened bacterial replication and disease, the administration of recombinant IL-17 in these 
mice has improved bacterial clearance indicating that induction of IL-17 remains a potential 
novel therapy [95]. In a recent study, recombinant IL-17F was administered just prior to S. 
pneumoniae infection in a murine model and the therapy resulted in decreased bacterial 
colonization in the lungs [122]. In general, modulation of IFN-I signaling, IL-17 production and 
the function of γδ T cells all remain intriguing areas of study for treatment of dual infections. 
3.3. Chemokine receptor antagonists 
 A rapidly developing area of therapeutic interest lies in the discovery of targeting chemokine 
receptors to modulate the hosts’ immune response to infection and improve outcome. 
Chemokine receptor expression on the cell surface of human neutrophils has been shown to be 
altered by inflammation. Influenza infection triggers a swift and dramatic increase in 
inflammatory chemokines such as CCL2, CCL3, CCL5, and CXCL10 this are ligands for many of the 
receptors studied [123]. These phenotypic changes of the cell surface not only offer insight into 
the development and progression of ARDS from coinfection, but also potential therapeutic 
targets.  Since a hallmark sign of influenza pneumonia coinfection includes uncontrolled 
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accumulation of neutrophils into the alveolar space, it follows that intervention to slow or block 
any step in neutrophil recruitment or migration should be explored as a potential therapeutic 
for this disease. In ARDS, a hallmark of severe influenza coinfection, there is one chemokine in 
particular that seems to play a pivotal role – IL-8 (CXCL8) which is seen in increased 
concentrations in pulmonary edema fluid from septic patients with ARDS [124] and is also found 
in lower concentrations in ARDS survivors as opposed to non-survivors and so can be used as a 
prognostic indicator [125]. Most chemokine receptors have multiple ligands and CXCR1 and 
CXCR2 are not exceptions. CXCL8 is one ligand that binds with both CXCR1 and CXCR2 in humans 
and is considered the most potent neutrophil chemoattractant in BAL fluid from ARDS patients 
[126].   
CXCR1 and CXCR2 are both G protein coupled receptors and are expressed in several 
granulocytes including eosinophils, mast cells, T cells, and, most notably, neutrophils [127, 128]. 
In addition to granulocytes, CXCR2 is also found on pulmonary endothelial and bronchial 
epithelial cells, and the additional role of CXCR2 on these non-hematopoietic cells has been 
shown to be necessary for the marked increase in lung microvascular permeability seen in an 
LPS-induced model of ARDS [129]. In addition to IL-8 (CXCL8), CXCR2 has at least six other 
ligands including CXCL1, CXCL2, CXCL3, and CXCL6 [130]. These chemokines are called ELR+ 
chemokines (glutamic acid-leucine-arginine containing) and have been shown to mediate 
aberrant vascular remodeling in addition to inflammatory cell recruitment in both the exudative 
and fibroproliferative stages of alveoli damage in ARDS [131]. In addition to a role in ARDS, 
CXCR2 has been a hot topic of study for several years due to promising roles in numerous 
diseases ranging from cancer to arthritis to other more chronic pulmonary diseases [132-136].  
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As previously discussed, the challenge and limitations of using an animal model for ARDS 
include challenges with the chemokines, their receptors and the roles these play in the disease 
pathogenesis. One such difference is that CXCL8 does not exist in the rodent model, although 
homologues do exist as CXCL1 (KC) and CXCL2 (MIP-2). It is also unclear whether the mouse 
analog for CXCR1 is functional in the same way as human CXCR1 as it seems to be activated in 
different ways and does not seem to play the same central role in the pathogenesis of ARDS that 
it does in humans [137]. The application of studying CXCR1 in an animal model to evaluate 
human disease is still in question and needs further investigation. 
CXCL8 is not the only chemokine that has been considered potentially important in the 
development and progression of influenza coinfection. Several chemokine receptors have been 
shown to be affected by inflammatory disease and further investigation may indicate a role as 
well. A study looking at chemokine receptor expression in patients with chronic obstructive 
pulmonary disorder (COPD) and rheumatoid arthritis found several significant alterations in 
neutrophil phenotype involving CCR1, CCR2, CCR3, CCR5, CXCR3, and CXCR4 in BAL fluid when 
compared to circulating neutrophils [138]. In addition to evaluating chemokine receptor 
expression, Hartl et al. also explored whether neutrophils would chemotax to a variety of CC and 
CXC ligands and found this to be the case [137]. These findings may have been inferred from 
chronic inflammatory disease, but do support that neutrophils with various receptors can 
respond to a variety of ligands, likely even in our model.  
CCR1 appears to play a role in neutrophil recruitment in a variety of inflammatory 
models. Mice lacking CCR1 were found to have 35% fewer neutrophils than those with the 
receptor in a murine model of renal ischemia-perfusion injury, and blocking this receptor with 
BX471, a CCR1 antagonist, also suppressed neutrophil recruitment to the area of injury [139]. 
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CCR1 antagonism with BX471 has further been shown to protect against subsequent lung injury 
in models of acute pancreatitis [140] and secondary lung and liver injury in a murine sepsis 
model [141]. CCR1 in addition to CCR2 and CCR5 antagonists have been evaluated in clinical 
trials for rheumatoid arthritis, but, unfortunately, have yet to show much success. In these trials, 
CCR2 and CCR5 are not critical for monocyte recruitment to the site of inflammation, but it has 
been pointed out that CCR1 blockade still has great potential in this area with continued, 
targeted research [142]. CCR5 shares about 74% identity with CCR2, and there are antagonists 
such as TAK-770 which will block both receptors [143]. In addition to CCR1, CCR2, and CCR5, 
another CC-receptor of interest is CCR3.  This receptor has been primarily researched in models 
of asthma and is best known for its roles in mediating the recruitment of eosinophils. However, 
blockade of this receptor is still in question since a CCR3 antagonist, GW766944, does not 
significantly reduce eosinophils in the airways [144].The roles of CCR1, CCR2, and CCR3 have 
been further studied in a more acute, LPS-induced ALI model. Antagonism of these three 
receptors was shown to have a protective effect – when a CCR2b and CCR1 antagonist was used, 
decreases in fibrinolysis, vascular leakage and inflammatory gene expression were all noted. 
These findings were further supported in CCR1, CCR2, and CCR3 knockout mice which had less 
pulmonary edema, infiltration and overall disease as compared with controls with ALI [145]. 
Finally, CCL2 and CCL7 are also chemokines that may play an interesting part– in a study 
performed by Mercer et al, antibody neutralization of these ligands significantly reduced 
neutrophil accumulation in the BAL fluid in mice with LPS-induced lung injury [146]. 
Of the CXC-receptor antagonists, CXCR3 has also been further evaluated with its ligand 
CXCL10. CXCL10 is considered a non-ELR chemokine. In addition to CXCL10, CXCR3 also binds 
CXCL9 and CXCL11, but CXCL10 is most induced in infection [147]. These ligands are all induced 
by interferon-γ and are believed to promote Th1 responses [143]. CXCL10 is a primary 
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chemoattractant for both T cells and NK cells [148]. CXCR3 activation stimulates interferon 
responses which have been shown to contribute to severity in a ferret H5N1 model, where 
CXCL10 gene expression is markedly increased over H3N2 and control models [147]. A CXCR3 
antagonist, AMG487, reduced disease severity through reducing viral leads, reducing pulmonary 
edema, and delaying lethality in this H5N1 model [147] and has also been shown to potently 
inhibit cellular recruitment [149]. Other CXCR3 antagonists of interest include SCH546738, which 
shows promise in autoimmune disease and transplant rejection [150], and VUF10085, a more 
specific CXCR3 antagonist of interest [143]. Ichikawa et al. evaluated both a viral and non-viral 
ARDS mouse model in mice deficient in CXCL10 and CXCR3 and found that mice lacking CXCL10 
and CXCR3 had improved severity of disease and survival in both models [151]. CXCR3 inhibition 
is even being explored in breast cancer therapy as a metastasis suppressant [152] and has been 
shown to improve mitochondrial function and reduce apoptosis in liver disease [153]. One major 
challenge that is being addressed with CXCR3 antagonists is their inability to prove their efficacy 
by the time they reach Phase II clinical trials. The current approach to this problem is to embrace 
the complexity of these diseases and test broader spectrum antagonists, such as TAK-779, which 
target multiple receptors and may have greater efficacy in vivo [143]. Therefore, this receptor 
continues to be another intriguing potential target for therapeutic therapy in models of acute 
inflammation, such as influenza coinfection.  
CXCL12 and its receptor, CXCR4, also appear to play a role in promoting chemotaxis of 
neutrophils as well as suppressing cell death. In a study looking at lipopolysaccharide (LPS)-
induced lung injury, CXCL12 was shown to be a chemoattractant for cells expressing CXCR4 as 
well as a suppressant of neutrophil cell death and CXCR4 was found to be increased on the 
neutrophil cell surface after migrating from circulation into the inflamed lungs, possibly via an L-
selectin mediated pathway [154]. Neutrophils leave trails rich in CXCL12 as they infiltrate and 
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migrate to sites of inflammation. These trails aid in migration of other cell types, such as T cells, 
as well [155]. AMD3100, a CXCR4 antagonist, has been shown to block these trails [155], but in 
another study, this same antagonist was shown to aid in the redistribution of neutrophils from 
primary immune organs to other sites without compromising the neutrophil tracking to these 
inflamed sites [156]. AMD3100 is well established as an FDA approved drug in cancer therapy 
and helps with mobilization of stem cells and mature leukocytes and has been used in 
nanotherapy to control lung cancer metastasis [156, 157]. 
Perhaps the most promising chemokine receptor blocking for the treatment of influenza 
pneumonia and secondary infections is with CXCR2. Blocking CXCR2 has been shown to inhibit 
release of neutrophils from the bone marrow as shown in a study evaluating neutrophils lacking 
CXCR2 which were retained in the bone marrow resulting in neutropenia similar to a human 
congenital disease called myelokathexis [158].  Of course, blocking CXCR2 to the degree of 
resultant neutropenia would be catastrophic in any acute inflammatory disease, but blocking 
50% of the receptor can still have significant reduction in neutrophil recruitment to the alveoli 
while still being effective and not resulting in neutropenia [129].  Although CXCR2 antagonists 
seem to most affect release of neutrophils from the bone marrow, CXCR2 is present in 
neutrophils in every area – bone marrow, circulation, tethered at the endothelium, and within 
the tissues – so CXCR2 antagonism is likely to affect neutrophils at all locations [159].  
Although there are a few selective CXCR2 antagonists that have been studied, finding an 
effective agent that blocks both CXCR1 and CXCR2 may be more appropriate since several CXC 
chemokines act on both receptors and both seem important. Several dual CXCR1/2 antagonists 
have been evaluated. One such antagonist is SCH527123, which has been shown to have a 
higher affinity for CXCR2 than CXCR1. In a study evaluating a rodent and nonhuman primate 
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model of pulmonary inflammation, this antagonist effectively reduced pulmonary neutrophilia 
and mucus hypersecretion which would be beneficial in combatting bacterial coinfection [160].  
SCH527123 has also been shown to be potent in vitro, and inhibited human neutrophil 
chemotaxis as well as myeloperoxidase release in response to both CXCL1 and CXCL8 [161]. In 
another study performed in healthy humans exposed to an ozone challenge in order to induce 
neutrophil chemotaxis, SCH527123 effectively lowered neutrophil counts in sputum as well as 
decreased CXCL8 and myeloperoxidase in sputum as compared with glucocorticoid and placebo 
treatment [162].  
Several other dual CXCR1/2 antagonists have also been evaluated [see Table 1]. 
Simvastatin initially appeared to be a promising therapeutic option when evaluated in a murine 
model of bacterial-induced ALI [163], but a more recent large study evaluating the agent in 
humans with ARDS showed no significant difference in outcome between those patients treated 
with Simvastatin versus those who received a placebo [164]. DF2156A, another dual antagonist, 
has been studied in radiation-induced lung disease in the murine model with reduction in lung 
fibrosis seen [165]. One more dual antagonist that has been studied is Reparixin. Reparixin is a 
little different in that it prefers CXCR1 antagonism to CXCR2 [166]. In a study evaluating the 
agent in a murine model of acid-induced ALI, the effect of Reparixin on vascular permeability 
and neutrophil recruitment into the lung vasculature, interstitium and alveoli was measured and 
shown to improve gas exchange and reduce neutrophil recruitment [167]. In general, Reparixin 
has mostly been studied in ischemia/reperfusion injury models and patients and further 
evaluation in a dual infection model is necessary to assess its efficacy. 
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Table 1: A summary of CXCR1/2 antagonists that have been tested in lung injury models. 
 
3.4. Other Potential Therapeutics and Vaccination 
 Multiple other therapies are being evaluated as well. Several agents to reduce vascular 
leakage have also been evaluated with varying effectiveness including Slit2N, vasculotide, atrial 
natriuretic peptide, S1P, activated protein C, and doxycycline [25, 168]. Mathieu, et al. has 
started evaluating the use of nanoparticles carrying a plant virus coat protein and ssRNA that 
trigger a strong innate immune response in the lung during a coinfection [169]. Antibodies to 
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angiopoitin-4 have been shown to reduce damage secondary to influenza since angiopoietin-4 
causes barrier breakdown and furthers inflammation [27]. In a murine model, extracellular 
adenosine has alters the recruitment and bactericidal function of neutrophils which may 
improve outcome in coinfection [41].  
 Vaccinations are also a key area of research, especially when considering the effect these 
vaccinations may have in pandemic preparedness. Pneumococcal capsular polysaccharide 
conjugate vaccines have been shown to be very effective (100%) against otherwise lethal 
pneumococcal disease, but in coinfection, the results are not as promising with less than 40% 
survival with vaccination in a murine model [170]. The value of the current vaccine is evident 
already though, with the vaccine being 84-94% efficacious against the serotypes included and 
reducing the severity of disease and risk for hospitalization in those affected [4]. In the U.S. 
alone, we have seen a 39% reduction in clinical pneumonia in children since the vaccine has 
been introduced [171]. Imagine how effective the current vaccine will be once it’s more 
available in developing countries. 
 Coinfection of S. pneumoniae with influenza promises to be a relevant disease for many 
years to come. Despite the many recent advances in our knowledge base regarding the disease, 
the complexity of pathogenesis implies that an effective “shotgun” approach to therapy is 
doubtful and a fine-tuned combination of antimicrobial agents with immunomodulators is likely 
to be more effective when treating the disease. Because of the expansive diversity in both 
influenza viral strains and pneumococcal disease and their ever-changing patterns of resistance 
and survival, therapy effective for one combination may not consistently work for all. This 
literature review touches on several approaches to consider in therapeutic design, but 
continued discovery will be needed to better prepare for the next pandemic. 
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 My research project helps to fill some of these gaps. I hypothesize that chemokine receptors 
can be potential therapeutic target sites for combination therapy of severe dual infection 
pneumonia. As displayed in Figure 3.1, a variety of key factors contribute to the pathology seen 
in dual infection pneumonia, such as an exaggerated neutrophil influx, the release of neutrophil 
extracellular traps, and continued damage to the pulmonary epithelial-endothelial barrier 
caused primarily by host defenses to the pathogens. These factors contribute to the formation 
of acute respiratory distress syndrome and bacteremia, resulting in lethality seen in a murine 
model that mimics that seen in severe pandemics. Chemokine receptor antagonists can be used 
to control innate responses to infection and reduce damage to the host so that the coinfection 
may be better resolved or prevented entirely. 
 To test this hypothesis, we established a murine model of bacterial superinfection following 
influenza that mimics our proposed idea for pandemic influenza outbreaks and subsequent 
pneumococcal secondary infections. This model was established and the neutrophils’ influx and 
NETs induction were analyzed. Next, based on the chemokine receptor expressions, we chose to 
target CXCR2 for therapeutic efficacy in the combination treatment together with antivirals and 
antibiotics. In addition, we also established a swine model for influenza pneumonia for further 
testing this combination therapy to explore the pathogenic role of neutrophils in an animal 
model closer to a human.  
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Figure 3.1 Project overview. Coinfection is a complex synergism resulting in increased 
morbidity and mortality. The lethal synergism of influenza and Streptococcus pneumoniae 
copathogens acts in conjunction with an excessive innate immune response to create acute 
respiratory distress syndrome through impaired neutrophil function, cytotoxicity, 
microthrombosis and additional damage from dead and dying bacteria. This project focuses on 
the neutrophil’s response to infection and ways to target these responses in order to improve 
outcome. Our hypothesis is that if we target the innate immune response using chemokine 
receptor antagonists (CR Antagonists) in addition to targeting the pathogens involved with 
antiviral and antibiotic therapy, we can improve clinical outcome in a murine model of ARDS 
caused by influenza pneumonia with subsequent pneumococcal infection. 
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CHAPTER II 
 
 
ESTABLISHING AND CHARACTERIZING A MURINE MODEL FOR INFLUENZA 
PNEUMONIA WITH SUBSEQUENT PNEUMOCOCCAL PNEUMONIA 
 
Summary: A murine model for pandemic H1N1 influenza outbreaks with secondary bacterial 
coinfection is proposed and characterized. Mice receiving 100 TCID50 PR/8 H1N1 influenza A 
followed by 200 CFU S. pneumoniae 72 hours after initial viral infection have lethally synergistic 
disease with 100% mortality. Those mice receiving 200 CFU S. pneumoniae alone had minimal 
clinical disease. A significant and excessive neutrophil influx is noted on day 5 after viral 
infection (48 hours post bacterial infection). In addition, severe protein leakage, barrier 
breakdown, pulmonary pathology and bacteremia is evident at this same time. Neutrophil 
extracellular traps (NETs) are released in viral-alone and dual infected groups and byproducts of 
these NETs, histones, contribute to the pathology and barrier breakdown seen in this model. 
Dual infection animal models are complex and highly variable. We tested a variety of models to 
achieve a mode that best mimics a pandemic setting with a fairly severe pneumonia infection 
followed by a sublethal bacterial infection that together is lethally synergistic. The proposed 
murine model serves as a good base for further studies on the pathogenesis explaining the 
lethal synergism seen in influenza coinfection as well as for testing potential therapeutics. 
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Background: Influenza virus has long afflicted the human population and shaped the course of 
history over the last century. Since 1918, four major influenza pandemics have occurred with 
varying severity, but each pandemic has clearly illustrated the importance of better 
understanding the viral interactions with host and other organisms to be better prepared for 
future outbreaks. Arguably the deadliest outcome with influenza pneumonia is secondary 
bacterial infections.  Coinfections are more frequent in pandemic outbreaks than in seasonal 
influenza and are linked to rates of higher mortality [6, 12]. Postmortem samples from victims of 
the 1918 H1N1 pandemic clearly show that secondary bacterial infections were present in over 
95% of deaths, and it is believed that without these “pneumopathogens” most would have 
survived [6]. Throughout all pandemics, secondary bacterial infections continued to complicate 
the disease with Streptococcus pneumoniae being the most common pathogen identified [6, 11, 
12]. About 41% of coinfections are due to S. pneumoniae during influenza pandemics and about 
17% in seasonal outbreaks with Staphylococcus species as a close second [12].  
 As the scientific community becomes increasingly aware of the importance of 
coinfection with influenza pneumonia, we have also become increasingly aware of the 
complexity of coinfection. No single factor can be claimed solely responsible for the lethal 
synergism seen with coinfection, but instead a complex network of viral, bacterial, host and 
environmental factors contribute to the pathogenesis of the disease.  Viral and bacterial 
neuraminidases work together to create more severe disease through exposure of bacterial 
adherence receptors and upregulation of the initial viral infection [24, 28]. Influenza virus has 
also been shown to desensitize sentinel lung cells to bacterial TLR ligands and these effects can 
last months after viral infection making coinfection more likely and severe [92]. Viral PB1-F2 
enhances inflammation by promoting proapoptotic effects and disrupting mitochondria in 
coinfections [31]. Importantly, the influenza virus also induces destructive, long-lasting alveolar-
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capillary barrier dysfunction [26, 27] and a loss of the ability to effectively repair this destruction 
[23].  
 Bacterial factors, in particular those of S. pneumoniae, are key contributors to 
pathogenicity in coinfection as well. Influenza has been shown to promote the migration of S. 
pneumoniae from the upper respiratory tract, where it can often live as a commensal bacteria, 
to the lower respiratory tract where it is considered pathogenic [21, 22]. Once in the lower 
respiratory tract, factors such as pneumococcal serine-rich repeat protein [35-37] and pili [35] 
allow the bacteria to better bind to the airway epithelium. As already stated, bacterial 
neuraminidases can upregulate influenza infections and promote epithelial binding through 
galectins [24, 28]. Virulence factors, most notably pneumolysin, also contribute significantly [32-
34]. The complexity of coinfection is only compounded by the complexity of the bacterial 
pathogen itself – S. pneumoniae has over 90 recognized serotypes of capsule and a high rate of 
genetic variation [17]. 
 The host’s immune response is a significant contributor to pathology and clinical 
severity seen with influenza coinfections. Various innate responders are involved including 
monocytes, natural killer cells, dendritic cells, and neutrophils [47, 48, 57, 93]. An excessive 
neutrophil response beyond 12 hours post S. pneumoniae infection results in a greater bacterial 
burden [19, 39, 41] and significant host damage due to factors such as the release of neutrophil 
extracellular traps [55, 57]. Alterations in the function of innate responders can also contribute 
to coinfection lethality. In addition, interferon type 1 [44, 95-98] and interleukins such as IL-6 
[32], IL-10 [24, 102], and IL-12 [93] contribute to the complexity of this disease. The adaptive 
immune response is also affected to promote coinfection – affecting not only virus-specific CD8+ 
T cells [103], but γδ T cells [95] and B cells as well [104, 105].  
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 What is clear from this brief summary is the need to better understand these pathogen 
and host interactions so that novel therapeutic options and pandemic planning can occur. As 
with any therapeutic development, a consistent and controlled animal model for the disease is 
needed to assess for therapeutic potential prior to future development of these drugs. Variation 
of dual infection in human disease outside of experimental conditions is so vast, that identifying 
a model that will work in all cases is near impossible. Many options have been considered in 
various animal models, including, but not limited to mice, ferrets and pigs. In addition to variety 
in animal type, the sequence and infectious doses need to be established to fit the needs of the 
researcher. Our goal is to identify and characterize a dual infection model the emulates a 
pandemic influenza outbreak resulting in lethal synergism and high rates of mortality. To do this, 
various models had to be tested and compared to ensure the appropriate choice for future 
experiments.  
 
Methods: 
Pathogens 
Influenza A/Puerto Rico/8/34, H1N1 (PR/8) virus was obtained from the American Type Culture 
Collection (ATCC, VA). Viral titers were determined by tissue culture infectivity dose (TCID50) 
assay via infection of Madin-Darcy canine kidney (MDCK) cells. Streptococcus pneumoniae 
(serotype 3) was also obtained from the ATCC. Bacterial growth curves were established prior to 
infection [Figure M.1]. All pathogens were stored at -80°C until use. 
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Figure M.1: Streptococcus pneumoniae growth conditions were optimized.  Absorbance was 
measured over a 12-hour period. Samples were plated at various dilutions at specific 
absorbance (0.150, 0.300, and 0.800 Abs). Bacterial growth concluded that 0.300 Abs results in 
10^5 CFU/10 µL sample. The growth curve obtained was consistent among three independent 
experiments (A, B, and C).   
 
Animals 
Female Balb/c mice ranging from 6 to 10 weeks’ old were purchased from Jackson Laboratories. 
Mice were group-housed in microisolator cages in a BSL-2 facility, and were provided with food 
and fresh water ad libitum. Mice were clinically scored based on a modified version of the 
“mouse clinical assessment scoring for sepsis” (M-CASS) [172] [Table M.2].  Infection was 
performed under a mixture of xylazine (0.1 mg/kg) and ketamine (7.5 mg/kg) anesthetic via 
intraperitoneal injection. Mice were infected intranasally (IN) with a sublethal dose of 1000-100 
TCID50 PR/8 (H1N1) influenza in a 50 μl volume or given an equal volume of sterile phosphate-
buffered saline in controls. For dual infection studies, mice were administered either 104, 5x103, 
103, or 200 colony forming units (CFU) of S. pneumoniae IN in 50 μl volumes 72 hours after initial 
influenza infection, or administered PBS IN for controls. Mice were monitored closely for weight 
loss and clinical signs based on a modified “mouse clinical assessment score for sepsis” [172, 
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173]. All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) of Oklahoma State University and were performed in strict accordance with 
their recommendations. 
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Table M.2: Murine Clinical Assessment of Septic Shock (MCASS) scoring was modified and used 
for murine studies. Mice were observed in an unstimulated, stimulated and disturbed state for 
the following criteria and weighed daily. An overall score from 1 – 4 with 1 being healthy and 4 
being most severe was assigned to each mouse. Any mouse receiving a score of 4 in any area 
was euthanized in these studies.  
 
Whole blood, bronchoalveolar lavage (BAL) fluid, and tissue collection 
For BAL fluid collection, the lungs were washed by intratracheal administration of 1.0 mL of 
sterile PBS in two 0.5 mL increments [55]. The recovery of BAL fluid was more than 85% for all 
animals. The BAL fluids were centrifuged at 200 xg for 10 minutes, and reconstituted in sterile 
PBS for cell counts and with 2% fetal bovine serum in PBS for flow cytometry analysis. BAL cells 
were concentrated using the CytoFuge 2 cytocentrifuge (StatSpin, Westwood, MA), and 
differential cell counts were performed using modified Giemsa staining. Whole blood was 
collected via terminal procedure of intra-cardiac collection. Blood and BAL cultures were 
performed at various dilutions after sterile collection. Cultures were performed on blood agar 
plates (Hardy Diagnostics) and incubated with CO2 at 37° C. Bronchoalveolar lavage fluid and 
whole blood (intracardiac) were collected from 3 to 5 days’ post influenza infection for many 
studies. Protein leakage was measured by the determination of the total BAL protein content 
using a DC Protein Assay Kit (Bio-Rad, CA). 
 
Histopathology 
Lungs from mice who did not have BAL collection were fixed with 4% formalin and collected for 
histopathology analysis after hematoxylin and eosin (H&E) staining. Mice were scored on a 1-4 
scale (4 being most severe) for severity in the following areas by a blinded, board-certified 
anatomic veterinary pathologist: necrotizing bronchiolitis, bronchiolar infiltrates, alveolitis, 
interstitial inflammation, hemorrhage, edema, and microvascular thrombosis. Necrotizing 
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bronchiolitis was defined as damage to the airway epithelial cells, presence of necrotic bodies or 
the total denudation of the airway lining. Total histopathologic scores were evaluated as a sum 
of all individual scores. 
 
Western Blot Analysis of Pulmonary Damage and Extracellular Histones 
BAL fluids were analyzed for the release of epithelial damage marker, T1-α, and the endothelial 
damage marker, Claudin-5. In addition, samples were also tested for extracellular histone 
release, which are indicative of NETs formation, as described previously [55]. Antibodies against 
histone protein H2A and citrullinated H4 (Millipore, MA) were used. Due to the absence of 
effective loading controls for BAL, normalization of protein content was accomplished through 
BAL collection methodology. BAL was collected with 1.0 mL sterile PBS with consistent recovery 
of 80-85%. Densitometry analysis was performed on all Western blots using ImageJ software 
version 1.51 (NIH).  
 
Transwell System Histone Experiments 
Transwell systems were established using 24 well plates and 6.5mm diameter, 3µm pore sized 
inserts (Corning). Initially, conditions were tested and optimized using epithelial (A549) and 
human umbilical vein hybrid endothelial cells (Eahy926) cell lines in both monolayer and 
coculture techniques. Cells were initially cultured in T25 flasks with DMEM media including fetal 
bovine serum and penicillin/streptomycin.  Cells were passaged once prior to culture on 
transwell membrane. In cocultures, Eahy926 cells were 2.0 x 105 cells were seeded on the 
basolateral side of the membrane and allowed to adhere and grow before reverting the inserts 
and seeing 2.0 x 105 A549 cells on the apical side. In monolayer cultures, only the apical side was 
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used. Epithelial resistance kinetics were established using an EVOM2 epithelial volt/ohm meter 
(World Precision Instruments).  
Initial histone experiments used coculture and added 10µg/mL histones to the apical 
chamber for 1 hours at 37°C before removing and adding 106 S. pneumoniae. Bacteria was then 
incubated with the cell culture for 6 hours and samples taken from the basolateral chamber for 
cultures at 30 minutes post inoculation, 2 hours, 4 hours, and 6 hours. Cultures were performed 
in multiple dilutions on blood agar plates. In addition, cells were stained with trypan blue at 6 
hours to assess for viability. All samples were performed in duplicate. For subsequent 
experiments, A549 cells were cultured in monolayer. And various concentrations of histones (0, 
10, 20, and 30 µg/mL) were incubated for 2 hours at 37°C before removal and addition of 106 S. 
pneumoniae to the apical chamber. Samples from the basolateral chamber were removed every 
2 hours for 12 hours starting at time 0 and cultured on blood agar plates. All samples were 
performed in duplicate and repeated for n=4.  
 
In vivo Histone Experiments 
Balb/c female mice were inoculated with either histones or PBS on day 0 ± 103 S. pneumoniae or 
PBS 24 hours after histone inoculation. The following conditions were established: 100µg 
histones + bacteria; 50µg histones + bacteria; 100µg histones (-) bacteria, (-) histones + bacteria, 
(-) histones (-) bacteria. Each group contained 6 mice. An additional group with 3 mice was 
inoculated with 300µg histones (-) bacteria. BAL, blood and tissue samples were collected 48 
hours after histone inoculation for cultures, cell counts, and histopathology. Mice were 
monitored closely and scored based on MCASS for the entire 48 hours.  
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Statistical Analysis 
The data are expressed as the means ± SEM. Statistical analyses were performed using Student’s 
unpaired t-test, paired t-test or analysis of variance (ANOVA) using GraphPad Prism 7 software. 
p < 0.05 was considered statistically significant. 
 
Results:  
1. Influenza and pneumococcal coinfection results in significant weight loss, inflammation, 
bacteremia, and enhanced pulmonary pathology. The first murine model assessed was 103 
TCID50 PR/8 H1N1 Influenza followed by 104 CFU S. pneumoniae 72 hours after initial viral 
infection. Both influenza-only and dual-infected groups are severely affected in this model and 
these groups lost significantly more weight than bacterial-only infected and healthy controls 
starting after day 2 [Figure 1.1]. Bacterial-only infected mice lost over 2% body weight by day 5. 
 
Figure 1.1: Mice with viral-alone and dual infection lose significant weight. Model tested: 1000 
TCID50 PR/8 H1N1 influenza ± 104 CFU S. pneumoniae (Serotype 3). [Control: Mice receive only 
PBS; Influenza: mice receive 1000 TCID50 PR/8 influenza; SP: mice receive 200 CFU S. 
pneumoniae on day 3; Dual: Dual infection model]. Bacterial infection was administered 72 
hours after initial viral infection. Influenza-only and dual infected groups lost significantly more 
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weight than bacterial-only or healthy controls beginning at day 2. Bacterial-only lost an average 
of 2.3% body weight by day 5 (day 2 post infection), whereas healthy controls steadily gained 
weight. n=5 mice per group. Statistical comparison performed by one-way ANOVA. 
****p<0.0001 (versus control). 
 
In addition to weight loss, influenza-only and dual infected groups saw sharp clinical decline 
beginning at day 2. Although weight loss matched between these groups, the dual infected 
group had a more severe clinical decline and progressed to endpoint on day 5. This clinical 
decline seen in the dual-infected group may be explained by cultures performed on the BAL and 
blood on day 5 [Figure 1.2]. 
 
Figure 1.2: Dual infection results in bacteremia by day 5. Balb/c mice were infected with 1000 
TCID50 PR/8 H1N1 influenza ± 104 CFU S. pneumoniae 72 hours after viral infection. Cultures 
were performed from 10 µL BAL and blood from each sample. No growth was noted in control 
or influenza-only groups and no contamination seen. Dual infected mice grew S. pneumoniae 
from both blood and BAL samples, whereas bacterial-only infected mice only grew S. 
pneumoniae from BAL. Symbols for Table A (CFU per 10µL sample): 0<+<10. 10<++<100. 
100<+++<1000. 1000<++++. n=2 shown in table. 
 
Dual-infected mice had marked bacteremia evident on day 5. In contrast, no bacteremia was 
seen in bacterial-only infected groups. Bacterial cultures from BAL were also denser than 
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bacterial-only, indicating that viral infection enhances bacterial growth both within the lung and 
the bloodstream, likely through barrier breakdown. Protein leakage within the BAL supernatant 
was measured [Figure 1.3 A]. The more severely affected groups, viral-alone and dual, have 
significantly higher amounts of protein leakage as compared to bacterial-alone and healthy 
controls, indicating increased inflammation in these groups. BAL cell counts were also higher in 
these groups due to a large inflammatory cell influx. Dual-infected mice had significantly more 
inflammatory cells in their BAL than viral-alone [Figure 1.3 B]. 
 
Figure 1.3: Viral-alone and dual infection results in marked vascular leakage and cellular 
infiltrations. Balb/c mice were infected with 1000 TCID50 PR/8 H1N1 influenza ± 104 CFU S. 
pneumoniae 72 hours after initial infection. BAL was collected on day 5 and the supernatant 
used for protein estimation using a DC Protein Assay Kit. A: Infected mice in both the influenza-
only and dual infection groups had significantly more protein than compared to healthy controls 
and bacterial only (SP) groups. There was no significant difference between influenza-only and 
dual-infected mice. B: Infected mice have significantly higher cell count numbers from BAL fluid 
collection. Dual infected mice are also significantly higher than influenza-only. Data are 
expressed as means ± SEM. n=4. Statistical comparisons performed via one-way ANOVA. 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 (relative to bacterial-alone (SP) unless otherwise 
indicated). 
 
Lung tissue was collected and formalin-fixed on day 5. Tissue sections were stained in 
hematoxylin and eosin for pathologic scoring, as performed by a blinded anatomic veterinary 
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pathologist. Mice were scored from 0 (healthy) to 4 (most severe) in 7 areas: necrotizing 
bronchiolitis, bronchiolar infiltrates, alveolitis, interstitial inflammation, hemorrhage, edema, 
and microvascular thrombosis. The sum of these scores for each mouse was calculated and used 
for overall comparisons between groups [Figure 1.4]. Mice receiving bacteria-alone had rare 
focal lesions with the majority of tissue mimicking that of healthy controls. Viral-alone infected 
mice were more severely affected with larger areas of pathology and more widespread disease. 
The most severely affected group was the dual-infected group with widespread pathology and 
large areas with complete loss of pulmonary architecture. 
 
Figure 1.4: Pulmonary pathology is severely enhanced in dual infection on day 5. Mice were 
scored from 0-4 in 7 areas: necrotizing bronchiolitis, bronchiolar infiltrates, alveolitis, interstitial 
inflammation, hemorrhage, edema, and microvascular thrombosis. After scoring, the sum of the 
scores for each mouse was calculated and used for overall comparisons. Severe pulmonary 
pathology was noted in influenza-only and dual infected groups as compared with healthy 
controls. Mice infected with only S. pneumoniae had few focal areas of moderate pathology, but 
were overall unaffected. Although no statistical difference was seen between influenza-only and 
dual infected mice, a trend toward enhanced pathology in dual infection was evident 
(p=0.0764). Data are expressed as means ± SEM. n=5 mice per group. Statistical comparisons 
made via one-way ANOVA. **p<0.01; ***p<0.001 (relative to controls). 
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2. Lower infective doses of pathogens maintain clinical model. Three additional models were 
next assessed with lower infective doses of both virus and bacteria. First, the dose of influenza 
virus was reduced 10-fold to 100 TCID50 while maintaining 104 CFU S. pneumoniae (serotype 3) 
on day 3. Bacterial-alone infected mice lost an average of 7% body weight by day 5, while the 
more severely infected viral-alone and dual groups lost significantly more weight [Figure 2.1]. 
 
Figure 2.1: Viral-alone and dual infected mice continue to lose significant weight at decreased 
viral dosage. 100 TCID50 PR/8 H1N1 influenza ± 104 CFU S. pneumoniae (Serotype 3). Bacterial 
infection was administered 72 hours after initial viral infection. [Control: PBS only; SP: S. 
pneumoniae on day 3; Influenza: PR/8 influenza-only; Dual: dual infection]. Influenza-only and 
dual infected groups lost significantly more weight than bacterial only or healthy controls most 
apparent after day 3. Bacterial-only lost an average of 7% body weight by day 5 (day 2 post 
infection), whereas healthy controls steadily gained weight. n=5 mice per group. Weights 
compared via one-way ANOVA. ****p<0.0001 (relative to controls). 
 
Bacterial cultures performed from BAL and blood samples on days 4-6 post viral infection 
mimicked that seen in the previous model. No growth was seen in viral-alone infected mice. 
Dual infected mice had significant growth of S. pneumoniae on all days in BAL with heavy 
bacterial burdens noted. In addition, bacteremia was evident in all dual samples on days 5 and 
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6, but not on day 4, indicating that barrier breakdown is occurring around this time. 
Interestingly, a single mouse had bacteremia on day 6 from the S. pneumoniae-alone infected 
group [Table 2.2]. 
 
Table 2.2: Primary influenza infection enhances bacterial dissemination.  Balb/c mice were 
infected with 100 TCID50 PR/8 H1N1 influenza ± 104 CFU S. pneumoniae 72 hours after viral 
infection. Cultures were performed from 10 µL BAL and blood from each sample. No growth was 
noted in influenza-only groups and no contamination seen. Dual infected mice grew S. 
pneumoniae from both blood and BAL samples, whereas bacterial-only infected mice grew S. 
pneumoniae from BAL and one sample grew S. pneumoniae 6 DPI from the blood. Symbols for 
Table A (CFU per 10µL sample): 0<+<100. 100<++<1000. 1000<+++<10,000. 10,000<++++. n=2 
shown in table. Table shows average growth. 
 
BAL was collected 4-6 days after viral infection (24-72 hours after bacterial infection) and used 
for cell counts and protein leakage estimation, both of which are indicative of inflammation. 
Viral-alone and dual infected groups had significantly more protein leakage as compared to 
healthy controls on days 5 and 6 [Figure 2.3 A]. On day 6, there is also a significant increase in 
protein leakage in the dual-infected group over viral-alone, indicated more severe damage to 
the lungs. Cell counts were also increased in dual infected mice on all three days [Figure 2.3 B]. 
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Figure 2.3: Infected mice exhibit significantly more inflammation. In this model, balb/c mice 
were infected with 100 TCID50 PR/8 H1N1 influenza ± 104 CFU S. pneumoniae 72 hours after 
initial infection. BAL was collected on days 4-6 and the supernatant used for protein leakage 
estimation (DC Colorimetric Protein Assay Kit (Bio-Rad). A: Infected mice in both the influenza-
only and dual infection groups had significantly more protein than compared to healthy controls 
and bacterial only groups on days 5 and 6 post influenza infection. In addition, there was a 
significant difference between influenza-only and dual-infected mice on day 6. B: Dual-infected 
mice have significantly higher cell count numbers from BAL fluid collection as compared with 
bacterial only groups. Dual infected mice are also significantly higher than influenza-only on day 
6 (p<0.05). Data are expressed as means ± SEM. Statistical comparisons made via one-way 
ANOVA. n=4. ***p<0.001; ****p<0.0001 (relative to healthy controls in Fig. 2.3a; relative to SP 
in Fig. 2.3b). 
 
Since this model resulted in a chance of bacteremia in bacterial-alone infected mice, the next 
two assessed models reduced the bacterial dose as well: 100 TCID50 PR/8 H1N1 influenza 
followed by either 103 or 5x103 CFU S. pneumoniae 72 hours after viral infection. This model 
maintained the weight loss previously noted in influenza-alone and dual infected groups, but the 
bacterial-alone infected mice, which were administered 103 CFU S. pneumoniae, gained weight 
over 5 days instead of losing weight [Figure 2.4]. 
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Figure 2.4: Influenza and Dual-Infected mice lose significant weight starting on day 3. Model: 
100 TCID50 PR/8 H1N1 influenza ± 103 or 5x103 CFU S. pneumoniae (Serotype 3). Bacterial 
infection was administered 72 hours after initial viral infection. Influenza-only and dual infected 
groups lost significantly more weight than bacterial beginning at day 2. Bacterial-only at this 
lower infective dose gained weight by day 5 (day 2 post infection). n=5 mice per group. 
Statistical comparisons made via one-way ANOVA.  ****p<0.0001 relative to SP. 
 
At this lower bacterial dosage, no mice from the bacterial-alone infected groups developed 
bacteremia and had a reduced bacterial burden within the lungs as well, based on BAL cultures 
[Figure 2.5]. Dual-infected mice mimicked that of previous groups with bacteremia developing 
on day 5 and significantly increased bacterial growth in BAL for both dual models. 
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Table 2.5: Dual infection results in bacteremia by day 5. Balb/c mice were infected with 100 
TCID50 PR/8 H1N1 influenza ± 103 or 5x103 CFU S. pneumoniae 72 hours after viral infection. 
Cultures were performed from 10 µL BAL and blood from each sample. No growth was noted in 
influenza-only groups and no contamination seen. Dual infected mice grew S. pneumoniae from 
both blood and BAL samples, whereas bacterial-only infected mice only grew S. pneumoniae 
from BAL. Symbols for Table A (CFU per 10µL sample): 0<+<100. 100<++<1000. 
1000<+++<10,000. 10,000<++++. n=3. Table shows average growth. 
 
Cell counts performed from BAL collected on days 4-6 indicate a significant increase in 
inflammatory cell numbers in the dual infected samples, especially apparent on day 6 [Figure 
2.6]. Overall, this latest murine model is similar to the previously tested models in severity for 
influenza-alone and dual infection groups with reduced disease in the bacterial-alone group. 
55 
 
 
Figure 2.6: Inflammatory cell influx is most notable on day 6. In this model, BAL fluid cell counts 
were significantly higher in influenza-only and dual-infected groups than that of bacterial-only 
infected mice. Data are expressed as means ± SEM. n=5 mice per group. Statistical comparison 
was performed via one-way ANOVA between same day samples. *p<0.05; **p<0.01 (relative to 
SP). 
 
3. Murine Models for dual infection result in significant pulmonary pathology and breakdown of 
the pulmonary epithelial and endothelial barriers. Further analysis of histopathology supports 
the severe clinical decline and inflammatory response seen in these models. Pulmonary tissue 
was collected and formalin-fixed on days 4-6. Lungs were scored as previously described.  
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Figure 3.1: Dual infection results in severe pulmonary pathology. Balb/c mice were infected 
with 100 TCID50 PR/8 H1N1 influenza, then 104 CFU S. pneumoniae 72 hours after initial 
infection. Bacterial only groups were administered 104 CFU S. pneumoniae. Dual infected mice 
received significantly higher scores than control mice. Influenza-only infected mice received 
significantly higher scores than control mice on 5 and 6 DPI. In addition, the dual infected group 
was significantly worse than the influenza-only group on all days (p<0.05 on 4,5 DPI and p<0.01 
6 DPI). Data are expressed as means ± SEM. Statistical comparison was performed via one-way 
ANOVA between same day samples. n=2 mice per group. ** p<0.01; *** p<0.001 (relative to 
healthy controls). 
 
Histopathology scores for the group receiving 100 TCID50 influenza ± 104 CFU S. pneumoniae are 
more severe in viral-alone and dual-infected groups than healthy controls. The dual infected 
groups are also statistically more severe on all three days as compared with viral-alone, with 
more widespread pathology and extreme damage [Figure 3.1].  After reduction in bacterial 
dosage, these trends do not change much, with dual-infected groups remaining the most severe 
on all days [Figure 3.2]. 
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Figure 3.2: Dual infection continues to result in severe pulmonary pathology after lowering 
bacterial dose. Balb/c mice were infected with 100 TCID50 PR/8 H1N1 influenza, then either 103 
or 5 x 103 CFU S. pneumoniae 72 hours after initial infection. Bacterial only groups were 
administered 103 CFU S. pneumoniae. Both dual infection groups received significantly higher 
scores than control mice. In addition, the dual infected group receiving 5 x 103 CFU bacteria was 
significantly worse than the influenza only group on all days (p<0.05). Data are expressed as 
means ± SEM. Statistical comparison was performed via one-way ANOVA between same day 
samples. n=2 mice per group. ** p<0.01; *** p<0.001 (relative to healthy controls). 
 
As previously described, histopathology scores were based on 7 major pathologic lesions. Of 
these, no mice in the bacterial-infected groups had evidence of necrotizing bronchiolitis or 
microvascular thrombosis. These mice also had only mild disease with few foci affected and 
most tissue appearing like that of healthy controls. Dual-infected mice scored higher in all 
categories than viral-alone and had the most severe disease with widespread areas of necrosis, 
pyogranulomatous inflammation and subsequent breakdown of pulmonary architecture [Figure 
3.3]. These severe, large areas of disease are clearly visualized in Figure 3.4 and can be 
compared with that of the other groups, showing less disease. 
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Figure 3.3: Dual infection results in significantly enhanced pathology in all infective models. 
Lungs were collected and formalin-fixed on day 5. Fixed sections were scored from 0 (healthy) to 
4 (severe) in the following areas: necrotizing bronchiolitis, bronchiole infiltrates, alveolitis, 
interstitial inflammation, hemorrhage, edema, and microvascular thrombosis. Bacterial-only 
infected mice had mild bronchiole infiltrates, alveolitis, interstitial inflammation, hemorrhage 
and edema at few focal locations. No necrotizing bronchiolitis or microvascular thrombosis were 
noted. Influenza-only and dual-infected mice had significantly more severe pathology. Data are 
expressed as means ± SEM. Statistical comparisons were made via one-way ANOVA. n=5 mice 
per group. *p<0.05; #p<0.01; @p<0.001; ^p<0.0001 (relative to healthy controls). 
 
 
Figure 3.4: Severe pulmonary pathology and extensive damage is evident on hematoxylin and 
eosin stained tissue sections. This figure acts as a visual representation of Figure 3.3. In 
addition, the extensive nature of pulmonary pathology evident in dual infection is evident with 
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large areas of severe pyogranulomatous inflammation and destruction of the pulmonary 
epithelium and endothelium affecting large areas of pulmonary tissue.  
 
The disease noted on histopathology is further confirmed by western blot analysis of Claudin-5 
and T1α. Claudin-5 is normally found at the tight junction of the endothelium and so is 
considered a sign of endothelial damage when identified in high quantities in BAL supernatant. 
T1α is typically part of type I pneumocytes and so is used as a marker for epithelial barrier 
breakdown in the lungs. Evidence of endothelial breakdown is seen in all infected groups based 
on western blot analysis, but is quantifiably more severe in dual and viral-alone groups [Figure 
3.5]. 
 
Figure 3.5: Dual infection results in significant pulmonary endothelial damage. Claudin-5, a 
marker for endothelial barrier breakdown, was measured from BAL supernatant using western 
blot technique. Findings confirm significant protein within the BAL supernatant indicating 
endothelial barrier breakdown within the pulmonary tissue in all infected samples. Samples 
were normalized by BAL collection technique (see materials and methods). 
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Epithelial barrier breakdown was also noted in all influenza-alone and dual infected mice from 
day 4-6 [Figure 3.6]. Detectable presence of this marker in bacterial-alone infected mice was not 
consistently noted, indicating some variation in the effect of the bacteria alone to increase 
epithelial permeability. 
 
 
Figure 3.6: Dual infection results in significant pulmonary epithelial damage. T1-α, a marker for 
alveolar epithelial breakdown, was measured from BAL supernatant using Western Blot 
technique. Epithelial breakdown is apparent in all infected samples, but most consistently in 
influenza-only and dual infected samples. Densitometry confirms that influenza-alone and dual 
infected mice have significantly more T1-α than bacterial-alone and healthy controls. Statistical 
comparisons made via one-way ANOVA. Data are expressed as means ± SEM. n=4. *p<0.05; 
**p<0.01 (relative to heathy controls). 
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4. Sublethal combination of influenza and S. pneumoniae results in a lethally synergistic murine 
model for influenza coinfection. In order to assess the effects of a much lower dosage of S. 
pneumoniae in combination with a severe, but not lethal dose of influenza, 100 TCID50 influenza 
was administered 3 days prior to administering 200 CFU of bacteria. Even at these low doses, 
viral-alone and dual infected mice lost significant weight between days 2-5, matching an 
increase in severity of clinical score. In addition, dual infected mice continued to be more 
severely affected than those with viral-alone infection [Figure 4.1]. 
 
Figure 4.1: Dual-infected and influenza-alone infected mice have similar weight loss, but have 
differences noted in clinical decline. Balb/c mice were infected with sublethal doses (100 TCID50 
intranasally) of influenza A/Puerto Rico/8/34 H1N1 virus or PBS followed by sublethal S. 
pneumoniae (200 CFU IN) or PBS three days after initial influenza infection. A and B: Infected 
mice lost significant weight and had significant increase in severity of clinical score starting on 
day 3 as compared with control and S. pneumoniae-only infected mice. In addition, significant 
differences (p<0.0001) in clinical score were noted between Influenza Only and Dual groups on 
days 4 and 5 post influenza infection. Data were expressed as means ± SEM. Statistical 
comparisons were made with one-way ANOVA and unpaired t-tests. n = 21 mice per group. 
**** p<0.0001. 
 
An excessive neutrophil influx is also noted on day 5, with significantly more total inflammatory 
cells seen in both viral-alone and dual infected groups and a trend toward the most cells in dual 
infected mice [Figure 4.2 A]. Images from cytospins clearly show this difference with the 
predominant cell type being neutrophils [Figure 4.2 B]. Differentials performed from these 
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cytospins confirm that neutrophils are the predominant cell type in both viral-alone and dual 
infected groups, with a higher percentage of neutrophils noted in dual than viral-alone, which 
had more macrophages present as a percentage of the cell population [Figure 4.3]. 
 
Figures 4.2: Excessive neutrophil influx seen in dual infection. Balb/c mice were infected with 
sublethal doses (100 TCID50 intranasally) of influenza A/Puerto Rico/8/34 H1N1 virus or PBS 
followed by sublethal S. pneumoniae (200 CFU IN) or PBS three days after initial influenza 
infection. A and B: Influenza-infected and dual-infected groups have significantly more cells in 
the BAL fluid than in S. pneumoniae-only infected groups as seen from cell counts performed via 
hemocytometer and cytospin data. A trend toward a significant increase in cell counts in dual 
infected mice compared with viral-only was also noted. Data were expressed as means ± SEM. 
Statistical comparisons were made via one-way ANOVA. n = 7-11 mice per group. * p<0.05; ** 
p<0.01 (relative to SP Only). 
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Figure 4.3: Neutrophils predominate inflammatory cell influx. Balb/c mice were infected with 
sublethal doses (100 TCID50 intranasally) of influenza A/Puerto Rico/8/34 H1N1 virus or PBS 
followed by sublethal S. pneumoniae (200 CFU IN) or PBS three days after initial influenza 
infection. Differentials performed on BAL fluid cells viewed after cytospin revealed majority 
neutrophils, especially noted in dual infections, with a significantly higher percentage of 
neutrophils in dual differentials compared with influenza alone. Data were expressed as means 
± SEM. Comparisons made via paired t-test. n = 3 mice per group. **** p<0.0001 relative to 
lymphocytes. #### p<0.0001 (relative to macrophages). 
 
Protein leakage as measured in BAL supernatant also supports the continued severity of the 
viral-alone and dual-infected models. Not only was more protein evident in these groups as 
compared with bacterial-alone and healthy groups, but these protein levels climbed from days 3 
through 6 [Figure 4.4]. 
64 
 
 
Figure 4.4: Protein leakage significantly increases between 3-6 DPI in both influenza-only and 
dual infected models. In this model, balb/c mice were infected with 100 TCID50 PR/8 H1N1 
influenza ± 102 CFU S. pneumoniae 72 hours after initial infection. BAL was collected on days 3-6 
and the supernatant used for protein estimation. 4-6 DPI samples in both the influenza-only 
infected group and dual infected group were significantly higher than that of controls or 
bacterial-only infected mice. In addition, there is a significant increase in protein leakage in 
these same groups from 3-5 days after initial viral infection with maximum damage resulting in 
leakage appearing on days 5 and 6. Data are expressed as means ± SEM. Comparisons 
performed via one-way ANOVA. n=4-8 mice per group. **p<0.01; ***p<0.001; ****p<0.0001 
(relative to healthy controls unless otherwise indicated). 
 
Similar trends to previously assessed models are also evident when evaluating histopathology. 
Lungs were collected and formalin-fixed on days 3-6 to be sectioned and scored by an anatomic 
veterinary pathologist. These sections were scored in the same manner as described previously. 
Notable pulmonary edema, pyogranulomatous inflammation, hemorrhage and widespread 
disease are evident on dual-infected lungs [Figure 4.5]. When compared in each key area scored, 
results remain similar to previous models as well, with minimally affected pulmonary tissue from 
bacterial infection alone and markedly more severe disease seen in influenza and especially 
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dual-infected groups [Figure 4.6]. These findings are again further supported by evaluating 
Claudin-5 and T1α markers through Western Blot analysis (data not shown). 
 
 
Figure 4.5: Dual infection results in severe pulmonary pathology. Lungs were collected and 
formalin-fixed for histopathology analysis between days 3-6 post influenza infection. Day 3 
samples for S. pneumoniae-only and dual infections were not collected since bacterial 
inoculation was performed at that time. Figure presents sum of scoring.  Paraffin-embedded 
lung tissues from 5 days post-challenge with infection or mock infection were stained with 
hematoxylin and eosin. Tissues affected through dual infection show most severe score with 
notable pulmonary edema, bronchiolitis, alveolitis, hemorrhage, microvascular thrombosis and 
interstitial disease. Infected samples were compared with controls. Data were expressed as 
means ± SEM. Comparisons evaluated via one-way ANOVA. n = 4 mice per group. * p<0.05; ** 
p<0.01; *** p<0.001. 
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Figure 4.6: Dual infection results in significantly enhanced pulmonary pathology. Individual 
areas scored include: necrotizing bronchiolitis, bronchiole infiltrates, alveolitis, interstitial 
inflammation, hemorrhage, edema, and microvascular thrombosis. Infected samples were 
compared with controls. Data were expressed as means ± SEM and compared via one-way 
ANOVA. n = 4 mice per group. * p<0.05; ** p<0.01; *** p<0.001. 
 
5. Lethally synergistic disease results in the release of neutrophil extracellular traps (NETs). NETs 
have been reported as a significant cause of pulmonary pathology and worsened clinical disease 
in influenza pneumonia [55, 83]. To identify if NETs release is apparent in this murine model, 
extracellular histones were measured from BAL supernatant. Both H2A [Figure 5.1] and 
citrullinated H4 [Figure 5.2] are quantifiably present in viral-alone and dual infected mice in all 
models, with minimal detection in bacterial-alone groups. Citrullinated H4 is considered a more 
specific marker for NETosis as histones must undergo citrullination in order to be released 
through NETs. 
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Figure 5.1: Accumulation of extracellular histones during influenza and dual infection. BAL 
supernatant was collected from all models on days 4-6. Figure shows sample of results on day 5 
for three tested models. H2A, extracellular histone, is present in all viral-alone and dual infected 
samples. H2A is minimally present to absent in bacterial-alone samples and absent in healthy 
controls. Densitometry confirms the increased presence of extracellular histone, H2A, in the 
BAL. Data are expressed as means ± SEM and compared via one-way ANOVA. n=4. *p<0.05; 
**p<0.01; ***p<0.001 (relative to healthy controls). 
 
68 
 
 
Figure 5.2: Neutrophil Extracellular Traps (NETs) are released in vivo during influenza-alone 
and dual infection. BAL supernatant was collected from all models on day 4-6 and western blot 
technique performed to assess presence of citrullinated H4 (citH4), an extracellular histone and 
by product of NETosis. Figure shows three results from day 5. CitH4 was present in all viral-alone 
and dual infection samples, while minimally present to absent in bacterial-alone groups. CitH4 is 
absent in healthy BAL. Data are expressed as means ± SEM and compared via one-way ANOVA. 
n=4. *p<0.05; **p<0.01; ***p<0.001 (relative to healthy controls unless otherwise indicated). 
 
Histones damage epithelial cells and increase bacterial translocation in vitro. 10 µg/mL histones 
were added to half of the inserts on the apical chamber of a co-culture transwell with A549 cells 
(epithelial) on the apical side of the membrane and Eahy926 (endothelial) cells on the 
basolateral side of the membrane. Histones were incubated on these cells for 1 hour before 
removal and the addition of 106 CFU S. pneumoniae to all apical chambers. Cultures from 
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basolateral chamber samples were performed over 6 hours by no growth was seen on any 
sample. However, after 6 hours, the cells were stained with trypan blue and a significant 
increase in the number of non-viable cells was noted in chambers treated with histones 
compared to those without (data not shown). 
 
Figure 5.3: Histones directly contribute to epithelial barrier breakdown and bacterial 
dissemination  An A549 epithelial cell monolayer was established on a transwell system and 
cells were exposed to varying levels of histones for one hour before incubation with S. 
pneumoniae. 10 µL samples were collected from the basolateral chamber and cultured over a 
12-hour time period. High levels of histones resulted in significantly more bacteria translocating 
across the epithelial barrier, but was not significantly noted until after 10 hours. Data are 
expressed as means ± SEM and are compared via one-way ANOVA. n=2. *p<0.05; ****p<0.0001 
(relative to no histone control). 
 
 Next, an A549 monolayer transwell system was established to test various 
concentrations of histones and their effects on translocation. The following conditions were 
tested: No histones, 10µg/mL histones, 20µg/mL histones, and 30µg/mL histones. After histone 
incubation, all wells were inoculated with 106 CFU S. pneumoniae and allowed to grow for 12 
hours. Samples were removed from the basolateral chamber every 2 hours for culture. 
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Statistical significance was only noted between groups starting at 10 hours post bacterial 
inoculation. The cells receiving 30µg/mL histones had significantly higher levels of bacterial 
translocation to the basolateral chamber than those receiving no or 10µg/mL histones at both 
10 and 12 hours [Figure 5.3]. Although significance is only established late, a trend toward this is 
apparent from early on, as can be seen in Figure 5.4, which outlines the first 6 hours of 
incubation. Overall bacterial growth for all conditions exponentially increases after 8 hours, 
although it increases much more in the wells treated with the highest amounts of histone 
[Figure 5.4].  
 
Figure 5.4: Histone effects on bacterial translocation. Although sample size is insufficient for 
statistical significance, a trend can be seen toward increased histone concentrations and an 
increase in bacterial translocation and subsequent bacterial growth from the basolateral 
chamber. This figures helps to illustrate the first 6 hours after inoculation. Overall, bacterial 
growth in all groups exponentially increases after 8 hours, but wells receiving higher levels of 
histones result in statistically significant increases in bacterial translocation. Data are expressed 
as means ± SEM. n=2.  
 
Histone inoculation in vivo results in increased morbidity and bacterial growth. Balb/c mice were 
inoculated with either 50 or 100 µg/mL histones IN ± 103 CFU S. pneumoniae intranasally 24 
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hours after histone inoculation and monitored over 72 hours for clinical signs and weight loss. 
Mice were euthanized after 72 hours and samples collected for cell counts, culture and 
histopathology. In addition, a smaller group was inoculated with 300 µg/mL histones, but the 
mice receiving 300 µg/mL histones had to be euthanized within an hour of inoculation due to 
steep clinical decline, likely from histone toxicity.  
 
Figure 5.5: Histones in combination with pneumococcal infection result in more pronounced 
weight loss. Balb/c mice were inoculated with either 50 or 100 µg/mL histones IN +/- 103 CFU S. 
pneumoniae IN and monitored over 72 hours for clinical signs and weight loss. The mice 
receiving 300 µg/mL histones had to be euthanized within an hour of inoculation due to steep 
clinical decline. Percentage weight lost over 3 days: Groups receiving S. pneumoniae lost 
between 3-5% of their weight over three days with the greatest weight loss noted in groups 
receiving both bacteria and histone inoculation. Clinically, mild lethargy was noted in the 100μg 
histone groups on day 1, and in the 100µg histone + SP groups on days 1, 2, and 3 (data not 
shown). Data are expressed as mean ± SEM. n = 6 mice per group for all studies.  
 
Groups receiving S. pneumoniae lost between 3-5% of their weight over three days with the 
greatest weight loss noted in groups receiving both bacteria and histone inoculation [Figure 5.5]. 
Clinically, mild lethargy was noted in the 100μg histone groups on day 1, and in the 100µg 
histone + SP groups on days 1, 2, and 3 (data not shown).  
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Figure 5.6: Histones enhance cellular influx and cause bacteremia in vivo. Balb/c mice were 
inoculated with either 50 or 100 µg/mL histones IN +/- 103 CFU S. pneumoniae IN and monitored 
over 72 hours for clinical signs and weight loss. Mice were euthanized after 72 hours and 
samples collected for cell counts, culture. A: BAL cell counts were significantly different between 
100µgHist+SP and SP only and controls. No other significant differences were noted. B: Cultures 
were taken on day 3. Results reflected are CFU/20μL sample. +: <50 CFU; ++: 50<CFU<500; +++: 
500<CFU<1000. n=3 Blood and BAL culture results indicated growth of SP in all BAL samples 
from mice inoculated with SP and in one blood sample, from a mouse within the 50 µg/mL 
histone+SP group. n=3. Data are expressed as mean ± SEM and compared via one-way ANOVA. n 
= 3 mice per group for all studies. * p<0.05 (compared with healthy controls unless otherwise 
indicated). 
 
Blood and BAL cultures were performed on day 3. Blood and BAL culture results indicated 
bacterial growth in all BAL samples from mice inoculated with SP and in one blood sample, from 
a mouse within the 50 µg/mL histone+SP group [Figure 5.6 B]. BAL cell counts were significantly 
higher in the 100µgHist+SP group as compared with the bacterial only and mock infected mice 
[Figure 5.6 A]. Histopathology shows increased pulmonary hemorrhage, especially in the mice 
inoculated with 300 µg/mL histones who were euthanized shortly after inoculation due to 
severe clinical decline [Figure 5.7]. 
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Figure 5.7: Histopathologic effects of histones in vivo include mild disease and hemorrhage. 
Balb/c mice were inoculated with either 50 or 100 µg/mL histones IN +/- 103 CFU S. pneumoniae 
IN. Mice were euthanized after 72 hours and samples collected for histopathology. The mice 
receiving 300 µg/mL histones were euthanized within an hour of inoculation due to steep 
clinical decline. Histopathology from mice show mild disease. Hemorrhage is most notable in the 
group receiving 300 µg histones. Mild alveolitis and bronchiolitis are also evident in those 
receiving histones. n = 3 mice per group for all studies.  
 
 
Discussion: 
Identifying animal models for influenza pneumonia with pneumococcal coinfection can 
be challenging due to the complexity of the disease. Variation of dual infection in human disease 
outside of experimental conditions is so vast, that identifying a model that will work in all cases 
is near impossible. My goal was to characterize and develop a murine model for dual infection 
pneumonia that resembles that seen in pandemic influenza outbreaks, where a severe H1N1 
influenza strain is predominant and coinfection results in a lethally synergistic outcome with 
high rates of morbidity and increased mortality. A murine model that best mimics this process 
can be used to better understand the pathogenesis of the disease and develop therapeutics that 
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may work well in combination with antibiotics and antivirals to combat the high morbidity and 
improve clinical outcome. 
 Various models have been tested. Factors to be considered include host, pathogens, 
infective dosages, and timing of secondary infection. Various hosts have been utilized in 
assessing dual infection: in particular mice, rats, ferrets and pigs. Due to the availability, cost, 
and ability to repeat consistent experiments, murine models are the most commonly used. 
Ferret models also appear rather ideal, and a ferret model has shown the same synergism seen 
in mice, dependent on the pneumococcal strain [16], but availability and cost is a factor for 
many. PR/8 H1N1 influenza A was chosen due to its consistency in a mouse model to limit 
variation. A sublethal dosage better mimics a pandemic for a typical, healthy population, where 
an individual may develop moderate to even severe disease, but does not always succumb to 
the virus alone. Streptococcus pneumoniae is the most common secondary bacterial agent seen 
in dual infection influenza pneumonia with over 40% of coinfections culturing S. pneumoniae 
during pandemic outbreaks [6, 11, 12], and so was chosen for the bacterial pathogen. As an 
often opportunistic pathogen, S. pneumoniae can be subclinical and often cause mild disease, 
which is complicated in dual infection, creating a synergistic model. The models tested in this 
study indicate that even decreasing the infective dose of S. pneumoniae by almost 1000-fold, 
still resulted in severe, lethally synergistic disease with bacteremia. Bacteremia is a common 
sequelae for severe influenza coinfection – during the 1918 H1N1 pandemic, over 95% of lungs 
cultured bacteria and an alarming 70.3% of assessed victims were bacteremic [6]. In this 
chapter’s proposed murine models, bacteremia is a consistent clinical finding from day 5 and 6 
(48-72 hours after bacterial infection) and correlates with a breakdown in the pulmonary 
epithelial and endothelial barriers, as seen by T1α and Claudin-5 detection as well as 
histopathologic changes at that time. Drastic differences were not seen between the tested 
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models. Due to the chance of bacteremia in our bacterial-only infected group at higher bacterial 
doses and the severity of the disease, our model essentially reduced infective dose to the lowest 
amount that still causes lethal synergism, which not causing significant disease in bacterial-only 
infected mice. 
 Timing of infection must also be considered. Consideration must be made to which 
agent is administered first, bacterial or viral, and how many days apart are they administered? If 
bacteria is introduced into the lower airways first, there may be a protective effect and 
enhanced adaptive response to influenza virus initially, although the ability of the host to 
neutralize the virus one month after infection is reduced [105]. In addition, pandemic outbreaks 
involve viral introduction first, with secondary agents taking advantage of the viral-induced and 
immunopathologic damage to the host to enter the lower airways and cause increased disease. 
If viral and bacterial agents are administered simultaneously, the synergism normally seen in 
infection is not present to the same degree [29]. However, if the viral burden is allowed to clear 
and the bacteria introduced seven days after viral infection, this synergism is clearly evident 
with an enhanced inflammatory response and bacterial burden [19, 29]. Significant neutrophil 
accumulation and functional impairment is noted in mice receiving secondary bacterial infection 
3 and 6 days after influenza infection as well [39]. The aim of our lab is to use this murine model 
to assess the therapeutic potential of neutrophils as a target for dual infection influenza 
pneumonia. Since the excessive inflammatory response is still present, our model allows for 3 
days between administration of influenza and S. pneumoniae. Based on our results, clinical 
disease develops from influenza on day 2, at which point bacteria is introduced 24 hours later. 
An excessive neutrophil influx is apparent in both viral-alone and dual infected groups, most 
notable at day 5 and 6. At this same time, pulmonary pathology and protein leakage are severe 
76 
 
in these models and support that pulmonary epithelial and endothelial barrier breakdown at 
this time allows for the bacteremia introduced on day 5 in the dual infected mice. 
There is also an increase in the release of neutrophil extracellular traps (NETs) in both 
influenza-only and dual infected BAL. We have previously shown that excessive neutrophils and 
NETs contribute to alveolar-capillary damage after influenza challenge in mice [174]. NETs 
formation is dependent on redox enzyme activities [55]. NETs were first identified as a process 
of cell death that released DNA, histones and granular proteins such as elastase and 
myeloperoxidase to entrap and kill pathogens [50]. Since the initial identification of NETs, they 
have also been shown to be detrimental to the host – particularly through histones which 
induce endothelial and epithelial cell damage and worsened disease [56]. Further, using 
pneumococcal superinfection following influenza, an extensive accumulation of NETs was 
recognized, especially in the damaged areas of the lungs, indicating their potential role in tissue 
injury. Moreover, NETs released during pneumococcal superinfection did not show any 
bactericidal or fungicidal activities. [57, 58]. A toxic byproduct of NETs, extracellular histones, 
are clearly present in those mice with more severe disease – the influenza-alone and dual-
infected mice. Transwell studies further support that histones alone can lead to epithelial and 
endothelial barrier breakdown, increasing permeability into the bloodstream, allowing for 
bacteremia and subsequent sepsis. Histones administered in vivo also appear to cause more 
severe disease and allow for barrier breakdown and bacteremia. Our data supports that 
increased NETs release and the presence of histones correlate with worsened histopathologic 
changes and clinical outcome in our murine model for dual infection pneumonia. 
In conclusion, the proposed murine model for influenza coinfection is a good 
representation of pandemic influenza outbreaks resulting in secondary infection that is lethally 
synergistic. Mice infected with 100 TCID50 PR/8 H1N1 and 200 CFU S. pneumoniae 72 hours after 
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initial viral infection have an exaggerated innate response, with predominantly 
pyogranulomatous inflammation. Significant protein leakage, pulmonary pathology, and barrier 
breakdown is noted on days 5 and 6 after influenza infection (48 hours after bacterial infection) 
and correlates with bacteremia in all dual infected mice. This murine model will serve as a good 
animal model to further assess the pathogenesis of the barrier breakdown and development of 
bacteremia and sepsis, as well as provide a consistent model for the testing of potential 
therapeutics for pandemic influenza coinfection [Figure 6.1]. 
 
Figure 6.1: Various strategies to be considered for the development of potential therapeutic 
targets in influenza coinfection. Upon development of the murine model, this schematic 
represents potential directions to consider for pathogenesis and therapeutic targets in severe 
dual infection pneumonia. This project focuses on targeting neutrophil influx in addition to 
bacterial and viral factors to improve clinical outcome. 
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CHAPTER III 
 
 
ASSESSING NEUTROPHIL CHEMOKINE RECEPTOR EXPRESSION AND 
PHENOTYPE IN A MURINE MODEL OF DUAL INFECTION PNEUMONIA 
 
Summary: It is well established that secondary bacterial infections complicate and promote 
lethality in cases of influenza pneumonia during pandemic outbreaks, and also in fatal cases of 
seasonal influenza infections. Current therapies rely on antibiotics and antivirals to work closely 
with supportive care measures to improve clinical outcome, but increasing evidence of antiviral 
resistance and continued severity associated with coinfection demand novel approaches to 
combination therapy be explored. The innate immune response to influenza pneumonia 
promotes coinfection and contributes significantly to pulmonary pathology and poor outcomes. 
We established a murine model for dual infection to evaluate the role of neutrophils in S. 
pneumoniae superinfection following influenza infection in mice. Previous studies in our lab has 
demonstrated pathogenic role of neutrophils in influenza pneumonia. Here, we characterized 
neutrophils for their phenotypic changes and functional responsiveness during primary influenza 
as well as secondary pneumococcal superinfection. Chemokine receptors are critical to 
neutrophil function and innate recruitment and are potential targets for the treatment of 
various diseases and clinical conditions.  For characterization of neutrophils, we evaluated 
expression of chemokine receptors including CC (CCR1, CCR2, CCR3, CCR5) and CXC (CXCR1, 
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CXR2, CXCR3 and CXCR4) and integrin molecules (CD16, CD62L and CD11b) during primary 
influenza and secondary pneumococcal infection in circulating and lung-recruited neutrophils. 
Our results have demonstrated that CXCR2 is the most predominantly expressed and induced 
chemokine receptor in both circulating and lung-recruited neutrophils during primary influenza 
and also S. pneumoniae superinfection. We also found that neutrophils acquire a novel 
expression of chemokine receptors including CCR1, CCR2, CCR3, CCR5, CXCR1, CXCR3 and CXCR4 
in lung-recruited neutrophils, but not in circulating neutrophils. CXCR2, which is highly 
expressed in both blood and bronchoalveolar lavage neutrophils, has diminished expression in 
pulmonary infiltrative neutrophils as compared with infected blood, but still is induced at the 
sites of inflammation in dual infection as compared with the less severe bacterial-only models. 
CC and other CXC chemokine receptors were minimally expressed (<10%) to absent in 
circulatory neutrophils, but acquire 30-40% expression on pulmonary neutrophils during severe 
infection.  Expression of CD16 was decreased in both circulating as well as lung-recruited 
neutrophils, while CD62L showed significant decreased in circulating neutrophils. Interestingly, 
CD11b was increased in both circulating as well as lung-recruited neutrophils. Functionally, 
blocking receptors such as CCR5 and CXCR2 can alter reactive oxygen species and phagocytosis 
function, complicating their effects. Chemokine receptors offer an interesting target for novel 
combination therapy in influenza with secondary pneumococcal pneumonia, and this study 
ensures their availability and highlights their potential for this role in a murine model of this 
disease. 
A. Introduction  
Bacterial co-infection is a common and often lethal sequela of influenza pneumonia.  
Among seasonal influenza outbreaks, bacterial co-infections contribute to an estimated 65,000 
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deaths in the United States alone each year [2, 12].  The lethality seen with bacterial co-infection 
of influenza pneumonia is only compounded in pandemics, and has been well documented for 
all major pandemics of this previous century, starting with the 1918 “Spanish Flu” [1-4]. 
Preserved lung tissue sections and autopsy analysis from lethal cases of this outbreak suggest 
that 95% of these deaths can be attributed to co-infection [5, 6]. Of the bacterial co-infections 
seen in influenza pandemics over the last century, 41% have been attributed to S. pneumoniae – 
other major pathogens include Staphylococcus spp. (in particular S. aureus), Haemophilus 
influenzae, and other Streptococcus spp. [12]. 
 Lethal pneumonia caused through coinfection often results in the development of 
acute respiratory distress syndrome (ARDS) and sepsis. Outside of anti-viral therapy and 
antibiotics, treatment of these complicating factors seen with dual infection pneumonia are 
largely supportive, and, unfortunately, many seemingly positive pharmacological agents (i.e., 
surfactant therapy, vasodilators, lisofylline, glucocorticoids) have no significant outcome on 
morbidity and mortality [175-180]. The need for more specific treatments is great, and 
neutrophils offer an intriguing prospect as a potential target for therapy. Unrestrained 
transmigration of neutrophils into areas of gas exchange in the lungs is a pathologic hallmark of 
influenza pneumonia and ARDS resulting in alveolar capillary damage, edema, parenchymal 
hemorrhage, pulmonary microvascular thrombosis, and hyperinflammatory cytokine responses. 
These changes are also documented in murine models of influenza pneumonia [55, 181, 182].  
The excessive innate response to influenza virus leads to a series of virus-inflicted and host-
mediated damages to the pulmonary epithelium and endothelium resulting in significant 
pathology and respiratory failure [3, 183, 184]. Acute lung damage seen in both influenza 
pneumonia and S. pneumoniae dual infections is well linked to excessive neutrophils and 
subsequent release of neutrophil extracellular traps (NETs) which are toxic to the host [18, 55, 
81 
 
57, 83, 185, 186]. The recruitment, extravasation, and activation of neutrophils are largely 
driven by chemokines and their receptors, justifying their value as potential therapeutic targets.  
A seemingly uncontrolled influx of neutrophils during the innate immune response to 
acute lung injury has long been thought to be a major contributor to the development of Acute 
Respiratory Distress Syndrome (ARDS) seen in severe dual infection pneumonia and resulting 
morbidity and mortality. This transmigration of neutrophils into the interstitial and alveolar 
spaces is controlled in part by the interaction of chemokines released from the site of injury with 
their corresponding receptors. Chemokines function as chemotactic cytokines to control 
transmigration, recruitment, and activation of immune cells to specific areas within the body.  
Not only are they crucial in pathologic disease processes including the initial response to acute 
inflammation, they are also necessary for maintenance of homeostasis [187]. Neutrophils are 
rapid and powerful protectors in the innate immune response, but are thought to be limited in 
their chemokine receptor expression with comparison to other leukocytes [138].  Neutrophils 
also appear to have a different phenotype of receptors as opposed to other leukocytes, with 
predominant expression of the CXC receptor family as opposed to the CC ligands; although it has 
been more recently shown that the CCR family plays a role in chronic inflammatory conditions 
such as chronic respiratory disease and rheumatoid arthritis [138].  The approximately fifty 
endogenous chemokine ligands and their respective receptors can be classified in many ways. 
Expressed on all leukocytes, chemokine receptors are often divided into two groups – G-protein 
coupled receptors which can be activated by pertussis toxin (PTX)- sensitive Gi-type G proteins, 
and atypical chemokine receptors which are independent of G protein [187]. They can also be 
divided into either inflammatory or homeostatic chemokines depending on whether they are 
expressed in inflamed tissues to recruit leukocytes or maintain physiologic movement of 
leukocytes for immune reconnaissance [188]. 
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A.1 Integrin Receptor Expression and Functional Changes in Neutrophil Biology.  
Before focusing on chemokines and their receptors, attention must be given to integrin 
expression and phenotypic changes in neutrophil biology that occur during dual infection 
pneumonia and subsequent ARDS. Further understanding phenotypic changes in neutrophils 
may help to clarify why some individuals are more susceptible to secondary infections after 
influenza pneumonia and how neutrophil phenotypic heterogeneity contributes to disease 
pathology.  
Various integrins and receptors have been used to characterize neutrophils via flow 
cytometry in addition to their forward and side scatter properties. Pillay, et al, described three 
morphologically distinct subsets of neutrophils that develop in response to chronic 
inflammation, two of which are not present in healthy controls [189]. In this study, the author 
used CD16 and CD62L to recognize these subsets, and defines the three groups as 
CD16dim/CD62Lbright, CD16bright/CD62Ldim, and CD16bright/CD62Lbright. Phenotypically, the 
CD16dim/CD62Lbright neutrophils are immature cells that have recently been released from the 
bone marrow, also called “bands”. The CD16bright/CD62Ldim neutrophils are older and 
hypersegmented and the CD16bright/CD62Lbright neutrophil subset population is seen in both 
infected and healthy controls alike. CD16, also known as FcγRIII, is a cell surface molecule that is 
expressed on several cell types including neutrophils, macrophages and natural killer cells, and 
has been shown to have reduced expression in many inflammatory conditions such as vaginitis, 
trauma, bacterial infection and viral pneumonia [190-192]. It has also been suggested that the 
decreased CD16 expression seen with acute inflammation could be due to the influx on 
immature neutrophils which are CD16dim [189]. CD62L, also known as L-selectin, mediates 
neutrophil rolling and adhesion to the endothelial cells. This receptor is shed when stimulated 
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by pro-inflammatory cytokines such as TNF-α in acute inflammatory insults such as with trauma 
[191, 193] and uremia [194]. 
CD11b is another frequently assessed integrin in models of acute inflammation. CD11b 
is a β2-integrin adhesion molecule that is part of the Mac-1 heterodimer, and is a major player 
in neutrophil recruitment and adhesion [190, 191, 193]. In contrast to CD62L, most studies have 
shown that CD11b significantly increases in cases of acute inflammation, corresponding to 
increased neutrophil activation [190, 191, 193, 195]. To summarize, models of acute 
inflammation such as bacterial pneumonia (primary or secondary), viral pneumonia, trauma or 
burns all seem to shed CD62L and reduce CD16 expression while increasing expression of 
CD11b. 
With increased activation during inflammatory conditions, the functional biology of 
these neutrophils is also drastically changed in an attempt to best combat the insult at hand. 
Apoptosis is downregulated during inflammation in order to prolong the neutrophil’s survival 
and viability to fight the infection [138, 191, 192]. This downregulation is thought to be partially 
driven by both the intrinsic pathway – through stabilization of the mitochondrial membrane 
potential by increases in Mcl-1 and decreases in Bax protein, and the extrinsic pathways – 
increased Fas and reduced activation [191]. This decrease in rate of apoptosis is especially seen 
in infiltrated neutrophils, such as those in pulmonary alveoli, as opposed to those in peripheral 
circulation [195]. Pro-inflammatory activation of neutrophils also results in increased reactive 
oxygen species production [191, 193, 194], increased degranulation [194], increased release of 
neutrophil extracellular traps [191], and decreased phagocytosis [190, 191]. Many of these 
biological changes are acting in an effort to best fight the immediate insult, without regard to 
secondary damage to the host tissues and subsequent risk for secondary infections. 
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A.2 Chemokines in dual infection pneumonia and subsequent ARDS 
Currently, treatment for ARDS is primarily supportive, and the need for more specific 
treatments is great. Several deceptively positive pharmacological agents have been evaluated in 
ALI (acute lung injury) and ARDS such as glucocorticoids, surfactants, nitric oxide and lysofylline, 
but several studies have now shown that these seemingly promising options do not have a 
significant effect on outcome and mortality [175]. Unrestrained transmigration of neutrophils 
into the areas of gas exchange in the lungs is a pathologic hallmark of the disease.   The 
extravasation of these neutrophils is driven by chemokines and their receptors, justifying their 
value as potential therapeutic targets. 
Chemokine receptor expression on the cell surface of human neutrophils has been 
shown to be altered by inflammation. These phenotypic changes of the cell surface not only 
offer insight into the development and progression of ARDS, but also potential therapeutic 
targets.  Since a hallmark sign of ALI and ARDS includes uncontrolled accumulation of 
neutrophils into the alveolar space, it follows that intervention to slow or block any step in 
neutrophil recruitment or migration should be explored. In ARDS, there is one chemokine in 
particular that seems to play a pivotal role – interleukin-8 (IL-8/CXCL8) which is seen in 
increased concentrations in pulmonary edema fluid from septic patients with ARDS [124] and is 
also found in lower concentrations in ARDS survivors as opposed to non-survivors, making IL-8 a 
prognostic indicator [125]. CXCL8 is one ligand that binds with both CXCR1 and CXCR2 in humans 
and is considered the most potent neutrophil chemoattractant in BAL fluid from ARDS patients 
[126].   
CXCR1 and CXCR2 are both G-protein coupled receptors and are expressed in several 
granulocytes including eosinophils, mast cells, T cells, and, most notably, neutrophils [127, 128]. 
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In addition to granulocytes, CXCR2 is also found on pulmonary endothelial and bronchial 
epithelial cells, and the additional role of CXCR2 on these non-hematopoietic cells has been 
shown to be necessary for the marked increase in lung microvascular permeability seen in an 
LPS-induced model of ARDS [129]. In addition to IL-8 (CXCL8), CXCR2 has at least six other 
ligands including CXCL1, CXCL2, CXCL3, and CXCL6 [130]. These chemokines are called ELR+ 
chemokines (glutamic acid-leucine-arginine containing) and have been shown to mediate 
aberrant vascular remodeling in addition to inflammatory cell recruitment in both the exudative 
and fibroproliferative stages of alveoli damage in ARDS [131]. In addition to a role in ARDS, 
CXCR2 has been a hot topic of study for several years due to promising roles in numerous 
diseases ranging from cancer to arthritis to other more chronic pulmonary diseases [132-136].  
CXCL8 is not the only chemokine that has been considered potentially important in the 
development and progression of ARDS. Several chemokine receptors have been shown to be 
affected by inflammatory disease, and further investigation may indicate a role in ARDS as well. 
A study looking at chemokine receptor expression in patients with chronic obstructive 
pulmonary disorder (COPD) and rheumatoid arthritis found several significant alterations in 
neutrophil phenotype involving CCR1, CCR2, CCR3, CCR5, CXCR3, and CXCR4 in BAL fluid when 
compared to circulating neutrophils [138]. In addition to evaluating chemokine receptor 
expression, Hartl et al. also explored whether neutrophils would chemotax to a variety of CC and 
CXC ligands and found this to be the case. These findings may have been inferred from chronic 
inflammatory disease, but do support that neutrophils with various receptors can respond to a 
variety of ligands, likely even in ARDS. 
The roles of CCR1, CCR2, and CCR3 have been further studied in a more acute, LPS-
induced ALI model. Antagonism of these three receptors was shown to have a protective effect 
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– when a CCR2b and CCR1 antagonist was used, decreases in fibrinolysis, vascular leakage and 
inflammatory gene expression were all noted. These findings were further supported in CCR1, 
CCR2, and CCR3 knockout mice which had less pulmonary edema, infiltration and overall disease 
as compared with controls with ALI [145]. CXCR3 has also been further evaluated for its role in 
ARDS with its ligand CXCL10. CXCL10 is considered a non-ELR chemokine. Ichikawa et al. 
evaluated both a viral and non-viral ARDS mouse model in mice deficient in CXCL10 and CXCR3 
and found that mice lacking CXCL10 and CXCR3 had improved severity of disease and survival in 
both models [151]. Therefore, this receptor poses another intriguing potential target for 
therapeutics in ARDS. CXCL12 and its receptor, CXCR4, also appear to play a role in promoting 
chemotaxis of neutrophils as well as suppressing cell death. In a study looking at 
lipopolysaccharide (LPS)-induced lung injury, CXCL12 was shown to be a chemoattractant for 
cells expressing CXCR4 as well as a suppressant of neutrophil cell death and CXCR4 was found to 
be increased on the neutrophil cell surface after migrating from circulation into the inflamed 
lungs, possibly via an L-selectin mediated pathway [154]. CXCR4 has been further described as 
acting antagonistically with against CXCR2 – CXCR4 expression promotes neutrophil retention in 
the bone marrow, whereas CXCR2 expression drives release [158]. Finally, CCL2 and CCL7 are 
also chemokines that may play an interesting part in ARDS – in a study performed by Mercer et 
al, antibody neutralization of these ligands significantly reduced neutrophil accumulation in the 
BAL fluid in mice with LPS-induced lung injury [146]. 
Neutrophils are generally thought to be limited in their chemokine receptor expression 
with comparison to other leukocytes [138, 196, 197], but several recent studies have shown that 
neutrophils acquire a novel chemokine receptor expression under various conditions of 
inflammation and injury [138, 198, 199]. These various chemokine receptors have been shown 
to be significant contributors to many diseases such as cancer [132, 134], arthritis [133], acute 
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lung injury [145], and various chronic pulmonary diseases [135, 136]. Despite what is known 
about neutrophils and their role in the pathogenesis of dual infection influenza pneumonia, this 
study is the first to our knowledge to provide a more complete understanding of the novel 
chemokine receptor expression obtained on neutrophils after infiltration to the lung in dual 
infection influenza pneumonia.  
A more thorough understanding of the neutrophils’ phenotype after recruitment to the 
lung in acute dual infection influenza pneumonia is required to better evaluate the neutrophil 
for targets with clinical potential in human disease. To address this need, we established a 
murine model for dual infection influenza pneumonia and evaluated neutrophil numbers as well 
as chemokine receptor expression at various time points through the disease course. Using flow 
cytometry analysis, we evaluated expression of chemokine receptors between circulating 
neutrophils and those which have recruited into the lungs in primary influenza pneumonia and 
with subsequent bacterial coinfection. In addition, effects of these altered chemokine receptors 
on neutrophil functional responsiveness were evaluated by neutrophil phagocytic activities and 
respiratory burst (measured by reactive oxygen species generation) by activating these 
chemokine receptors with their corresponding ligands in the presence or absence of receptor 
antibodies or antagonists/inhibitors.  
 
B. Methods 
Virus and Bacteria 
Influenza A/Puerto Rico/8/34, H1N1 (PR/8) virus was obtained from the American Type Culture 
Collection (ATCC, VA). Viral titers were determined by tissue culture infectivity dose (TCID50) 
assay via infection of Madin-Darby canine kidney (MDCK) cells. Streptococcus pneumoniae 
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(serotype 3) was also obtained from the ATCC. Bacterial growth curves were established prior to 
infection. All pathogens were stored at -80°C until use.  
 
Animals 
Female Balb/c mice ranging from 6 to 10 weeks’ old were purchased from Jackson Laboratories. 
Mice were group-housed in microisolator cages in a BSL-2 facility, and were provided with food 
and fresh water ad libitum. Mice were clinically scored based on a modified version of the 
“mouse clinical assessment scoring for sepsis” (M-CASS) [172].  Infection was performed under a 
mixture of xylazine (0.1 mg/kg) and ketamine (7.5 mg/kg) anesthetic via intraperitoneal 
injection. Mice were infected intranasally (IN) with a sublethal dose of 100 TCID50 PR/8 (H1N1) 
influenza in a 50 μl volume or given an equal volume of sterile phosphate-buffered saline in 
controls. For dual infection studies, mice were administered 200 colony forming units (CFU) of S. 
pneumoniae IN in 50 μl volumes 72 hours after initial influenza infection, or administered PBS IN 
for controls. Mice were monitored closely for weight loss and clinical signs based on a modified 
“mouse clinical assessment score for sepsis” [172, 173]. All animal experiments were approved 
by the Institutional Animal Care and Use Committee (IACUC) of Oklahoma State University and 
were performed in strict accordance with their recommendations. 
 
Whole blood, bronchoalveolar lavage (BAL) fluid, and tissue collection 
For BAL fluid collection, the lungs were washed by intratracheal administration of 1.0 mL of 
sterile PBS in two 0.5 mL increments [55]. The recovery of BAL fluid was more than 85% for all 
animals. The BAL fluids were centrifuged at 200 xg for 10 minutes, and reconstituted in sterile 
PBS for cell counts and with 2% fetal bovine serum in PBS for flow cytometry analysis. BAL cells 
were concentrated using the CytoFuge 2 cytocentrifuge (StatSpin, Westwood, MA), and 
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differential cell counts were performed using modified Giemsa staining. Whole blood was 
collected via terminal procedure of intra-cardiac collection. Bronchoalveolar lavage fluid and 
whole blood (intracardiac) were collected from 3 to 5 days’ post influenza infection for flow 
cytometry analysis and other studies. Lungs from mice who did not have BAL collection were 
fixed with 4% formalin and collected for histopathology analysis after hematoxylin and eosin 
(H&E) staining. Mice were scored on a 1-4 scale (4 being most severe) for severity in the 
following areas by a blinded, board-certified anatomic veterinary pathologist: necrotizing 
bronchiolitis, bronchiolar infiltrates, alveolitis, interstitial inflammation, hemorrhage, edema, 
and microvascular thrombosis. Total histopathologic scores were evaluated as a sum of all 
individual scores. 
 
Flow Cytometry  
The following antibodies were purchased from R&D (MN) Systems and used throughout the 
course of this study for chemokine receptor expression characterization of murine neutrophils: 
Mouse CCR1 Fluorescein isothiocyanate (FITC)-conjugated antibody, mouse CCR2 phycoerythrin 
(PE)-conjugated antibody, mouse CCR3 PE-conjugated antibody, mouse CCR5 FITC-conjugated 
antibody, mouse CXCR1/IL-8 RA PE-conjugated antibody, mouse CXCR2/IL-8 RB PE-conjugated 
antibody, mouse CXCR3 PE-conjugated antibody, and mouse CXCR4 fluorescein-conjugated 
antibody. These antibodies were selected due to their previously reviewed relevance in chronic 
inflammatory conditions and potential for therapeutic targeting [138]. Additional antibodies 
used in this study include mouse Ly6G (1A8) Peridinin Chlorophyll Protein Complex (PerCP)-
conjugated antibody (Biolegend, CA), mouse Fc gamma RIII (CD16) FITC-conjugated antibody 
(R&D, MN), mouse L-selectin (CD62L) PE-conjugated antibody (R&D, MN), mouse integrin alpha 
M/CD11b FITC-conjugated antibody (R&D, MN). In all flow cytometry studies, control BAL fluid 
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was not compared due to a lack of pulmonary neutrophils in naïve Balb/c mice. The collected 
whole blood and BAL fluid were aliquoted into 200 μl volumes for antibody staining.  2.0 ml of 
1x PharmLyse Buffer was used for red blood cell lysis and allowed to lyse for 15 minutes at room 
temperature. Samples were allowed to stain for 30 minutes, covered, at room temperature on a 
shaker. All samples were then centrifuged and washed with chilled PBS (with 2% FBS) 1-3 times 
before performing flow cytometry. Flow cytometry was performed on the BD FACSCalibur flow 
cytometer and analyzed with the corresponding CellPro software. Neutrophils were gated as 
Ly6G-1A8+SSCmed-hi. CD11b analysis was performed comparing mean fluorescence intensity 
between samples.  
 
PMN Functional Assays 
A 2’-7’-Dichlorodihydrofluorecein diacetate (DCFH-DA) flow cytometric assay (Invitrogen, CA) 
was used to assess reactive oxygen species production (ROS) in neutrophils from BAL fluid. In 
brief, BAL cells, with no added stimulation after collection, were treated with DCFH-DA and 
Ly6G-1A8 (Per-CP) antibody for 30 minutes at room temperature. The cells were then 
immediately analyzed using flow cytometry, and mean fluorescence intensity (X-Mean) 
compared between samples. In order to assess ROS function for CCR1, CCR3, CCR5, CXCR2, 
CXCR3, and CXCR4, a DCFH-DA (abcam, UK) flow cytometric assay was again used. BAL and 
blood were collected 3 days’ post influenza infection (1000 TCID50 PR/8) from 6 mice. Two mice 
were pooled for each sample. Neutrophils were isolated using the MACS neutrophil isolation kit 
(Miltenyi Biotec, Germany) as per protocol. Neutrophils were then divided between tubes with 
105 cells/100 µL volume per sample. 1 µg BX 471 (CCR1 Antagonist; Cayman Chemicals, MI), 
SB328437 (CCR3 Antagonist; Sigma, MN), CCR5 (Novus, CO), CXCR2 (Cell Applications, CA), 
CXCR3 (Bio X Cell, NH) blocking antibodies, and AMD3100 (CXCR4 Antagonist (R&D, MN) were 
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added in half the samples and incubated for 30 minutes at 37° C before adding 10 ng of the 
appropriate ligand (CCL3, CCL11, CCL4 (R&D, MN), IL-8, CXCL11, and CXCL12 (R&D, MN)) to all 
samples. 20 µM DCFH-DA was then added to each sample and the samples were incubated at 
37°C for 30 minutes before analysis via flow cytometry. Flow cytometry was performed on the 
BD FACS Aria. Results were compared via mean fluorescence intensity (MFI) using X-means. 
Data was graphed as relative function of the blocked samples to unblocked (x:1).  
 
For phagocytosis assays, BAL and blood were collected 3 days’ post influenza infection (1000 
TCID50 PR/8) and neutrophils isolated, divided and treated with or without the appropriate 
CCR1, CCR3, CCR5, CXCR2, CXCR3, and CXCR4 blockers and ligands as per ROS assay. 1 µg BX 471 
(CCR1 Antagonist; Cayman Chemicals, MI), SB328437 (CCR3 Antagonist; Sigma, MN), CCR5 
(Novus, CO), CXCR2 (Cell Applications, CA), CXCR3 (Bio X Cell, NH) blocking antibodies, and 
AMD3100 (CXCR4 Antagonist (R&D, MN) were added in half the samples and incubated for 30 
minutes at 37° C before adding 10 ng of the appropriate ligand (CCL3, CCL11, CCL4 (R&D, MN), 
IL-8, CXCL11, and CXCL12 (R&D, MN)) to all samples. pHrodoTM Red E. coli BioParticles 
(ThermoFisher, MA) were added to each sample (1 mg/mL), and cells were allowed to incubate 
at 37°C for 1.5 hours. Cells were then stained with Ly6G-1A8 antibody for 30 minutes at room 
temperature and washed twice to remove excess bacteria before flow cytometry. Flow 
cytometry was performed on the BD FACS Aria. Unstained, single-stained and no cell controls 
were used for data analysis. Results were compared via MFI. Data was graphed as relative 
function of the blocked samples to the unblocked (x:1). 
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Statistical Analysis 
The data are expressed as the means ± SEM. Statistical analyses were performed using Student’s 
unpaired t-test, paired t-test or analysis of variance (ANOVA) using GraphPad Prism 7 software. 
p < 0.05 was considered statistically significant. 
 
C. Results 
C.1. Dual infection results in excessive neutrophil influx and extensive pulmonary damage. Our 
murine model for dual infection pneumonia is highlighted by the development of bacteremia 
(confirmed by culture) approximately 48-60 hours after administration of S. pneumoniae with 
100% lethality before day 7 post influenza infection. Clinically, the mice receiving the dual 
infection have severe weight loss [Fig. 1.1] and rapid clinical decline from the time of bacterial 
superinfection on day 3 [Fig. 1.2]. S. pneumoniae alone infected mice did not lose significant 
weight. The weight loss seen in the dual infection groups mimic that in the influenza-only 
infected groups with a matched decline beginning at three days’ post infection [Fig. 1.1]. 
Although the decline in clinical scores is similar start at day 2 post infection with influenza-only 
and dual-infected mice, the clinical scores for mice with dual infection pneumonia is more 
severe by the endpoint, day 6, than in viral infection only [Fig. 1.2]. The sharp decline in clinical 
scores in the dual-infected mice correlates with the onset of bacteremia and the development 
of severe ARDS.  
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Figure 1.1 and 1.2 (see also Fig. 4.1 in Ch. 2): Dual infected mice lose considerable weight and 
have most severe clinical score by day 5. Balb/c mice were infected with sublethal doses (100 
TCID50 intranasally) of influenza A/Puerto Rico/8/34 H1N1 virus or PBS followed by sublethal S. 
pneumoniae (200 CFU IN) or PBS three days after initial influenza infection. 1.1 and 1.2: Infected 
mice lost significant weight and had significant increase in severity of clinical score starting on 
day 3 as compared with control and S. pneumoniae-only infected mice. Significant differences 
(p<0.0001) were also noted between influenza only and dual infected clinical scores on days 4 
and 5. Data were expressed as means ± SEM and compared via one-way ANOVA. n = 21 mice per 
group. **** p<0.0001 (relative to healthy controls). 
 
BAL fluid cell counts performed on days 3-5 post influenza infection show an increase in total 
cell numbers through day 5 of the dual-infected group with cell counts about 1.5 times higher in 
dual infected BAL as compared with influenza-only groups [Fig. 1.3, 1.4].  
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Figures 1.3 and 1.4 (See also Fig. 4.2 in Ch. 2): Significant inflammatory cell influx noted in both 
dual and influenza only infected mice. Balb/c mice were infected with sublethal doses (100 
TCID50 intranasally) of influenza A/Puerto Rico/8/34 H1N1 virus or PBS followed by sublethal S. 
pneumoniae (200 CFU IN) or PBS three days after initial influenza infection. 1.3 and 1.4: 
Influenza-infected and dual-infected groups have significantly more cells in the BAL fluid than in 
S. pneumoniae-only infected groups as seen from cell counts performed via hemocytometer and 
cytospin data. A trend toward a significant increase in cell counts in dual infected mice 
compared with viral-only was also noted. Data were expressed as means ± SEM and compared 
via unpaired t-tests. n = 7-11 mice per group. * p<0.05; ** p<0.01 (relative to SP Only). 
 
BAL differentials consistently indicate that the majority of these cells are neutrophils in both the 
influenza-only and dual infected groups, however there is a significantly greater percentage of 
neutrophils in the dual-infected mice than in the influenza-only infected mice [Fig. 1.5].  
 
Figure 1.5 (see also Fig. 4.3 in Ch. 2): Inflammatory cell influx is marked by neutrophilia. Balb/c 
mice were infected with sublethal doses (100 TCID50 intranasally) of influenza A/Puerto 
Rico/8/34 H1N1 virus or PBS followed by sublethal S. pneumoniae (200 CFU IN) or PBS three 
days after initial influenza infection. Differentials performed on BAL fluid cells viewed after 
cytospin revealed majority neutrophils, especially noted in dual infections, with a significantly 
higher percentage of neutrophils in dual differentials compared with influenza alone. Data were 
expressed as means ± SEM and compared via unpaired t-test. n = 3 mice per group. **** 
p<0.0001 relative to lymphocytes and #### p<0.0001 relative to macrophages. 
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C.2. Histopathology analyses. The clinical decline seen in our murine model can further be 
explained by examining histopathology. The following pulmonary pathologies were scored on a 
1-4 scale with 4 being most severe: necrotizing bronchiolitis, bronchiolar infiltrates, alveolitis, 
interstitial inflammation, hemorrhage, edema, and microvascular thrombosis. Total score (sum 
of individuals) was most severe in viral-only and dual-infected mice with only mild pathology 
noted in bacterial-only infected mice [Fig. 2.1].  
 
Figures 2.1 and 2.2 (See also Fig. 4.5 in Ch. 2): Dual infection results in severe pulmonary 
pathology and extensive damage. 2.1: Lungs were collected and formalin-fixed for 
histopathology analysis between days 3-6 post influenza infection. Day 3 samples for S. 
pneumoniae-only and dual infections were not collected since bacterial inoculation was 
performed at that time. Figure presents sum of scoring. 2.2: Paraffin-embedded lung tissues 
from 5 days post-challenge with infection or mock infection were stained with hematoxylin and 
eosin. Tissues affected through dual infection show most severe score with notable pulmonary 
edema, bronchiolitis, alveolitis, hemorrhage, microvacular thrombosis and interstitial disease. 
Infected samples were compared with controls. Data were expressed as means ± SEM and 
compared via one-way ANOVA. n = 4 mice per group. * p<0.05; ** p<0.01; *** p<0.001 (relative 
to healthy controls). 
 
Mice infected with influenza-only and dual infection develop marked pulmonary edema, 
interstitial inflammation, necrotizing bronchiolitis, alveolitis, and hemorrhage, with dual infected 
lungs more severely and diffusely affected than that of influenza-only infected pulmonary tissue 
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[Fig. 2.2, 2.3]. This damage as well as a heavy influx of neutrophils is evident when viewing the 
tissue from fixed specimens. In addition, large areas of pulmonary tissue are severely affected in 
our dual-infected model with little recognizable pulmonary architecture [Fig. 2.2]. Microvascular 
thrombosis was only recognized in influenza-only and dual-infected mice [Fig. 2.3].  No 
pathology was noted in the heart, liver, kidney, spleen, esophagus, small intestine, pancreas, or 
brain in any sample (data not included) in our model. 
 
Figure 2.3 (See also Fig. 4.6 in Ch. 2): Dual and Influenza Only infected mice have significant 
pulmonary pathology and microvascular thrombosis. Individual areas scored include: 
necrotizing bronchiolitis, bronchiole infiltrates, alveolitis, interstitial inflammation, hemorrhage, 
edema, and microvascular thrombosis. Infected samples were compared with controls. Data 
were expressed as means ± SEM and compared via one-way ANOVA. n = 4 mice per group. * 
p<0.05; ** p<0.01; *** p<0.001 (relative to healthy controls). 
 
C.3. Lung-Infiltrated neutrophils acquire a novel chemokine receptor expression in a murine 
dual infection model. We gated circulatory and infiltrated pulmonary neutrophils based on their 
FSC/SSC characteristics and expression of Ly6G-1A8. This approach was able to differentiate 
neutrophils (FSCmedSSCmed-hiLy6G-1A8+) from other leukocytes present in the samples [Fig 3.1].  
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Figure 3.1: Selection of neutrophils using flow cytometry. FSCmedSSCmed-hiLy6G-1A8+ cells are 
over 99% neutrophils as confirmed through cell sorting using the FACSAria flow cytometer. 
 
We selected a wide variety of chemokine receptors to assess through flow cytometry (CCR1-3, 
CCR5, CXCR1-4) from day 3 through day 5 after influenza infection, based in part by their clinical 
potential and previous interest in other models [138]. In dual infection samples, S. pneumoniae 
was administered on day 3, hence the lack of variance between influenza-only and dual 
infection groups on day 3. Our results indicate that neutrophils acquire a novel chemokine 
receptor expression upon infiltration into the lungs after infection with both influenza and 
influenza with subsequent pneumococcal pneumonia.  
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Figure 3.2: CCR1-Receptor Expression is induced in infiltrative pulmonary neutrophils. Blood 
and bronchoalveolar lavage (BAL) fluid were collected from influenza-only, dual, and mock-
infected mice on days 3-5 post initial infection. Sample were analyzed via flow cytometry and % 
expression on neutrophils compared between groups. Neutrophils were gated as Ly6G-1A8+ 
cells for subsequent analysis. Column 1 shows dot plots for blood and BAL fluid neutrophil flow 
analysis, respectively, from 4 days’ post influenza infection. Column 2 shows comparisons in % 
of neutrophils expressing the indicated receptor in blood and BAL fluid samples from 5 days’ 
post influenza infection and demonstrates the overall trend in % expression of receptor on 
neutrophils in all samples from days 3 through 5 post influenza infection.  3.2: CCR1 is induced in 
infiltrative pulmonary neutrophils (compared to control blood), most notably on days 4-5 
(compared to day 3), but no differences are noted between influenza-only and dual-infected 
groups. Data are expressed as mean ± SEM and comparisons were made via one-way ANOVA 
and unpaired t-tests. n = 3 mice per group for all studies. * p<0.05; ** p<0.01; *** p<0.001; **** 
p<0.0001 
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Figure 3.3: CCR2-Receptor Expression is induced in infiltrative pulmonary neutrophils. CCR2 is 
induced in infiltrative pulmonary neutrophils (compared to control blood), most notably on days 
4-5 (compared to day 3), but no differences are noted between influenza-only and dual-infected 
groups. Data are expressed as mean ± SEM and were compared via one-way ANOVA and t-tests. 
n = 3 mice per group for all studies. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 
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Figure 3.4: CCR3-Receptor Expression is induced in infiltrative pulmonary neutrophils. CCR3 is 
induced in infiltrative pulmonary neutrophils (compared with control blood), with no significant 
changes in BAL neutrophils from days 3-5, and no significant differences between influenza-only 
and dual-infected groups. Data are expressed as mean ± SEM and comparisons made via one-
way ANOVA and t-tests. n = 3 mice per group for all studies. * p<0.05; ** p<0.01; *** p<0.001; 
**** p<0.0001. 
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Figure 3.5: CCR5-Receptor Expression is induced in infiltrative pulmonary neutrophils. CCR5 is 
induced in infiltrative pulmonary neutrophils (compared to healthy blood), most notably on days 
4-5 (compared to day 3), and a trend toward differences exists between influenza-only and dual-
infected groups.  Data are expressed as mean ± SEM and comparisons made via one-way 
ANOVA and t-tests. n = 3 mice per group for all studies. * p<0.05; ** p<0.01; *** p<0.001; **** 
p<0.0001 
 
Aside from CXCR2, chemokine receptor expression was minimal to absent in control, influenza-
only, or dual-infected blood samples [Figures 3, 4] with fewer than 10% of circulating 
neutrophils expressing these receptors. In comparison with circulatory neutrophils, our results 
show that infiltrated neutrophils in BAL fluid have a significant increase in chemokine receptor 
expression for all receptors analyzed other than CXCR2 [Figures 3, 4] with most resulting in 
about 30-40% expression on pulmonary neutrophils. The acquisition of this novel receptor 
expression is most notable on days 4 and 5 post influenza infection with significant increases in 
expression seen in CCR1, CCR2, CCR5, CXCR1, CXCR3, and CXCR4 by day 4 as compared with day 
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3 [Figures 3, 4]. CCR5 expression appears to be higher in dual-infected pulmonary neutrophils 
than in viral-only infected pulmonary neutrophils (p=0.0592) [Fig. 3.5], and a significant 
difference seen between viral and dual-infected pulmonary neutrophils with CXCR4 [Fig. 3.9].  
 
Figure 3.6: CXCR1-Receptor Expression is induced in infiltrative pulmonary neutrophils. Blood 
and bronchoalveolar lavage (BAL) fluid were collected from influenza-only, dual, and mock-
infected mice on days 3-5 post initial infection. Sample were analyzed via flow cytometry and % 
expression on neutrophils compared between groups. Neutrophils were gated as Ly6G-1A8+ 
cells for subsequent analysis. Column 1 shows dot plots for blood and BAL fluid neutrophil flow 
analysis, respectively, from 4 days post influenza infection. Column 2 shows comparisons in % of 
neutrophils expressing the indicated receptor in blood and BAL fluid samples from 5 days post 
influenza infection and demonstrates the overall trend in % expression of receptor on 
neutrophils in all samples from days 3 through 5 post influenza infection. CXCR1 is induced in 
infiltrative pulmonary neutrophils (compared to control blood), most notably on days 4-5 
(compared to day 3), but no differences are noted between influenza-only and dual-infected 
groups. Data are expressed as mean ± SEM and comparisons were made via one-way ANOVA 
and t-tests. n = 3 mice per group for all studies. * p<0.05; ** p<0.01; *** p<0.001; **** 
p<0.0001. 
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Figure 3.7: CXCR2-Receptor Expression is induced in infiltrative pulmonary neutrophils. CXCR2 
is reduced in infiltrative pulmonary neutrophils as compared with blood, but induced within the 
BAL between days 3-5 post infection, but no differences in % expression are noted between 
influenza-only and dual-infected groups on 5 DPI. Data are expressed as mean ± SEM and 
comparisons made via one-way ANOVA and t-tests. n = 3 mice per group for all studies. * 
p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
104 
 
 
Figure 3.8: CXCR3-Receptor Expression is induced in infiltrative pulmonary neutrophils. CXCR3 
is induced in infiltrative pulmonary neutrophils (compared with control blood), most notably on 
days 4-5, but no differences are noted between influenza-only and dual-infected groups. Data 
are expressed as mean ± SEM and comparisons made via one-way ANOVA and t-tests. n = 3 
mice per group for all studies. * p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001. 
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Figure 3.9: CXCR4-Receptor Expression is induced in infiltrative pulmonary neutrophils. CXCR4 
is induced in infiltrative pulmonary neutrophils (compared with control blood), most notably on 
days 4-5, and a significant difference exists between influenza-only and dual-infected BAL 
groups on day 5 post influenza infection. Data are expressed as mean ± SEM and comparisons 
made via one-way ANOVA and t-tests. n = 3 mice per group for all studies. * p<0.05; ** p<0.01; 
*** p<0.001; **** p<0.0001. 
 
These overall trends can be further visualized through Figure 3.10, 3.11, and 3.12 which show 
significant differences in pulmonary infiltrated neutrophils versus those in circulation from day 3 
through 5 post initial influenza infection. Although this induction is apparent from 3 days after 
influenza infection, it significantly increases after the third day and is maximally expressed on 
days 4 and 5 post initial influenza infection. Figure 5 also clearly shows that CXCR2 is highly 
expressed in both blood and BAL neutrophils under healthy conditions, and this chemokine 
receptor is the only one tested that has reduced expression upon infiltration into the infected 
lung. 
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Figures 3.10-3.12: Novel chemokine receptor expression apparent in influenza-only and dually 
infected PMNs – CXCR2 is especially highly expressed on infected neutrophils. Overall view of 
chemokine receptor expression comparing % expression with numbers of neutrophils expressing 
each receptor. Blood and bronchoalveolar lavage (BAL) fluid were collected from influenza-only, 
dual, and mock-infected mice on days 3-5 post initial infection. Samples were analyzed via flow 
cytometry and % expression on neutrophils compared between groups. Neutrophils were gated 
as Ly6G-1A8+ cells for all analysis. Since S. pneumoniae was administered on day 3, there is no 
difference between influenza-only and dual-infected groups on day 3. CXCR2 expression is 
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reduced on infiltrative pulmonary neutrophils, but remains high in all samples. Remaining 
receptors are minimally expressed in blood and significantly induced in infected BAL neutrophils. 
No significant differences are noted between influenza-only and dual-infected groups when 
comparing % neutrophils expressing receptor. Data are expressed as mean ± SEM. n = 3 mice 
per group for all studies. Statistical comparisons shown on previous figures. 
 
C.4. CXCR2 expression is induced in dual-infected mice. In contrast to other chemokine 
receptors analyzed in our study, our results indicate that CXCR2 is highly expressed in all 
circulating neutrophils with about 90% of neutrophils in healthy blood expressing CXCR2 and 97-
100% of neutrophils expressing CXCR2 in infected blood samples. Upon infiltration into areas of 
pulmonary inflammation, these neutrophils lose some CXCR2 expression, but the receptor 
remains highly expressed with over 75% of infiltrated pulmonary neutrophils expressing CXCR2 
[Fig. 3.7]. Despite the overall decrease in expression of CXCR2 upon pulmonary infiltration 
compared with circulatory neutrophils, expression is still induced in our dual infection model by 
day 5 as compared with day 3 [Figure 3.7]. This contrast between CXCR2 and other receptors 
analyzed can be especially visualized in Figure 3.10-3.12.  
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Figures 4.1-4.3: CXCR2 is induced in dual infection pneumonia. % neutrophils expressing a 
specified receptor was converted to quantity based on cell counts from BAL samples. After 
conversion, an overview is given comparing all receptors from 3-5 days after influenza infection. 
3 DPI is shown in 4.1. As clearly shown in % graphs, CXCR2 is significantly higher expressed than 
other chemokine receptors evaluated in this study. No dual comparison is provided since 
bacterial infection is administered on day 3 in our model. 4.2 and 4.3: A significant difference is 
seen in the numbers of pulmonary neutrophils expressing CXCR2 between influenza-only and 
dual-infected groups on days 4 and 5 post initial infection. Data are expressed as mean ± SEM 
and comparisons made via one-way ANOVA. n = 3 mice per group for all studies.  *** p<0.001. 
 
Since the BAL fluid cell counts are about 1.5 times higher in our dual infection model than they 
are in the influenza-only model, we used differences in BAL cell counts to convert these 
percentages to reflect numbers of neutrophils expressing each receptor type. After conversion 
from percentage to quantity, we clearly show a significant difference between the numbers of 
neutrophils expressing CXCR2 in our dual-infected versus our influenza-only infected models on 
day 5 post influenza infection [Figure 4]. 
 
C.5. Reduced CD16 and CD62L integrin expression in severely infected models. Various integrins 
present on neutrophils have been evaluated for their roles and prognostic potential in 
inflammatory models of disease. Two frequently assessed integrins are CD16 (Fc Gamma RIII) 
and CD62L (L-selectin). These integrins have been previously shown to be shed or expression 
decreased in several models including trauma, bacterial infection and viral pneumonia [190-
192]. 
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Figures 5.1 and 5.2: CD16 expression is reduced in more severe influenza-only and influenza 
coinfection. Blood and BAL were collected from mice 4 days’ post influenza infection for 
comparison. S. pneumoniae-only infected BAL is used as a model with minimal to no clinical 
disease for comparison. CD16 expression is significantly reduced in more severely affected 
models (influenza-only and dual-infected) as compared with S. pneumoniae-only and control 
samples in both circulatory [5.1] and pulmonary infiltrated PMNs [5.2]. Data are expressed as 
mean ± SEM and comparisons made via one-way ANOVA. n = 3-4 mice per group for all studies. 
* p<0.05; ** p<0.01 (relative to control blood or SP Only BAL). 
 
Integrin expression was evaluated 3-5 days’ post initial infection and results are shown from 4 
days’ post infection. Pulmonary infiltrative neutrophils from influenza and dual-infected mice 
have significantly reduced expression of CD16 when compared with bacterial-only infected mice 
[Fig. 5.1]. A significant difference was not seen in CD62L from the same samples [Fig. 5.3]. We 
show a significant reduction in both CD16 and CD62L expression in viral and dual-infected blood 
as compared with the less severe S. pneumoniae-only infected mice and healthy controls [Fig. 
5.2, 5.4]. 
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Figures 5.3 and 5.4: CD62L expression is reduced in circulatory PMNs in more severe disease. 
Blood and BAL were collected from mice 4 days’ post influenza infection for comparison. S. 
pneumoniae-only infected BAL is used as a model with minimal to no clinical disease for 
comparison. CD62L expression is significantly reduced in more severely affected (influenza-only 
and dual-infected) blood samples as compared with control [5.3], but no significant differences 
are noted in infiltrated pulmonary neutrophils between models [5.4]. Data are expressed as 
mean ± SEM. n = 3-4 mice per group for all studies. * p<0.05; ** p<0.01 (relative to control 
blood).   
 
C.6. Increases in CD11b Expression as a result of acute inflammation. CD11b is part of the Mac-
1 heterodimer that plays an active role in neutrophil recruitment and adhesion [200]. CD11b is 
also known as a potential prognostic indicator and marker for acute inflammation due to its role 
in neutrophil activation [201, 202]. CD11b was measured in control and infected blood samples 
as well as infected BAL fluid samples.  There was no significant difference noted between 
control and infected blood [Fig. 6.1]. In addition, no difference was noted between CD11b 
expression of infiltrative pulmonary neutrophils in viral-infection alone and coinfection models. 
Although no significant differences were seen within blood and BAL samples, a significant 
increase in expression of CD11b was noted in infiltrative neutrophils from BAL collection over 
neutrophils in circulation [Fig. 6.1]. 
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Figure 6.1: CD11b expression is enhanced in more severe disease. Blood and BAL were collected 
from mice 4 days’ post influenza infection for comparison. S. pneumoniae-only infected BAL is 
used as a model with minimal to no clinical disease for comparison. CD11b is significantly 
increase in influenza and dual-infected BAL as compared with all blood samples. Data are 
expressed as mean ± SEM and comparisons made via one-way ANOVA. n = 3-4 mice per group 
for all studies. * p<0.05; ** p<0.01 (relative to control blood).  
 
C.7. Effects of induced chemokine receptors on neutrophil functional responsiveness. In order 
to further assess chemokine receptor function in dual infection pneumonia, we selected six 
receptors (CCR1, CCR3, CCR5, CXCR2, CXCR3 and CXCR4) to perform functional studies based on 
their presence in BAL collected neutrophils and previously reported therapeutic potential in 
other models of inflammatory and chronic disease. CCR2 was not included due to its primary 
role and expression on macrophages. CXCR1 was not included due to differences in mouse 
versus human CXCR1 receptors and ligands. Functional properties evaluated include reactive 
oxygen species production and phagocytosis capacity.  
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Figures 7.1 and 7.2: Blocking specific chemokine receptors affects functional potential of the 
neutrophil. Infected BAL and blood were collected from mice. Reactive oxygen species (ROS) 
production was assessed using DCFH-DA ROS flow cytometric assays and phagocytosis was 
measured using pHrodo E. coli BioParticles and flow cytometry. 7.1: A trend (p=0.0742) toward 
increased ROS production in dual-infected pulmonary infiltrative neutrophils is seen as 
compared with influenza-only infected PMNs. 7.2: In an influenza infected model, there was a 
significant difference noted in ROS production between circulatory and pulmonary PMNs, with 
significantly more ROS production within the infected BAL PMNs. Data are expressed as mean ± 
SEM and comparisons made via paired t-test. n = 3 mice per group for 7.1 and n=9 mice per 
group for 7.2. Two mice were pooled per sample. ****p<0.0001 relative to circulatory 
neutrophils. 
 
C.7a. Reactive oxygen species (ROS) production assay. ROS effect of chemokine receptor 
expressions on ROS generation was first evaluated between influenza-only and dual-infected 
mice and was measured using a DCFHda flow cytometric assay on recently collected BAL 
neutrophils. Significant production was measured in all infected samples with a trend toward 
greater ROS production in dual infected BAL neutrophils over influenza-only infected samples, 
but no significant difference was noted between the groups [Figure 7.1]. Since the chemokine 
receptor expressions were showing similar pattern between influenza and dual-infected mice, 
we chose to evaluate the effects of these chemokine receptors expression on ROS generation. 
An influenza-only infected mouse model was then used for further ROS production studies as 
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expression of all chemokine receptors were comparable between primary influenza and S. 
pneumoniae superinfection. Blood and BAL were collected from infected mice 3 days after viral 
infection and neutrophils were isolated. Neutrophils collected from the infected BAL had 
significantly higher ROS production than those in the blood [Fig. 7.2].  
 
Figures 7.3 and 7.4: Blocking specific chemokine receptors affects functional potential of the 
neutrophil. Infected BAL and blood were collected from mice. Reactive oxygen species (ROS) 
production was assessed using DCFH-DA ROS flow cytometric assays and phagocytosis was 
measured using pHrodo E. coli BioParticles and flow cytometry. Data was compared as relative 
function of neutrophils with receptor blocked as compared with no blocking (x:1) 7.3: Blocking 
CCR1 significantly reduced ROS function for neutrophils within the BAL. Blocking CCR3, CCR5, 
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CXCR2, CXCR3, and CXCR4 had no significant effect. 7.4: For circulating neutrophils, blocking 
CCR5 and CXCR2 significantly enhanced production. Blocking CCR1, CCR3, CXCR3, or CXCR4 had 
no significant effect on ROS production. Data are expressed as mean ± SEM and comparisons 
made via paired t-test. n = 3 mice per group for all studies. *p<0.05; **** p<0.0001. Two mice 
were pooled per sample. 
 
Isolated neutrophils were also incubated in the presence or absence of CCR1, CCR3, CCR5, 
CXCR2, CXCR3 and CXCR4 blocking antibodies to assess changes in function. Our results indicate 
that blocking CCR1 significantly reduces ROS function in lung-infiltrated neutrophils [Figure 7.3]. 
In contrast, blocking CCR5 and CXCR2 in the circulating neutrophils significantly enhanced ROS 
production [Figure 7.4]. No other significant differences were noted in blocking the remaining 
receptors.  
 
Figures 7.5 and 7.6: Blocking specific chemokine receptors affects functional potential of the 
neutrophil. Infected BAL and blood were collected from mice. Phagocytosis was measured using 
pHrodo E. coli BioParticles and flow cytometry. Data was compared as relative function of 
neutrophils with receptor blocked as compared with no blocking (x:1).  7.5: Pulmonary 
neutrophils had reduced phagocytic capacity when compared with those in circulation. 7.6: 
Blocking CXCR2 reduced phagocytic capacity of circulatory neutrophils in a viral-infection model. 
Data are expressed as mean ± SEM and comparisons made via paired t-test. n = 3 mice per 
group for all studies. **** p<0.0001. Two mice were pooled per sample. 
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C.7b. Phagocytic activity. We measured phagocytosis capacity using pHrodoTM E.coli BioParticles 
on isolated neutrophils from viral-infected mice under a variety of conditions. Phagocytosis 
function is significantly reduced in neutrophils collected from infected BAL as compared with 
those from infected blood [Fig. 7.5]. Isolated neutrophils from blood were also incubated in the 
presence or absence of CXCR2 blocking antibodies. Blocking CXCR2 significantly reduced 
phagocytosis function in the blood [Fig. 7.6]. Isolated neutrophils from infected BAL were also 
incubated with CCR1, CCR3, CCR5, CXCR2, CXCR3, and CXCR4 blocking antibodies in the 
presence of their appropriate ligand to assess for receptor roles in phagocytic functions. 
Interestingly, blocking CCR5 and CXCR2 significantly reduces phagocytosis capacity of the 
pulmonary infiltrative neutrophil, while no significant effect was seen when blocking the 
remaining receptors [Fig. 7.7].  
 
Figure 7.7: Blocking CCR5 and CXCR2 significantly reduce phagocytic capacity of pulmonary 
infiltrated neutrophils. Infected BAL and blood were collected from mice. Phagocytosis was 
measured using pHrodo E. coli BioParticles and flow cytometry. Data was compared as relative 
function of neutrophils with receptor blocked as compared with no blocking (x:1).  Blocking CCR5 
and CXCR2 reduced phagocytic capacity of pulmonary infiltrative neutrophils in a viral-infection 
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model while no change was noted with blocking CXCR3. In addition, a reduction in phagocytic 
capacity was also seen when blocking CXCR2 in circulatory neutrophils which also have high 
levels of this receptor. Circulatory neutrophils without blocking were also performed to further 
compare blood to BAL neutrophils in other groups. Data are expressed as mean ± SEM and 
comparisons made via paired t-test. n = 3 mice per group for all studies. *** p<0.001; **** 
p<0.0001. Two mice were pooled per sample. 
 
Discussion 
One of the primary goals of this study is to characterize the changes seen in chemokine 
receptor expression, and identify the availability key receptors that may act as important targets 
with therapeutic potential. As seen in our results, the influenza-only infected and dual infected 
mice lose significant weight and show rapid and severe progression of clinical scores between 
days 3 and 5. Those mice given only S. pneumoniae showed mild weight loss without any 
obvious clinical signs and recovered shortly after infection. The viral-infected mice that are 
administered the subsequent pneumococcal infection decline rapidly and become bacteremic 
within 48-60 hours after bacterial administration, reaching their endpoint by day 6. 
Histopathology of pulmonary tissue from these infected mice showed pathologic lesions of 
ARDS with severe pulmonary damage, alveolitis and endothelial necrosis. Widespread disruption 
of alveolar epithelial-endothelial barrier was more prominently seen in dual-infected mice and 
this could cause exposure of basement membrane.  The exposure could facilitate bacterial 
adherence and dissemination into deeper lungs. In support of this, we found increased bacterial 
load, dissemination into deeper lungs and bacteremia within 48 hours after S. pneumoniae 
superinfection, while mice infected with bacteria-alone clear the bacteria within 24 hours. This 
model will serve as a good representation for pathogenic progression and severity that can be 
seen with pandemic influenza outbreaks wherein bacterial superinfections are involved. Due to 
complexity of the coinfections that can occur in nature, we had tested various coinfection 
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models as described in Chapter 2 and based on our analysis, we chose sublethal influenza 
followed by sublethal S. pneumoniae to explore the role of neutrophils.  
Previous studies from our laboratory and other investigators have demonstrated 
pathogenic role of neutrophils in bacterial superinfection following influenza [18]. Although 
neutrophils are essential in bacterial clearance, accumulated evidences indicate pathogenic 
contribution of excessive neutrophils recruited during bacterial superinfection. Interestingly, 
chronic inflammatory disease conditions have shown altered neutrophil phenotypic signature, 
which potentially influence their functional responsiveness [138]. It is not known whether 
neutrophils display any change in phenotypic changes or functional responsiveness during acute 
influenza pneumonia or bacterial superinfections. Hence, this study aimed to fill this critical void 
by characterizing neutrophils during primary influenza and S. pneumoniae superinfection for 
their phenotypic signature by evaluating chemokine receptors (CRs) expressions and their 
functional responsiveness. We evaluated CC and CXC CRs and integrins in circulating as well as in 
lung-recruited neutrophils.  Because healthy Balb/c lab mice contain extremely low numbers of 
neutrophils in their lung alveolar air spaces, it is difficult to draw comparisons using control mice 
to the healthy uninfected human population. Hence, we compared bacterial-only infected mice, 
which display minimum neutrophil influx without clinical signs. Our results clearly demonstrate a 
large influx of neutrophils in dual-infected mice and also influenza-alone infected mice 
compared to bacteria-only infected group that is most drastic at 5 dpi. This can be clearly seen 
both in our flow results and in cell counts. This neutrophil influx was found to be more 
prominent in dual infected samples with overall BAL fluid cell counts being over 1.5 times higher 
in dual infected samples at 5 dpi than in influenza-only infected samples. 
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Our data has shown that CXCR2 is a most predominant chemokine receptor expressed in 
circulating neutrophils. Neutrophils were positively identified by Ly6G positive expression and 
the total percent of CXCR2 positive cells were significantly increased in circulation in both 
primary influenza and secondary S. pneumoniae superinfection. Interestingly, all CC chemokine 
receptors were minimally expressed in circulating neutrophils in controls as well as infected 
mice. These findings suggest that CXCR2 is most critical chemokine receptor involved in 
neutrophil recruitment in response to these infections. In support of this, our recent findings 
demonstrated significant increase in CXCR2 ligand, mouse KC, levels in blood and BAL samples 
from influenza infected mice [83, 203].  
On the other hand, CXCR2 has a slight decrease in percentage of neutrophils expressing 
in the BAL compared with peripheral blood. This finding is supported by previous studies 
evaluating receptor expression in chronic inflammation [204]. CXCR2 has been shown to be 
suppressed by TNF-α previously with a suggestion that this allows for a modulation in the IL-8 
response so that neutrophils can be retained in the vascular space and also have enhanced 
production of reactive oxygen species [205]. CXCR2 is highly expressed in infected blood with 
almost all neutrophils present having the receptor. Despite this relative downregulation, CXCR2 
is the majorly expressed chemokine receptor found in lung-recruited neutrophils. Targeting 
CXCR2 has been shown to ameliorate lung injury in sublethal infected-infected mice [206]. Our 
recent study demonstrated that a combination of a CXCR2 antagonist together with antiviral 
agent confers high protection against lethal-influenza challenge in mice [83] thus suggesting a 
potential pathogenic role of CXCR2 induction during influenza. Another critical finding from our 
studies is that influenza and S. pneumoniae superinfection, triggers induction of CC chemokine 
receptors (CCR1, CCR2, CCR3, CCR4 and CCR5) in lung-recruited neutrophils. Expression of these 
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CC chemokine receptors were minimally expressed in circulating neutrophils from control as 
well as infected mice. 
Antagonism of CCR1, CCR2, and CCR3 receptors was shown to have a protective effect – 
when a CCR2b and CCR1 antagonist was used, decreases in fibrinolysis, vascular leakage and 
inflammatory gene expression were all noted. These findings were further supported in CCR1, 
CCR2, and CCR3 knockout mice which had less pulmonary edema, infiltration and overall disease 
as compared with controls with ALI [145]. CCR1 antagonism also has shown promise in limiting 
pulmonary injury resulting from acute pancreatitis [140] and sepsis [141] as well as in a renal 
ischemia model [139].  
In addition, we also found increased CXCR3 and CXCR4 expressions in the lung-recruited 
neutrophils. CXCR3 has also been further evaluated for its role in ARDS with its ligand CXCL10. 
Ichikawa et al. evaluated both a viral and non-viral ARDS mouse model in mice deficient in 
CXCL10 and CXCR3 and found that mice lacking CXCL10 and CXCR3 had improved severity of 
disease and survival in both models [151]. Antagonism of CXCR3 has also been shown to reduce 
disease severity in an H5N1-infected ferret model [147]. Therefore, this receptor poses another 
intriguing potential target for therapeutics in coinfections. CXCL12 and its receptor, CXCR4, also 
appear to play a role in promoting chemotaxis of neutrophils as well as suppressing cell death. 
In a study looking at lipopolysaccharide (LPS)-induced lung injury, CXCL12 was shown to be a 
chemoattractant for cells expressing CXCR4 as well as a suppressant of neutrophil cell death and 
CXCR4 was found to be increased on the neutrophil cell surface after migrating from circulation 
into the inflamed lungs, possibly via an L-selectin mediated pathway [154]. CXCR4 has been 
further described as acting antagonistically with against CXCR2 – CXCR4 expression promotes 
neutrophil retention in the bone marrow, whereas CXCR2 expression drives release [158]. 
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Finally, CCL2 (ligand for CCR1/2) and CCL7 (ligand for CCR1-3, 5) are also chemokines that may 
play an interesting part in ARDS – in a study performed by Mercer et al, antibody neutralization 
of these ligands significantly reduced neutrophil accumulation in the BAL fluid in mice with LPS-
induced lung injury [146]. Although the full potential of these receptors as therapeutic targets in 
pneumonia must still be explored, this study shows availability of each of these receptors in dual 
infection pneumonia and recommends further studies to elucidate their potential.  
Various integrins have been used to characterize neutrophils in addition to their forward 
and side scatter properties. We found that the expression of integrins, including CD16 and 
CD62L, decreased in circulating neutrophils isolated from both primary influenza and S. 
pneumoniae superinfection compared to the S. pneumoniae alone infected animal group. CD16 
expression was reduced on both circulating and lung-recruited neutrophils. Expression of CD62 
was decreased in both circulating as well as in pulmonary infiltrative neutrophils. CD16, also 
known as FcγRIII, is a cell surface molecule that is expressed on several cell types including 
neutrophils, macrophages and natural killer cells, and has been shown to have reduced 
expression in many inflammatory conditions such as vaginitis, trauma, bacterial infection and 
viral pneumonia [190-192]. It has also been suggested that the decreased CD16 expression seen 
with acute inflammation could be due to the influx on immature neutrophils which are CD16dim 
[189]. CD62L, also known as L-selectin, mediates neutrophil rolling and adhesion to the 
endothelial cells. This receptor is shed when stimulated by pro-inflammatory cytokines such as 
TNF-α in acute inflammatory insults such as with trauma [191, 193] and uremia [194]. CD11b is a 
frequently assessed integrin in models of acute inflammation and is a β2-integrin adhesion 
molecule that is part of the Mac-1 heterodimer, and is a major player in neutrophil recruitment 
and adhesion [190, 191, 193]. In contrast to CD62L, most studies have shown that CD11b 
significantly increases in cases of acute inflammation, corresponding to increased neutrophil 
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activation [190, 191, 193, 195]. Models of acute inflammation such as bacterial pneumonia 
(primary or secondary), viral pneumonia, trauma or burns all seem to shed CD62L and reduce 
CD16 expression while increasing expression of CD11b. Our results indicate that there is a 
significant increase in CD11b expression on infiltrative pulmonary neutrophils over those 
neutrophils identified in circulation, as seen by comparing mean fluorescence intensity between 
the two groups. Not only does this imply a heightened level of neutrophil activation from the 
neutrophils within the lavage, but CD11b also presents itself as an interesting target with high 
availability to block neutrophil recruitment and activation. CD11b has been shown to be a 
necessary component for successful diapedesis of neutrophils from the pulmonary 
microvasculature to the alveoli spaces in a LPS-induced model of acute pulmonary inflammation 
[200]. In addition, blocking CD11b has been shown to have significant effect in controlling the 
early inflammatory response by reducing neutrophil numbers in both the BAL fluid and lung 
tissue in an LPS-induced model of pulmonary inflammation [207]. Therefore, CD11b blockade 
may present an interesting and novel approach to treating dual infection pneumonia and 
improving clinical outcome for ARDS. 
Reactive oxygen species have long been shown to be important contributors to the 
endothelial damage seen in models of ARDS, sepsis and pneumonia. These ROS are released by 
neutrophils after being sequestered and activated in the pulmonary vasculature and are key 
substances in modulating pulmonary endothelial damage [208]. Production of reactive oxygen 
species from neutrophils collected in infected BAL fluid is significant, as expected, and our 
results also suggest a trend toward increased ROS production in dual-infected BAL versus that 
infected with influenza alone. Our results also concluded that ROS production was significantly 
enhanced with neutrophils from within the BAL versus those in circulation. Since the effect of 
ROS on the endothelium has been well-established, it would be logical to believe that these 
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toxic products are contributing to the severe histopathologic changes seen in the lungs of dual-
infected mice and potentially to bacterial dissemination as well. Further, to determine the role 
of induced chemokine receptors on ROS generation, we incubated neutrophils isolated from 
influenza infected mice with receptor specific ligands in the presence or absence of antagonists 
or antibodies to the receptors.  Our data show that blocking CCR1 in the lung-infiltrated 
neutrophils results in a reduction in ROS production. In addition, blocking CCR1 in the circulating 
neutrophils also trends to a decrease in ROS production. In contrast to CCR1, our data show that 
blockade of CCR5 and CXCR2 results in enhanced ROS production from circulating neutrophils. 
CCR3, CXCR3 and CXCR4 blockage had no effect on ROS production in either infected blood or 
BAL neutrophils. Due to the excessive neutrophil-mediated damage already noted [55, 83, 186], 
this should be taken into consideration when designing therapeutics. Our studies indicate a 
different result with phagocytosis capacity. Pulmonary infiltrative neutrophils have significantly 
reduced phagocytic ability as compared with those in circulation and blockade of CCR5 and 
CXCR2 in BAL and CXCR2 in blood further weakened the phagocytic ability of the cell. Reduced 
neutrophil function can contribute to the likelihood of severe co-infections and should also be 
considered when evaluating potential for antagonists in clinical disease. 
There are several challenges and limitations of using an animal model for ARDS including 
the host-specific differences in chemokines, their receptors and the roles these play in the 
disease pathogenesis. One such difference is that CXCL8 does not exist in the rodent model, 
although homologues do exist as CXCL1 (KC) and CXCL2 (MIP-2). It is also unclear whether the 
mouse analog for CXCR1 is functional in the same way as human CXCR1 as it seems to be 
activated in different ways and does not seem to play the same central role in the pathogenesis 
of ARDS that it does in humans [137]. The application of studying CXCR1 in an animal model to 
evaluate human disease is still in question and needs further investigation. In addition to 
124 
 
challenges common to animal models, this study is merely a partial characterization of the 
neutrophil during dual infection. Chemokine receptors, integrins, and functional studies were 
selected based on clinical therapeutic potential and previous studies. In particular, a more 
complete analysis of the functional impact of each receptor should be evaluated in this model. 
CCR1, CCR3, CCR5, CXCR2, CXCR3, and CXCR4 were chosen for initial analysis due to a variety of 
reasons. CXCR2 is highly expressed during infection and is a readily available target being 
analyzed in a variety of models. CXCR3 and CCR5 were also consistently induced after infiltration 
to sites of pulmonary infection and also show therapeutic potential in other models of disease 
that make these readily available antagonists to be tested in future trials. CCR2 is primarily 
involved in macrophage function and so was excluded. CXCR1 was also excluded due to limited 
functional role in murine models due to homology concerns with human CXCR1. Work should 
continue to gain a more complete picture of the neutrophil during dual infection. 
 In conclusion, our study revealed several novel findings. Firstly, we found that 
neutrophils acquire new phenotypic characteristics after they recruit into the lungs during acute 
influenza infection and also S. pneumoniae superinfection. Expression of CC chemokine 
receptors (CCR1, CCR2, CCR3, and CCR5) and CXC chemokine receptors (CXCR3, and CXCR4) 
were induced in lung-recruited neutrophils in primary influenza and S. pneumoniae 
superinfection compared to S. pneumoniae alone infected animal groups. Secondly, CXCR2 is the 
most predominant chemokine receptor expressed in both circulating as well as lung-recruited 
neutrophils compared to S. pneumoniae infected animals. Thirdly, these findings also 
demonstrate significant decrease in integrins expression on neutrophils during infection. Our 
findings also demonstrate that induced chemokine receptors including CCR5 and CXCR2 
significantly influence neutrophil functional responsiveness including phagocytic activities and 
respiratory burst. Our recent studies have demonstrated that stimulation of CXCR2 with IL-8 
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significantly induce NETs, which can potentially contribute to the acute lung injury. Overall, 
identifying induction of novel chemokine receptor expressions on neutrophils helps in not only 
understanding their pathogenic role in influenza as well as S. pneumoniae superinfection but 
also opens a new avenue to develop novel therapeutic strategies in alleviating lung 
pathogenesis during primary influenza as well as S. pneumoniae superinfection.   
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CHAPTER IV 
 
 
THE THERAPEUTIC POTENTIAL OF SCH527123, A CXCR1/2 ANTAGONIST, IN A 
MURINE MODEL OF DUAL INFECTION PNEUMONIA 
 
A. Introduction  
Our work to identify availability and functional properties of chemokine receptors 
achieves relevance through their clinical application in the dual infection model. As previously 
outlined, influenza coinfection is complex, and a lethally synergistic response is clear when 
bacterial, viral and host influences are all considered. The immune system’s response to 
infection is well documented to further aggravate injury and breakdown epithelial and 
endothelial barrier integrity within the pulmonary tissue, resulting in increased chances of 
bacteremia and worsened disease. Due to the complexity of coinfections, a simple targeted 
monotherapy is insufficient to treat such cases [109]. In addition, resistance to antivirals and 
antibiotics further insists on a combined approach to treatment. Combinations of antibiotics, 
and effective antiviral, and therapies that target the immune response are considered more 
optimal approach to treating these infections.  
Antibiotic therapy is a mainstay for treatment of any pneumococcal pneumonia, whether 
community acquired, healthcare-associated, or seen as secondary to viral infection. Three main 
classes of antibiotics have been more thoroughly considered in treatment of these infections:  
127 
 
β-lactams, macrolides, and fluoroquinolones. β-lactams – such as penicillin, cephalosporins and 
ampicillin – are broad spectrum and widely used drugs that inhibit cell wall synthesis in the 
bacteria by preventing the final cross-linking in the peptidoglycan layer. The result is a 
bacteriocidal effect. Historically, this class is the most commonly used for pneumococcal 
pneumonia, but a shift in the last couple of decades is pushing for other classes in combination 
or instead of β-lactams. Studies have shown significant resistance to penicillin in pneumococcal 
strains – one study revealed that in the United States, 34% of pneumococcal strains are 
penicillin non-susceptible with over 18% fully resistant [209]. In addition to resistance profiles, 
β-lactams such as ampicillin are not as effective as other classes either. In another model of 
secondary bacterial infection to influenza pneumonia, ampicillin only resulted in 56% survival, 
while azithromycin was at 92% survival with improved inflammation and less severe 
histopathology [112]. 
Macrolides (such as azithromycin, clarithromycin, and erythromycin) act by reversibly 
binding to the 50S subunit in ribosomes and therefore, preventing bacterial protein synthesis. 
The effects are bacteriostatic. Macrolides have been shown to not affect granule mobilization, 
but inhibit O2- generation from neutrophils selectively, which may contribute to their effects 
[210]. One approach considered is to use macrolides in combination with β-lactams for 
treatment in influenza coinfections and other forms of pneumococcal pneumonia. An 
ampicillin/azithromycin treatment effectively reduced inflammation, improved bacterial 
clearance, decreased inflammatory cytokines such as TNF-α, IFN-γ and IL-6, reduced damaging 
myeloperoxidase, improved permeability, and decreased overall inflammatory cell recruitment 
in pneumococcal pneumonia [113]. Combination therapy of amoxicillin and clarithromycin in 
community-acquired pneumonia is more effective than either monotherapy [211]. In addition, 
the dosing regimen may also be influential to clinical outcome – pulsatile therapy, such as giving 
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an antibiotic every two hours for the first 6 hours of each day, results in improved outcome as 
compared with more standard dosing regimens such as every 12 hours [211]. Using mutant 
prevention concentration as a novel approach to evaluate drug-bacterial interactions for 
resistance, several studies have more thoroughly detailed resistance patterns between 
macrolides [212]. Interestingly, azithromycin is shown to be more likely to develop resistance 
than other macrolides, in particular clarithromycin [212-214]. Concerns regarding adverse 
effects of macrolides, in particular azithromycin are also to be considered. Some suggest that 
the cardiotoxicity seen with azithromycin usage in healthcare-associated pneumonia outweighs 
the benefits of the drug, making azithromycin usage contraindicated in this particular form of 
pneumonia [215]. 
Fluoroquinolones (most ending in –floxacin) are bacteriocidal drugs which prevent 
bacterial DNA from unwinding and replicating. Flouroquinolone resistance has also been shown 
to be on the rise, as opposed to most other classes which are starting to decline [209]. There is 
also some question as to the effectiveness of fluoroquinolones as compared with macrolides. In 
a murine bacterial rhinosinusitis model, moxifloxacin had a limited effect while azithromycin 
rapidly cleared the bacteria and reduced inflammation [114]. However, it is unclear if these 
differences would be apparent in a human host. Fluoroquinolones may become especially 
essential to treatment of otherwise resistant pneumococcal pneumonia. A combination therapy 
including levofloxacin and ceftriaxone shows promise in such cases by downregulating 
inflammation, improving clearance of the bacteria, and, additionally, downregulating expression 
of two key pneumococcal virulence factors – pneumolysin and autolysin [111]. Outside of these 
classes of antibiotics, there are several other therapeutics targeting bacterial virulence factors. 
For example, artocarpin, a bacterial neuraminidase inhibitor, shows promise in future therapies 
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by providing bactericidal effects without harming pulmonary epithelial cells in pneumococcal 
pneumonia [108]. 
Antivirals are a mainstay of treatment for any influenza pneumonia. Oseltamivir is the 
primary antiviral used at this current time to combat influenza outbreaks. Oseltamivir an oral 
antiviral that is a neuraminidase inhibitor acting on both influenzas A and B, the primary causes 
of seasonal influenza outbreaks. Although most agree that oseltamivir improves clinical 
outcome, the evidence is controversial. A fairly recent, and controversial, report indicated that 
oseltamivir did not reduce hospitalizations or severe complications associated with influenza, 
but these findings and the benefits of oseltamivir continue to be debated today [216]. 
Combination of antivirals with antibiotics are especially important during influenza pandemics 
and in high risk individuals. A study performed in human volunteers with confirmed influenza A 
and no comorbid pneumonia showed that combination therapy of oseltamivir and azithromycin 
resulted in earlier resolution of clinical disease [217]. Many are looking for alternatives to 
oseltamivir and inhaled zanamivir due to increasing concern for resistance to this medication 
[106]. Peramivir is another neuraminidase inhibitor that reduced mortality in coinfected mice 
better than oseltamivir by inhibiting viral replication resulting in improved bacterial clearance 
and survival [107]. Although oseltamivir has shown effectiveness to both viral and bacterial 
neuraminidase, peramivir only seems to inhibit viral neuraminidase, and must be administered 
intravenously [107, 108]. Historically, amantadine and rimantadine have been used as antiviral 
therapy, but these medications are only effective toward influenza A, not B, and have significant 
(>99%) resistance recorded for several strains of Influenza A, including circulating H3N2 and the 
2009 H1N1. For these obvious reasons, these medications are no longer recommended for use 
as antiviral therapy. There is increasing concern that similar resistance could develop with 
neuraminidase inhibitors, although levels of resistance this severe have yet to be documented.  
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The importance of controlling both the bacterial infections and host responses to those 
infection is clear. In a dual infection model, a clear link can be seen between severe pulmonary 
neutrophilia with resultant immunopathology and poor clinical outcome [42]. If neutrophils are 
depleted, the immunopathology is improved, but clinical outcome remains unchanged; on the 
other hand, if only azithromycin is used to treat the infection, we see improved outcome and 
bacterial clearance, but no improvement in immunopathology [42]. These findings support a 
combined approach. CXCR2 antagonists are currently showing the most promise in treatment of 
both chronic and acute inflammatory diseases, especially disease such as Chronic Obstructive 
Pulmonary Disorder (COPD) [218-221]. Under healthy, basal conditions, less than 2% of the 
neutrophil pool is in circulation at any one time [222]. CXCR2 activation releases mature 
neutrophils from the bone marrow as an innate response to inflammation, which is 
counteracted by CXCL12 activation of CXCR4, which retains neutrophils in the bone marrow 
[158]. There are several potent CXCR1/2 and CXCR2 selective antagonists on the market or in 
trials at this time. AZD5069, a selective CXCR2 antagonist, shows good potential as a drug in 
COPD models and human trials [220, 223, 224]. MK-7123 is another currently being tested in 
models of COPD [218]. Another well studied antagonist is Sch527123, a dual CXCR1/2 
antagonist. The full name is 2-hydroxy-N,N-dimethyl-3- [[2-[[1(R)-(5-methyl-2-
furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl] amino] benzamide [225]. First characterized 
in 2006 [225], this therapeutic has been shown to have good oral availability and acts as an 
allosteric antagonist binding both receptors, but having a preference for CXCR2 [161]. These 
pharmacological properties have also been thoroughly evaluated in a murine, rat and non-
human primate model [160]. Sch527123 binds with high affinity in mice (Kd = 0.20 nM) and is a 
potent antagonist of CXCR2-mediated chemotaxis (IC50 ~ 3-6 nM) [160]. When evaluated in 
COPD, Sch527123 effectively decreased neutrophil chemotaxis, while dexamethasone did not 
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[221]. In addition, Sch527123 has been shown to block pulmonary neutrophilia in an LPS-
induced murine model for pneumonia with an ED50 of 1.2 mg/kg [160]. There may be some 
benefit to using a CXCR1/2 antagonist. Although CXCR1 and CXCR2 may appear functionally 
redundant in their effects, this really isn’t true. Very different outcomes are derived from their 
activation and CXCR1 has a wider range of antimicrobial effects than CXCR2 activation [226]. As 
a dual CXCR1/2 antagonist, Sch527123 more effectively reduces neutrophil migration and 
activation than the selective CXCR2 antagonist, SB265610 [227]. 
After establishing an influenza coinfection model with significant neutrophil influx and 
resultant immunopathology and identifying availability of chemokine receptor targets, we 
selected a combination therapy including oseltamivir, clarithromycin and Sch527123 to test in 
this model. I hypothesized that a CXCR2 antagonist would reduce neutrophil recruitment to the 
lungs, and when used in combination with antiviral and antibiotic therapy, reduce 
immunopathology and improve clinical outcome. 
B. Materials and Methods: 
Pathogens 
Influenza A/Puerto Rico/8/34, H1N1 (PR/8) virus was obtained from the American Type 
Culture Collection (ATCC, VA). Viral titers were determined by tissue culture infectivity dose 
(TCID50) assay via infection of Madin-Darcy canine kidney (MDCK) cells. Streptococcus 
pneumoniae (serotype 3) was also obtained from the ATCC. Bacterial growth curves were 
established prior to infection. All pathogens were stored at -80°C until use. 
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Animals and Murine Model 
Female Balb/c mice (6-8 weeks old) were purchased from the Jackson Laboratories. 
Mice were group-housed in microisolator cages in a BSL-2 facility, and were provided with food 
and fresh water ad libitum. Mice were clinically scored based on a modified version of the 
“mouse clinical assessment scoring for sepsis” (M-CASS) [172].  Infection was performed under a 
mixture of xylazine (0.1 mg/kg) and ketamine (7.5 mg/kg) anesthetic via intraperitoneal 
injection. Mice were infected intranasally (IN) with a sublethal dose of 100 TCID50 PR/8 (H1N1) 
influenza in a 50 μl volume or given an equal volume of sterile phosphate-buffered saline in 
controls. For dual infection studies, mice were administered 200 colony forming units (CFU) of S. 
pneumoniae IN in 50 μl volumes 72 hours after initial influenza infection, or administered PBS IN 
for controls. Mice were monitored closely for weight loss and clinical signs based on a modified 
“mouse clinical assessment score for sepsis” [see supplemental figure 1] [172, 173]. All animal 
experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of 
Oklahoma State University and were performed in strict accordance with their 
recommendations. 
 
Therapeutic Model 
Mice were treated with combinations of the following three drugs: oseltamivir 
phosphate, clarithromycin, and SCH527123. Oseltamivir 75 mg phosphate capsules (Alvogen) 
were stored at room temperature. Before use, the capsules were emptied and powder weighed 
for the appropriate amount. 75 mg of drug were present in 160 mg of total weight powder. The 
powder was then redistributed in phosphate-buffered saline to the appropriate volume. 
Clarithromycin 500 mg tablets (Citron Pharma L) were crushed with mortar and pestle and 
coating removed. The powder was also measured (500 mg drug per 780 mg total powder 
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weight) for the appropriate dosages and redistributed in PBS to be delivered in set volumes of 
100 µL per mouse. SCH5271213 was dissolved in dimethyl sulfoxide (DMSO) at 50 mg/500 µL 
and stored at -20°C. Before use, the appropriate volume of SCH527123 was dissolved in 0.4% 
methyl cellulose to be administered. All drugs were administered via gastric lavage.  
For survival studies, mice were infected intranasally (IN) with a sublethal dose of 100 
TCID50 PR/8 (H1N1) influenza in a 50 μl volume and then were administered 200 colony forming 
units (CFU) of S. pneumoniae IN in 50 μl volumes 72 hours after initial influenza infection. All 
combinations of therapeutics were tested. Depending on the particular experiment, oseltamivir 
phosphate was administered at 10-20 mg/kg every 24 hours for 3 doses starting on day 3 post 
influenza infection. Clarithromycin was administered at either 40, 50 or 100 mg/kg every 24 
hours for 3-7 doses beginning on day 3 post influenza infection. SCH527123 was administered at 
3 mg/kg every 24 hours for 3 doses beginning on day 3 post initial infection. All mice were 
monitored for weight loss and clinical score as per our approved guidelines. 
 
Whole blood, bronchoalveolar lavage (BAL) fluid, and tissue collection 
For BAL fluid collection, the lungs were washed by intratracheal administration of 1.0 
mL of sterile PBS in two 0.5 mL increments [55]. The recovery of BAL fluid was more than 85% 
for all animals. The BAL fluids were centrifuged at 200 xg for 10 minutes, and reconstituted in 
sterile PBS for cell counts and with 2% fetal bovine serum in PBS for flow cytometry analysis. 
BAL cells were concentrated using the CytoFuge 2 cytocentrifuge (StatSpin, Westwood, MA), 
and differential cell counts were performed using modified Giemsa staining. Whole blood was 
collected via terminal procedure of intra-cardiac collection. Bronchoalveolar lavage fluid and 
whole blood (intracardiac) were collected from 3 to 5 days’ post influenza infection for flow 
cytometry analysis and other studies. Lungs from mice who did not have BAL collection were 
134 
 
fixed with 4% formalin and collected for histopathology analysis after hematoxylin and eosin 
(H&E) staining. Mice were scored on a 1-4 scale (4 being most severe) for severity in the 
following areas by a blinded, board-certified anatomic veterinary pathologist: necrotizing 
bronchiolitis, bronchiolar infiltrates, alveolitis, interstitial inflammation, hemorrhage, edema, 
and microvascular thrombosis. Total histopathologic scores were evaluated as a sum of all 
individual scores. BAL and blood cultures were also performed on blood agar plates, incubated 
overnight at 37° C. 
 
Flow Cytometry 
The following antibodies were purchased from R&D Systems and used throughout the 
course of this study for chemokine receptor expression characterization of murine neutrophils: 
mouse CCR2 PE-conjugated antibody, mouse CXCR2/IL-8 RB PE-conjugated antibody, mouse 
CXCR3 PE-conjugated antibody, and mouse CXCR4 fluorescein-conjugated antibody. These 
antibodies were selected based on availability and due to their previously reviewed relevance in 
chronic inflammatory conditions and potential for therapeutic targeting [138]. Additional 
antibodies used in this study include mouse Ly6G (1A8) PerCP-conjugated antibody (Biolegend). 
In all flow cytometry studies, control BAL fluid was not compared due to a lack of pulmonary 
neutrophils in naïve Balb/c mice. The collected whole blood and BAL fluid were aliquoted into 
200 μl volumes for antibody staining.  2.0 ml of 1x PharmLyse Buffer was used for red blood cell 
lysis and allowed to lyse for 15 minutes at room temperature. Samples were allowed to stain for 
30 minutes, covered, at room temperature on a shaker. All samples were then centrifuged and 
washed with chilled PBS (with 2% FBS) 1-3 times before performing flow cytometry. Flow 
cytometry was performed on the BD FACSCalibur flow cytometer and analyzed with the 
corresponding CellPro software. Neutrophils were gated as Ly6G-1A8+SSCmed-hi.  
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Statistical Analysis 
The data are expressed as the means ± SEM. Statistical analyses were performed using Student’s 
unpaired t-test, paired t-test or analysis of variance (ANOVA) using GraphPad Prism 7 software. 
Survival studies were analyzed using GraphPad Prism 7 as well and statistical analyses 
performed using Mantel-Cox and Gehan-Breslow-Wilcoxon tests.  p < 0.05 was considered 
statistically significant. 
 
 
C. Results 
C.1. Sch527123, a CXCR1/2 antagonist, effectively reduces neutrophil influx in dual infection 
pneumonia. Before assessing the effect of Sch527123 in a murine survival model, I first had to 
establish that the drug would effectively reduce the inflammatory neutrophil influx to the lungs 
during infection. Balb/c mice were infected with either 100 TCID50 PR/8 H1N1 influenza only or 
in combination with 200 CFU S. pneumoniae (day 3) and BAL cell counts compared on day 5 post 
influenza infection [Figure 1.1]. 
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Figure 1.1: A CXCR2 antagonist, Sch527123, significantly reduces inflammatory neutrophil 
influx in dual infection pneumonia. 8 week old Balb/c mice were infected with either 100 TCID50 
PR/8 H1N1 influenza only or in combination with 200 CFU S. pneumoniae (day 3 post infection). 
Sch527123 was administered at 3 mg/kg every 24 hours via gastric lavage 3-5 days post 
influenza infection. Sch527123 effectively reduces neutrophil influx in either infection model, 
but is most notable in dual infection. Data are expressed as means ± SEM and comparisons 
made via unpaired t-test. n=5 mice per group. ** p<0.01. 
 
These cell counts were then more thoroughly compared over a 3-day period from 4 through 6 
days after influenza infection using both the influenza-only and dual infection models. Although 
Sch527123 appears to effectively reduce neutrophil influx regardless of day or model, this 
impact is most notable in the murine dual infection model on day 5 [Figure 1.2]. Day 5 after 
influenza infection (48 hours post bacterial infection) has the highest cell count numbers of the 
days measured as well as the most significant reduction in this population via Sch527123. 
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Figure 1.2: Sch527123 significantly reduces inflammatory cell influx with peaking effects 5 day 
after influenza infection. Balb/c mice were infected with either 100 TCID50 influenza PR/8 or 100 
TCID50 influenza PR/8 + 200 CFU Strep. pneumoniae (Dual) and then either treated with 3 mg/kg 
Sch527123 every 24 hours for 3 days beginning on day 3 or with water for mock treatment. Cell 
counts were highest in untreated groups on day 5 [dual p=<0.05; flu p=0.0683]. Sch527123 
significantly reduced cell influx in dual infected mice on day 5 post influenza infection. All data 
expressed as means ± SEM and comparisons made via unpaired t-test. n=3 mice per group. **** 
p<0.0001. 
 
C.2. CXCR2 expression on infiltrated PMNs is reduced in dual infection pneumonia. In addition 
to an overall reduction in the numbers of cells infiltrating the lungs during infection, there is also 
an apparent reduction in CXCR2 expression on these cells when treated with the CXCR2 
antagonist, Sch527123 [Figure 2.1]. This change in expression is not evident in circulatory 
neutrophils in the dual infection model. Although this study was limited in sample size, flow 
cytometry was used to assess the expression of CXCR2 with and without Sch527123 treatment 
in both influenza-only and dual infection models. Analysis was performed from day 3-6 post 
infection. In addition to CXCR2, a handful of other chemokine receptors were tested to see if 
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there was any obvious effect of the treatment on the expression in receptors other than CXCR2. 
The other receptors tested were CCR2, CXCR3, and CXCR4. No changes were noted in these 
other receptors regardless of treatment or model (data not shown). 
 
Figure 2.1: CXCR2 Expression is suppressed in infiltrated neutrophils with Sch527123 
Treatment. CXCR2 expression was measured on PMNs (Ly6G-1A8+) via flow cytometry 3-6 days 
post influenza infection. Although the sample size is too small for statistical significance, it is 
apparent that treatment Sch527123, a CXCR2 antagonist, reduces expression of CXCR2 on 
neutrophils infiltrating the lung in dual infection, while not affecting circulatory neutrophil 
expression. No differences were noted in either the BAL or circulatory samples for other 
receptors tested – CCR2, CXCR3, and CXCR4. n=1. 
 
C.3. Sch527123 significantly delays lethality when used in combination with oseltamivir and 
clarithromycin. In order to assess the clinical potential of Sch527123 in influenza coinfection, 
the established murine dual infection model was used as outlined in Figure 3.1. 
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Figure 3.1: An outline of the survival study plan. PR/8 H1N1 influenza was administered at 100 
TCID50 intranasally on day 0. 200 CFU S. pneumoniae, a sublethal infectious dose, was then 
administered 72 hours later. Various combinations of therapy including oseltamivir, 
clarithromycin, and Sch527123 were used. Survival studies were not carried out beyond 21 days 
after influenza infection. 
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Figure 3.2: Treatment outline for each survival study. This figure outlines the treatment 
protocols used for each survival study group in both table and schematic formats. Variations in 
dosage, frequency and timing were all employed to assess differences in treatment.  
 
Combinations of therapy tested are outlined in Figure 3.2. For initial comparison, we will look at 
group 1 – this treatment model did not start any treatment until 12 hours after bacterial 
infection. All medications were administered via gastric lavage every 24 hours. For group 1, 3 
doses of each medication were administered – 10 mg/kg oseltamivir, 100 mg/kg clarithromycin, 
and 3 mg/kg Sch527123 respectively. In group 1, four combinations of therapy were tested: no 
treatment, clarithromycin (antibiotic) only, Clarithromycin + Sch527123, and Clarithromycin + 
oseltamivir + Sch527123.  
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Figure 3.3: Group 1 did not have any significant differences in weight loss between the four 
tested groups. Data displayed as means ± SEM and comparisons made via one-way ANOVA each 
day. n=5 mice per group.  
 
As can be seen in Figure 3.3, no significant differences in weight loss between groups is noted. 
However, when clinical score is assessed using the modified murine scoring system for 
assessment of septic shock (MCASS), the combination therapy does show statistically significant 
improvement in clinical score when comparing groups seven days after initial influenza infection 
[Figure 3.4]. The outline for this scoring system is available in Chapter 2. In general, clinical 
features such as lethargy, hair coat, respiratory distress, posture and behavior are closely 
observed in both a stimulated and unstimulated state. Mice are assigned a score from 1 through 
4 with 1 being healthy and 4 being severely affected and requiring euthanasia. 
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Figure 3.4: Combination therapy slows clinical decline of dual infection influenza pneumonia in 
a murine model. Balb/c mice were infected with influenza and S. pneumoniae as per the dual 
infection protocol. No significant clinical improvement can be seen with antibiotic only or 
antibiotic + Sch527123 therapy, but those mice treated with a combination of all three therapies 
– antibiotic, antiviral, and the CXCR2 antagonist – have a slower clinical progression and a 
significantly improve clinical score on day 7 post influenza infection. Data expressed as means ± 
SEM and comparisons made via one-way ANOVA. n=5 mice per group. **** p<0.0001 (relative 
to no treatment group). 
 
As expected upon comparing clinical progression of the treatment groups, a delay in lethality is 
also noted in the combination therapy group [See Figure 3.5]. No difference in survival was seen 
between the group receiving no treatment and that receiving clarithromycin only with 100% 
fatality by day 7. The group receiving clarithromycin in combination with Sch527123 had 80% 
lethality by day 8 and 100% by day 10. In contrast, the group receiving all three medications 
survived the longest with 100% still surviving through day 9. Between days 9 and 11 all mice in 
the final group reached their endpoint, which correlated with completion of their medication 
and subsequent clinical decline. Overall, the groups receiving antibiotic and SCH527123 had 
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significantly improved lethality over that with no treatment. Combination therapy resulted in 
significant delay in lethality over all other groups. 
 
Figure 3.5: Combination therapy results in delayed lethality in a murine model of dual infection 
pneumonia. Mice were infected with PR/8 H1N1 influenza and S. pneumoniae as previously 
described. Treatments were administered as outlined in Table 3.2. No differences were seen in 
survival between the untreated group and that treated with clarithromycin alone. 
Clarithromycin in combination with Sch527123 delayed lethality slightly with only 20% survival 
on day 8 and 100% lethality by day 10, but was significantly improved survival over mice 
receiving no treatment. Combination therapy with all three – clarithromycin, oseltamivir, and 
Sch527123 – resulted in 100% survival through day 9 and was significantly improved over all 
other groups. Rapid clinical decline occurred between days 9-11 with 100% lethality by day 11. 
Overall, this combination was a statistically significant improvement over the other treatment 
models and the untreated group. n=5 mice per group. *p<0.05; **p<0.01 (relative to no 
treatment group. 
 
C.5. Modulation of treatment groups can result in survival in our murine dual infection model. 
After thorough evaluation of the previously described treatment model, an addition two 
protocols were outlined to be assessed. See figure 3.2 for treatment outlines for groups 2 and 3. 
Based on the previous steep decline of the combination therapy group between 9-11 days 
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resulting in 100% lethality, a model was proposed that allowed for 7 doses of antibiotic to be 
administered instead of just 3. This more closely mimics a typical antibiotic course in human 
disease. In addition, groups were compared starting antiviral and Sch527123 treatments at the 
start of more evident clinical disease (about 12 hours prior to bacterial infection), or only after 
the secondary infection was established. 
 
Figure 4.1: Surviving mice begin to recover weight after day 9. No significant differences were 
noted between groups regarding weight lost during infection. Group 2 included treatment 
groups which were administered antiviral and Sch527123 prior to bacterial infection – this group 
had more overall weight recovery between days 7-10, whereas Group 3, with fewer surviving, 
did not see weight recovery until after day 12. Abx: 50 mg/kg Clarithromycin, AV: 20 mg/kg 
oseltamivir; SCH: 3 mg/kg Sch527123. n=5 mice per group. 
Although weight loss was similar between all groups in the first week of infection, Figure 4.1 
shows that of those mice surviving beyond 7-10 days, a steady increase in weight gain can be 
seen as early as day 7-9 in some groups, with most surviving mice fully recovering their weight 
lost by day 21. In general, this steady improvement in weight gain is more evident about 2-3 
days earlier in those mice surviving group 2 compared with those in Group 3, which did not 
receive any medication prior to bacterial infection. This further highlights the importance of 
early intervention when there is a risk for coinfection.  
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Figure 4.2: Effective combination therapy requires antiviral administration. The above figure 
illustrates clinical scores comparisons on day 7 post influenza infection. Significant improvement 
in clinical scores is only noted in those groups receiving antiviral therapy, regardless of group. 
Treatment groups receiving the antiviral oseltamivir 12 hours prior to bacterial infection had the 
least severe clinical decline based on MCASS scoring through the first week. Of those treatment 
groups in Group 3, groups receiving both antibiotic and antiviral out-performed others. Full 
combination therapy with all three agents had significantly improved clinical scores (p<0.001) 
compared with no treatment and monotherapy, other than antiviral only. Abx: 50 mg/kg 
clarithromycin; AV: 20 mg/kg oseltamivir; SCH: 3 mg/kg Sch527123. Data expressed as means ± 
SEM. N=5 mice per group. ***p<0.001; ****p<0.0001 (relative to no treatment group). 
 
A closer look at clinical scoring through MCASS also illustrates significant differences between 
treatment groups that help to explain this recovery. Figure 4.2 compares clinical scores on day 7 
after infection, which is the time point where most mice either commit to their endpoint or start 
to show signs of clinical recovery, even if their weight loss persists for a few more days. Early 
intervention with antiviral therapy plays a large role in improved clinical score at day 7 as seen 
by viewing results from Group 2. In group 3, treatment groups receiving antibiotic and antiviral 
therapy did best. Combination therapy with all three medications was significantly improved as 
compared with no treatment and most monotherapy in both groups. These differences in 
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clinical scores also help to explain differences in survival seen between treatment groups. Group 
2 had to most overall survival [Figure 4.3].  
 
Figure 4.3: Early intervention key to survival. Treatment groups performing best were those 
receiving early intervention with antiviral therapy. Combination (**), AV+SCH (**), Abx+AV (*), 
and AV monotherapy all performed significantly better than the untreated mice. There was no 
statistical improvement between untreated mice and Abx+SCH or SCH/Abx monotherapies. 
Combination therapy also outperformed monotherapy except for antiviral monotherapy. 
Antiviral monotherapy was the exception with 40% overall survival and 80% of mice surviving 
through day 10. 40% overall survival was also seen in Abx+AV and Abx+AV+SCH groups. Most 
mice survived through day 10-11 in the Abx+AV+SCH group as compared to Abx+AV where a 
decline was noted at day 7. 20% survival was seen in dual therapy groups – Abx+SCH and 
AV+SCH. No statistical significance is seen between dual and combination therapy groups. n=5 
mice per group. *p<0.05; **p<0.01 (listed in text – relative to no treatment group). 
The antibiotic only group matched the group receiving no treatment in survival with 100% 
lethality by day 7.  Only mild improvement was noted in Sch527123 monotherapy, with 100% 
lethality on day 9. The only monotherapy that performed well was the oseltamivir only group, 
with 80% still alive through day 10 and 40% surviving through day 21. As a part of group 2, these 
mice received antiviral therapy at the start of significant clinical signs, which was 12 hours prior 
to bacterial infection. In addition to the antiviral monotherapy group, 40% overall survival was 
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also seen in the antibiotic + oseltamivir and antibiotic + oseltamivir + Sch527123 groups. 
Sch527123 improved combination therapy group outcome over Abx+AV – although their 
ultimate survival matched, the remaining mice survived through days 10/11 whereas a decline 
was noted in the group not receiving Sch527123 treatment on day 7. 20% survival was noted in 
the antibiotic + Sch527123 and oseltamivir + Sch527123 groups as well. Overall, combination 
therapy with 2 or 3 therapeutic agents outperformed monotherapy and early intervention 
appears to be significant in improving clinical outcome.  
 
Figure 4.4: Sch527123 therapy less effective when administered after bacterial infection. 
Overall, fewer mice survived from the Group 3 study than Group 2. 60% survival is noted in the 
Abx+AV dual therapy group and 20% in the antiviral monotherapy group. Most mice declined 
and reached end point at earlier time points compared with Group 2 as well. Several groups 
performed significantly better than the untreated mice: antiviral monotherapy (*), Abx+AV (**), 
AV+SCH (**), and combination therapy (**). Combination therapy also performed significantly 
better than Abx or SCH monotherapy (**) and Abx+SCH dual therapy (**). Abx: 50 mg/kg 
clarithromycin; AV: 20 mg/kg oseltamivir; SCH: 3 mg/kg Sch527123.  n=5 mice per group. 
*p<0.05; **p<0.01 (listed in text – relative to no treatment group). 
Group 3 focused on initiating therapy only after bacterial infection, with all medications starting 
12 hours after the administration of S. pneumoniae. Severe clinical decline is seen about 24 
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hours prior to this time, so it is not surprising that survival was not as prominent in these 
treatment groups as it was in Group 2. Only two groups saw any survival – antiviral 
monotherapy and antibiotic/antiviral dual therapy. A remarkable 60% survived in the 
antibiotic/antiviral dual therapy group. The 40% which did not survive were euthanized quickly 
by day 8. Overall, most groups saw significant declines in survival around day 8. Antiviral/SCH 
dual therapy fared better with 80% survival through days 10 and 11. However, without 
antibiotic therapy, none of this group survived to 21 days. Combination therapy with all three 
medications also saw a delay in lethality with mice surviving through day 10, even though none 
survived to day 21. Another interesting comparison comes from looking at the Sch527123 
monotherapy treatment groups between Group 2, where it was administered 12 hours prior to 
bacterial infection, and group 3, 12 hours after bacterial infection. In Group 3, all the mice 
reached endpoint on day 7, but these mice survived an extra 1-2 days when therapy was 
initiated earlier. Finally, combination therapy was compared between groups 1, 2 and 3 in Figure 
4.5. Although combination therapy effectively delayed lethality as compared with most 
monotherapy groups, only mice with early intervention antiviral and Sch527123 therapy 
survived through day 21.  
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Figure 4.5: Early intervention is key in successful combination therapy. Mice receiving 
combination therapy (clarithromycin, oseltamivir and Sch527123) had significantly delayed 
lethality over most monotherapy groups and those not receiving treatment. Survival (40%) is 
only noted in mice receiving combination therapy with early intervention of antiviral and 
Sch527123 treatments, starting at the onset of severe clinical decline, approximately 12 hours 
prior to bacterial administration. Refer to Table 3.2 for group descriptions. n=5 mice per 
treatment group. **p<0.01 (relative survival to both groups 1 and 3). 
 
C.5. Combination therapy reduces pulmonary pathology and clinical disease by day 5. In order 
to more thoroughly investigate why combination therapy is effective in delaying lethality in mice 
infected with dual infection pneumonia, an experiment was performed comparing no 
treatment, antibiotic-only, SCH527123-only and combination therapy (antiviral, antibiotic and 
SCH527123) on day 5 after influenza infection. Therapeutics were administered based on the 
Group 2 model, with antiviral and SCH527123 treatment beginning 12 hours prior to bacterial 
infection and antibiotic therapy starting 12 hours after bacterial infection. Our results indicate 
that combination therapy significantly reduces weight loss on day 4 and 5 when compared with 
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untreated groups. Antibiotic therapy also had significant reduction in weight loss compared with 
the group receiving no treatments [Figure 5.1]. 
 
Figure 5.1: Mice treated with combination therapy lose less weight. Balb/c mice were infected 
with 100 TCID50 PR/8 H1N1 followed by 200 CFU S. pneumoniae 72 hours after viral infection. 
SCH527123 was administered at 3 mg/kg every 24 hours beginning 12 hours prior to bacterial 
infection. Oseltamivir was administered at 20 mg/kg beginning 12 hours prior to bacterial 
infection. Clarithromycin was administered at 50 mg/kg beginning 12 hours after bacterial 
infection. Mice treated with antibiotic alone and combination therapy did not lose as much 
weight as the untreated mice on day 5 (p<0.01 for combination and p<0.05 for antibiotic 
monotherapy). Combination therapy also lost less weight than the SCH527123 treated group on 
day 5 (p<0.05). These same groups were also statistically different on day 4 (p<0.05). Data are 
expressed as means ± SEM. n=6 mice per group per day. **p<0.01; *p<0.05 (relative to no 
treatment group). 
Clinically, improvement was also seen with combination therapy. M-CASS scores over the 5-day 
period were used to compare groups. By day 5, mice treated with monotherapy have 
significantly lower clinical scores than untreated mice and combination therapy is significantly 
improved over all other groups. No differences were noted between antibiotic-alone and SCH-
alone treated mice [Figure 5.2]. 
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Figure 5.2: Combination therapy reduces clinical severity more than monotherapy. Dual-
infected mice were monitored over 5 days for clinical severity and scored based on the MCASS 
System (1 (healthy) to 4 (severe)). Beginning at day 3, there is statistical significance in 
differences between all groups (p<0.0001) other than SCH Only and combination therapy on day 
3 and the two monotherapies on day 4. Clinically, mice were statistically improved with 
monotherapy over no treatment and combination therapy of all three agents was better than 
any other group. Data are expressed as means ± SEM and comparisons made via one-way 
ANOVA. n=6 mice per group.  
Bronchoalveolar lavage was collected from 3 mice in each group on day 5 and cell counts were 
performed [Figure 5.3]. Mice receiving no treatment had significantly higher inflammatory cell 
influx compared with all other groups. Treatment with SCH527123 alone reduced the 
inflammatory cell influx by about 50%. Combination therapy had the greatest effect with the 
lowest number of inflammatory cells in the BAL on day 5. These findings can be further 
visualized with the provided images from cytospins of those BAL samples. 
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Figure 5.3: SCH527123 effectively reduces neutrophil influx in both monotherapy and with 
combination therapy. BAL was collected from dual-infected mice 5 days after influenza infection 
(48 hours post bacterial infection) and cell counts were performed. Mice receiving no treatment 
had the most excessive inflammatory cell response. Treatment with SCH527123 reduced this 
response by over 50%. Combination therapy with all three treatments had the lowest cell counts 
on day 5. Cytospins were stained and pictures provided. Data are expressed as means ± SEM. 
n=3 mice per group. ***p<0.001; **p<0.01; *p<0.05 (relative to no treatment group). 
Finally, histopathology was scored and compared between groups on day 5. Three mice in each 
group were euthanized and lungs collected and fixed in formalin for comparison. Lungs were 
scored from 0-4 (4 being most severe) based on 7 focus areas: necrotizing bronchiolitis, 
bronchiolar infiltrates, alveolitis, interstitial inflammation, hemorrhage, edema, and 
microvascular thrombosis. A sum of scores is provided for comparison in Figure 5.4. 
Combination therapy has significantly reduced pulmonary pathology on day 5 compared with 
untreated and antibiotic-alone infected mice. This reduction in severity as compared with other 
groups is clearly evident when viewing the lung tissue in the provided images.  
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Figure 5.4: Combination therapy reduces pulmonary pathology on day 5. Mice were 
euthanized on day 5 after influenza infection (48 hours after bacterial infection). Lungs were 
collected and formalin-fixed for histopathology scoring and comparison. Lung pathology was 
scored from 0-4 (4 being most severe) in these areas: necrotizing bronchiolitis, bronchiolar 
infiltrates, alveolitis, interstitial inflammation, hemorrhage, edema and microvascular 
thrombosis. These individual scores were summated and used from comparisons. On day 5, 
combination therapy resulted in significantly improved scores compared with both untreated 
and antibiotic monotherapy. Sample images from hematoxylin and eosin stained slides used for 
scoring are provided. Data are expressed as means ± SEM and comparisons made via one-way 
ANOVA. n=3 mice per group. *p<0.05; **p<0.01. 
 
D. Discussion 
 These research findings support that Sch527123 is an effective CXCR2 antagonist in 
murine models of influenza coinfection with a significant reduction in neutrophil influx seen by 
day 5 after influenza infection (48 hours after bacterial infection). In addition to controlling the 
hyperinflammatory innate response to infection, Sch527123 appears to reduce CXCR2 
expression on these infiltrated neutrophils within the lungs.  
 Overall, a delay in lethality is noted with this use of combination, triple agent therapy. 
These results are promising despite lack of significant survival. Our murine model used for these 
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studies is very severe with 100% lethality seen in all dual infected mice between days 6-7 after 
influenza infection. With combination therapy, most mice survive through day 10-11, regardless 
of when the therapy is initiated. In our dual infection murine model, the untreated mice decline 
rapidly. Without supportive care and fluid therapy, all mice lose significant weight within the 
first week, even those in treated groups. This makes it difficult to have mice recover before 
reaching their endpoint for the study. However, this makes survival in this model all the more 
impressive and supports that delays in lethality are also clinically relevant.  
Not surprisingly, Sch527123 monotherapy is ineffective at improving survival and clinical 
outcome in this model. With the complexity of influenza coinfection, it is relatively well 
established that monotherapy is unlikely to improve outcome in most severe cases of 
coinfection, especially during a pandemic outbreak. Interestingly, even though we do not see 
survival with any Sch527123 monotherapy treatment group, we do see a delay in lethality when 
started early (12 hours prior to bacterial infection) as opposed to after bacterial infection. Our 
results also support the need for early antiviral intervention. These are both key findings in our 
influenza coinfection research which provide evidence for the importance of early intervention 
with combination therapy by healthcare professionals, and the need for patients who think they 
may have influenza to see a healthcare provider as soon as possible. In our experiment 
comparing SCH527123 monotherapy, antibiotic monotherapy and combination therapy with 
untreated mice, we can see that even by day 5 there are marked differences between groups. 
Combination therapy effectively reduces pulmonary pathology and inflammatory cell influx. 
Both antiviral therapy and Sch527123 therapy lost some effectiveness when administered later. 
The mice in these studies saw a significant clinical decline due to their influenza infection 
between days 2 and 3. Therapy should really be administered at the start of moderate clinical 
signs, before a patient is hospitalized. 
155 
 
This research opens up several avenues for continued work in the area of combination 
therapy in influenza coinfection. One question yet to be answered asks how effective is 
Sch527123 if given over various time points? And is there a point at which it could be considered 
detrimental? When reviewing results from treatment groups receiving early intervention of 
Sch527123, the greatest effect on clinical outcome is noted in those groups receiving this drug 
near the start of severe clinical signs and before a secondary bacterial infection has occurred. In 
contrast, we can shift our focus to Group 3 which did not receive any medication prior to 
bacterial infection, regardless of treatment group. In this group we see 60% survival in those 
mice treated with dual therapy antibiotic and antiviral (no Sch527123), but by merely adding 
Sch527123 to this group to make it a triple combination therapy, we see 100% lethality. Does 
this mean that antagonizing CXCR2 and inhibiting neutrophil influx after bacterial infection is 
present can lead to poorer outcomes in influenza coinfection? We can’t draw that conclusion at 
this time, but continued studies in other animal models with various protocols should be 
continued to fully understand the nature of this antagonism before suggesting it be used in 
human disease.  
In conclusion, chemokine receptors continue to be an intriguing target for combination 
therapy in influenza coinfection. As the effectiveness of antiviral therapy and antibiotics alone is 
continually questioned due to resistance and variation in potency, identifying further therapies 
that can be used in combination with these two will be critical to improving clinical outcome 
moving forward. Influenza coinfection is complex and identifying an effective animal model 
difficult. In addition, antagonists may target multiple receptors, which has the potential to have 
an even greater effect, but may prove to be quite complicated in fully understanding how these 
therapies work. Although significant progress has been made in studying the potential for 
chemokine receptor antagonists is models of chronic inflammation, immune-mediated disease, 
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and cancer, this progress has not been as detailed in acute inflammatory conditions, in 
particular influenza coinfections. Results from this study support exciting findings that these 
antagonists may offer some hope to improving clinical outcome in severe cases, especially 
during pandemic influenza outbreaks when mortality is higher and treatments often prove 
ineffective.  
157 
 
CHAPTER V 
 
 
INFLUENZA PNEUMONIA IN A SWINE MODEL RESULTS IN A 
HYPERINFLAMMATORY INNATE REPSONSE AND THE RELEASE OF 
NEUTROPHIL EXTRACELLULAR TRAPS 
 
A. Introduction 
 The sharing of influenza viruses between pigs and humans has been apparent since at 
least 1918 [228, 229]. Even though the role of the pig in human influenza pandemics has long 
been speculated, it has been more widely recognized and researched over the last 25 years, 
especially due to the “swine flu” pandemic in 2009 [229]. Pigs are natural hosts for influenza A 
viruses, and pose an increased risk of transmission to humans with direct contact, as well as 
through aerosolized droplets and fomites. Transmission may occur from any swine source, but 
reports have detailed that increased risk to humans is present whenever pigs and humans come 
in close contact [230], such as in show pigs [231] and pigs as companion animals [232]. In 
addition, feral swine serve as a reservoir for swine influenza since they are often in close contact 
with wild birds and water fowl. In the US, it is estimated that about 5% of feral pigs carry 
antibodies to influenza A – these antibodies are mostly to swine influenza, but avian influenza is 
also present in substantial amounts [233]. Surveillance methods will be key to pandemic 
planning in the future [228], but are difficult due to variation in serological data collected and 
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a lack of standardization [234]. RT-PCR methods have been developed and protocols are now 
available for more standardized diagnostics [235]. 
 Pigs are animals of interest primarily due to their capability to serve as mixing vessels 
for various strains of influenza viruses to reassert and potentially cause more significant human 
disease. A recent review looked at over 1400 cases of swine and avian influenza in naturally-
infected humans and found that the avian-influenza infections were primarily H5N1, but other 
H5, H6, H7, H9 and H10 were all reported as well [230]. Of the highly pathogenic H5N1 human 
cases (HPAI), the World Health Organization reported that 59% of those infected died, and 
death spanned 15 countries. This high mortality associated with avian viruses emphasized the 
threat of reassortment in pigs to make an even more pathogenic virus which can more readily 
infect humans. Of the swine viruses, H1 and H3 predominate [230]. A primary consideration 
includes the availability of sialic acid receptors to bind the virus and create disease. The human 
respiratory tract has predominantly α-2,6 receptors on the ciliated cells of the upper respiratory 
tract, but a mixture of α-2,6 and α-2,3 as the tract progresses to the non-ciliated respiratory 
epithelium [236]. Human influenza viruses include α-2,6 galactose viruses which prefer to bind 
to α-2,6 sialic acid receptors [237]. Avian influenza viruses prefer α-2,3 receptors [238]. Pigs are 
infected by both α-2,3 and α-2,6 SA-galactose viruses and have both receptor types present in 
the respiratory epithelium, somewhat similar to human [239]. Transmission is much more 
complex than just receptor availability and many factors are still being researched to better 
understand this transmission. 
 Since pigs can naturally be infected with both avian and human influenza A viruses, they 
serve as high risk vessels for viral reassortment. The segmented viral genome facilitates simple 
exchange of genetic material if a pig is co-infected with two different influenzas, referred to as 
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antigenic shift if hemagglutinin is involved in this reassortment of genetic material [230]. 
Humans have little to no pre-existing immunity to viruses undergoing antigenic shift. The 
influenza virus may also undergo a series of mutations during replication, often amino acid 
substitutions. If hemagglutinin is directly affected by these mutations, the virus can undergo 
antigenic drift, which also exposes an otherwise naïve population to a virus with novel surface 
antigens [230]. Pigs have been used more recently in experimental models to try to recreate this 
antigenic shift or drift with varying levels of success. It has proven difficult for pigs to 
experimentally create the pandemic virus from 2009 through introducing triple reassortment 
virus and Eurasian swine influenza virus, supporting that this particular pandemic was a 
relatively rare event involving many complex and yet unknown factors [240]. More recently, a 
pig model has been successfully used to reassert H3N2 swine influenza with H1N1 avian/duck 
influenza [241]. In another study more closely evaluating the evolutionary dynamics of influenza 
virus in pigs, serial passages of virus effectively created a reassorted virus with enhanced 
pathogenicity [242]. 
 These shifts in viral subtypes can occur over longer periods of time between pandemics 
and season to season. During the 1918 “Spanish flu” pandemic, the predominant strain was 
H1N1, but a shift to H2N2 was seen around the time of the “Asian Flu” pandemic in 1957 and 
then another shift to H3N2 for the “Hong Kong” pandemic in 1968. Since the “swine Flu” 
pandemic in 2009-2010, seasonal influenza outbreaks have been predominantly the pandemic 
2009 strain of H1N1, which stems from the North American triple reassortment and Eurasian 
avian-like swine influenza viruses, as opposed to the previous H1N1 strains. H3N2 has replaced 
H2N2, which is now circulating in birds and pigs, but not humans. Climate and time of year also 
contributes to viral outbreaks and should be considered when planning for pandemics [243]. 
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 Various animal models have been considered for further studying influenza virus 
vaccines, treatment, and the pathogenesis behind the disease. Mouse models are the most 
widely used due to their availability and affordability, but several downsides are present to using 
mice to model this disease. First, mice require adapted viruses to see the same clinical disease 
anticipated in humans [244]. They also lack the influenza virus receptors found in humans [245] 
and don’t shed the virus, so transmission studies are not possible [246]. Ferrets are better 
models because they work well for transmission studies [247] and don’t need adaptation [244], 
but come at a much higher cost with limited availability and fewer available reagents [244]. 
Guinea pigs are a smaller, more manageable size and so have reduced cost, but also have few 
available reagents [244] and diminished clinical signs [248]. 
In contrast to many of the setbacks with other animal models, pigs are excellent models 
for influenza infection studies. Anatomically, their respiratory tract is very similar to the human 
anatomy [249] and has similar distribution of influenza A virus receptors [250]. The virus 
replicates easily in both the upper and lower respiratory tracts [251], and, as a natural host, can 
be infected with the same subtypes endemic in both species [250]. Swine influenza has a high 
morbidity and low mortality and results in a high fever and nasal discharge in most models – the 
clinical disease and pathogenesis are also similar to that of human disease [250, 251]. Pigs also 
make a great model for human immune parameters and response to infection since the H1N1 
virus induces a similar acute inflammatory immune response [251, 252]. In the last few years, 
the entire swine genome has been sequenced as well [253] and been found to be similar in size 
and complexity to the human genome. Several coinfection models have been evaluated in pigs 
[254-257]. In coinfection models with Bordetella bronchiseptica [255, 256], pigs have similar 
synergism to that noted in human disease and increased viral replication, enhanced bacterial 
colonization, production of proinflammatory cytokines, and exacerbated pulmonary pathology 
161 
 
are all seen in coinfection. This synergism is also evident in a coinfection model of swine 
influenza with Actinobacillus pleuropneumoniae [257]. Identifying and characterizing a swine 
model allows for many opportunities for studies related to viral pathogenesis, coinfection, 
therapeutics, and vaccine development [258]. This chapter outlines a swine model for influenza 
pneumonia that shows great potential for further studies assessing therapeutics and potential 
coinfection models of disease. 
 
B. Materials and Methods: 
Pathogen 
Influenza A/swine/Iowa/15/30 (H1N1) virus was obtained from the American Type Culture 
Collection (ATCC, VA). Viral titers were determined by tissue culture infectivity dose (TCID50) 
assay via infection of Madin-Darby canine kidney (MDCK) cells. Virus was stored at -80°C until 
use. 
Animals 
Piglets ranging from 10 to 12 weeks’ old were purchased from controlled farms and housed in 
large cages in a BSL-2 facility. Fresh food and water were provided ad libitum. Piglets were 
clinically evaluated each day for weight loss, nasal or ocular discharge, resting respiratory rates, 
lethargy and rectal temperatures. Infection was performed under a mixture of xylazine (2 
mg/kg) and ketamine (10 mg/kg) administered via intramuscular injection. Piglets were infected 
intranasally with a sublethal dose of 1 x 106 TCID50 Influenza A/swine/Iowa/15/30 (H1N1) 
delivered in two 0.5 mL increments. All animal experiments were approved by the Institutional 
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Animal Care and Use Committee (IACUC) of Oklahoma State University and were performed in 
strict accordance with their recommendations. 
Whole blood, bronchoalveolar lavage (BAL) fluid, and tissue collection 
Sample collection occurred on days 3 or 6 after influenza infection. Piglets were anesthestized 
with a xylazine (2 mg/kg) and ketamine (33 mg/kg) combination administered intramuscularly. 
Euthanasia was performed with 1 mL/10lbs pentobarbital administration via intravenous 
injection. For BAL fluid collection, the left lung was washed by intratracheal administration of 20 
mL of sterile PBS in two 10 mL increments. The recovery of BAL fluid was more than 85% for all 
animals. The BAL fluids were centrifuged at 200 xg for 10 minutes, and reconstituted in sterile 
PBS for cell counts. BAL cells were concentrated using the CytoFuge 2 cytocentrifuge (StatSpin, 
Westwood, MA), and differential cell counts were performed using modified Giemsa staining. 
Bronchoalveolar lavage fluid was collected on days 3 and 5 for infected piglets and at day 0 for 
healthy controls.  
 
Immunohistochemistry 
Immunohistochemistry analysis was performed on formalin-fixed pulmonary tissue sections for 
the detection of neutrophils and viral particles in the lungs using anti-CXCR2 and anti-PR/8 
antibodies respectively. 
 
Histopathology 
The right lung was fixed with 4% formalin and collected for histopathology analysis after 
hematoxylin and eosin (H&E) staining. Mice were scored on a 1-4 scale (4 being most severe) for 
severity in the following areas: necrotizing bronchiolitis, bronchiolar infiltrates, alveolitis, 
interstitial inflammation, hemorrhage, edema, and microvascular thrombosis. Necrotizing 
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bronchiolitis was defined as damage to the airway epithelial cells, presence of necrotic bodies or 
the total denudation of the airway lining. Total histopathologic scores were evaluated as a sum 
of all individual scores. 
 
C. Results: 
 
Figure 1.1: Infected piglets do not lose weight. Piglets were infected with Influenza 
A/swine/Iowa/15/30 (H1N1) at 1 x 106 TCID50 per piglet. Pigs were monitored daily for weight, 
rectal temperature, resting respiratory rate and clinical signs. Weights were unaffected by 
infection with an overall slight increase in piglet weight over 6 days. Other clinical signs included 
mild ocular and mild to moderate nasal discharge, first noted at 2 DPI and sustaining through 6 
DPI. Data are expressed as mean ± SEM. n = 6 pigs per group for all studies.  
 
1. Infected piglets have mild clinical disease in our model. Before assessing treatment efficacy in 
piglets infected with H1N1 influenza, a model for the clinical disease course was established. 
Our lab infected piglets with 1 x 106 TCID50 Influenza A/swine/Iowa/15/30 (H1N1) intranasally 
and compared weight loss, clinical signs, cell counts and gross and histopathology with mock-
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infected piglets. Infected piglets did not lose any weight and continued to eat and drink through 
the course of infection [Fig. 1.1].  
 
Figures 1.2 and 1.3: Clinical signs in infected piglets peak on days 4 and 5 post infection. Piglets 
were infected with Influenza A/swine/Iowa/15/30 (H1N1) at 1 x 106 TCID50 per piglet. Pigs were 
monitored daily for weight, rectal temperature, resting respiratory rate and clinical signs. 1.2: 
Rectal temperature peaked at day 5 with an average temperature of 103.2°F (Normal: 101.5-
102.5°F). 1.3: Resting respiratory rate peaked on day 4. Other clinical signs included mild ocular 
and mild to moderate nasal discharge, first noted at 2 DPI and sustaining through 6 DPI. Data are 
expressed as mean ± SEM. n = 6 pigs per group for all studies. 
 
Rectal temperatures peaked at day 5 with an average rectal temperature of 103.2°F (normal 
101.5-102.5°F) [Fig. 1.2]. Resting respiratory rates peaked at day 4 post influenza infection [Fig. 
1.3]. Mild to moderate nasal discharge was noted in all infected piglets beginning at day 2 and 
two infected piglets had mild ocular discharge. The pigs remained active and only mild lethargy 
was noted starting at day 3 post infection. 
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Figure 2.1: Inflammatory cellular influx is noted in infected pigs. BAL was collected in control 
pigs as well as on days 3 and 6 post influenza infection. Data from control pigs was unreliable 
due to some secondary infections present in the piglets at the time of sample collection. 
Therefore, an established average for cell counts in healthy pigs is provided as a comparison. An 
increase in BAL fluid cell counts is noted highest at day 6, and is significantly higher that day 3 
Both day 3 and day 6 cell counts are significantly higher than typical healthy pigs. Data are 
expressed as mean ± SEM. n = 6 pigs per group for infected studies and n=2 for control. *p<0.05 
relative to healthy controls. 
 
2. Infected piglets have hyperresponsive neutrophil recruitment to the lungs. As noted in our 
murine model, infected piglets continue to an excessive innate response despite a mild clinical 
disease course. Cell counts from bronchoalveolar lavage samples collected at 3 and 6 days after 
influenza infection are higher than healthy controls with an exaggerated response noted by day 
6 [Fig. 2.1]. In addition, the populations within these BAL cells shift over the course of infection – 
macrophages predominate at day 3, but by day 6, significant neutrophil recruitment is noted 
with neutrophils being the predominant cell type [Fig. 2.2]. These populations can be better 
visualized with the images provided in Figure 2.3.  
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Figure 2.2: Differential counts shift from predominantly macrophages to neutrophil by day 6. 
BAL was collected on day 3 and day 6 post influenza infection. Cytospins were prepped and 
differential counts performed manually. Alveolar macrophages predominate in control pigs as 
well as those 3 days post infection, but a clear shift to marked neutrophilia is seen by day 6. 
Other cells noted in minimal numbers include lymphocytes and eosinophils.  
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Figure 2.3: Neutrophils predominate on day 6 post influenza infection. BAL was collected from 
pigs 3 and 6 days after influenza infection. Cells were spun down for cytospin and stained with 
Diff Quick for differential counts and imaging. Stained cytospin samples provide a visual for the 
differential counts. On day 3, macrophages predominate with neutrophils as the second most 
populous cell type. On day 6, a marked shift to neutrophilia can clearly be seen in BAL cells with 
macrophages as the second most populous cell type. Eosinophils and lymphocytes were also 
present in small numbers. 
 
Immunohistochemistry was performed to further visualize the extent of neutrophil influx and to 
assess for viral spread with influenza infection. Fixed lungs were sectioned, prepped and stained 
with anti-CXCR2 antibodies to assess for pulmonary infiltrated neutrophils. CXCR2 is a 
chemokine receptor predominantly expressed on neutrophils. A marked increase in neutrophil 
influx is seen on day 6 after influenza infection as compared with healthy controls [Figure 2.4]. 
 
Figure 2.4: Neutrophil influx noted in viral-infected lung. Lungs were collected at 6 DPI and 
fixed for immunohistochemistry. Anti-CXCR2 were used to assess pulmonary-infiltrated PMNs. A 
marked increase in neutrophil influx is noted in infected lung samples [arrowheads indicate 
CXCR2 staining on pulmonary-infiltrated neutrophils].  
 
In addition to the extensive influx of neutrophils seen with influenza infection, the virus also has 
a widespread effect on the lung. Additional immunohistochemistry was performed on day 6 
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infected lungs sections using anti-PR/8 H1N1 antibodies which bind to the virus for visualization. 
As seen in Figure 2.5, infected lungs are diffusely infected with viral particles. 
 
Figure 2.5: Diffuse viral load present in influenza-infected pig lungs. Lungs were collected at 6 
DPI and fixed for immunohistochemistry. Anti-PR/8 antibodies were used to assess for viral 
particles within the lung section. Infected lung samples are diffusely infected with Influenza 
H1N1 particles as can be seen by extensive red fluorescence in infected tissue. Viral particles 
were detected in both the bronchioles and alveoli, as marked by the white arrows. 
 
3. Influenza infection causes multifocal pulmonary disease and extensive release of neutrophil 
extracellular traps. Lungs were grossly evaluated at the time of collection (day 3 and day 6) and 
compared with healthy control. On gross examination, infected lungs have expanses of dark red, 
multifocal pathology affecting all lung lobes, with some lung lobes being more severely affected 
than others [Figure 3.1 and 3.2]. The remaining pulmonary tissue appeared normal on 
examination. 
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Figure 3.1 and 3.2: Influenza infection results in focal areas of hemorrhage on gross pathology 
examination. Lungs were evaluated in all pigs at the time of sample collection. 3.1: Control 
lungs appeared healthy on gross examination, whereas those of infected pigs had expanses of 
dark red, multifocal disease affecting all lung lobes, with some more severely affected than 
others. The remaining pulmonary tissue was normal on gross examination. 3.2: Another view is 
provided for gross examination. Heart and mediastinum are labeled for reference. Within this 
left lung there are multifocal, dark red, well outlined regions affecting the entire lung. 
Remaining tissue unaffected by lesions appears normal on gross examination. Lungs were 
removed and formalin-fixed for further histopathologic analysis. 
 
Formalin-fixed lungs were sectioned and prepped on slides before being stained with 
hematoxylin and eosin for histopathology scoring. Lungs were scored from 0 (healthy) to 4 
(severe) in the following areas: necrotizing bronchiolitis, bronchiolar infiltrates, alveolitis, 
interstitial inflammation, hemorrhage, pulmonary edema, and microvascular thrombosis. A sum 
of each set of scores was calculated and used to compare overall pulmonary pathology between 
groups [Figure 3.3]. Severe alveolitis and necrotizing bronchitis with massive neutrophil influx in 
alveolar air spaces and bronchioles were prominently seen in 6 dpi infected lungs compared to 3 
dpi infected piglets. Alveolar epithelium showed disintegration and collapsed alveolar 
architecture within the damaged areas of the lungs. Although statistical significance was not 
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established for every area scored due to the small sample size, infected pigs showed increased 
pathology in every key area compared with controls [Figure 3.4].  
 
Figure 3.3: Infected pigs have enhanced pulmonary pathology and disease. Lungs were 
collected and formalin-fixed to be sectioned and stained with hematoxylin and eosin for 
histopathology. Samples were scored from 0 (healthy) to 4 (severe) in seven areas: necrotizing 
bronchiolitis, bronchiolar infiltrates, alveolitis, interstitial inflammation, hemorrhage, edema, 
and microvascular thrombosis. A sum of these scores is used in this figure for overview. Infected 
piglets scored significantly higher on day 6 as compared with controls. Data are expressed as 
means ± SEM and compared via one-way ANOVA. n=2-3 pigs per group. *p<0.05 (relative to 
healthy control). 
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Figure 3.4: Infected pigs have enhanced pulmonary pathology. Formalin-fixed lungs were 
sectioned and stained for histopathology. Scores were given in seven areas: necrotizing 
bronchiolitis, bronchiolar infiltrates, alveolitis, interstitial inflammation, hemorrhage, edema, 
and microvascular thrombosis. Pigs on both 3 and 6 days after influenza infection scored 
significantly higher than controls for necrotizing bronchiolitis. Infected pigs also scored higher 
than controls in bronchiolar infiltrates and alveolitis on day 6. Although statistical significance is 
not noted in other groups due to the limited samples size, it appears that infected pigs have 
notably worse pathology in all areas scored. Data are expressed as means ± SEM and 
comparisons made via one-way ANOVA. n=2-3 pigs per group. *p<0.05; **p<0.01 (relative to 
controls). 
 
Histopathology sections were also examined for the release of neutrophil extracellular traps 
(NETs). NETs were especially prevalent in areas of severe pyogranulomatous inflammation and 
disease in infected lung sections [Figure 3.4]. The areas with significant NETs release were 
mostly areas with complete disruption of the pulmonary architecture and severe alveolitis. 
Healthy controls did not have the same abundance of NETs, nor did the less severely affected 
areas of infected lungs. 
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Figure 3.4: Neutrophil extracellular trap (NET) release abundant in areas of severe 
pyogranulomatous inflammation. Infected lungs have large areas of moderate to severe 
pyogranulomatous inflammation. These areas are extensive and disrupt the pulmonary 
architecture. Upon closer examination of these more severely affected areas, neutrophils can be 
seen releasing neutrophil extracellular traps, NETs, through cellular membrane breakdown and 
the release of nuclear contents (appears as dark purple extruding from neutrophils). Control 
lungs retain normal architecture with no notable NETs release. 
 
D. Discussion: 
Establishing a swine model for influenza virus offers such potential for future studies. 
But before this experimental model can be put to use, we must ensure that it accurately reflects 
the clinical disease and inflammatory response required to best mimic human disease 
appropriate to the study. Our goal was to identify a swine model for influenza that resulted in 
moderate clinical disease and an excessive innate immune response to infection, of which 
neutrophilia predominated. Results indicate that piglets infected with 1 x 106 TCID50 Influenza 
A/swine/Iowa/15/30 (H1N1) intranasally developed clinical signs from days 2-6, with fever and 
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nasal discharge predominating as generally noted in swine influenza. Signs were mild to 
moderate and seemed to peak on day 4. Piglets did not lose weight over the 6-day time frame. 
This clinical disease is a great base for an experimental model to test therapeutics over a limited 
period of 6 days since the disease appeared to peak at day 4-5.  
In addition to clinical disease, infected piglets saw a sharp increase in cell counts 
responding to pulmonary infection. Although neutrophilia predominates throughout clinical 
infection in mice, pigs initially have a majority macrophage population within the 
bronchoalveolar lavage, which shifts to a marked, predominant neutrophilia by day 6.  Areas of 
severe pulmonary pathology were marked by heavy neutrophil influx through large areas of 
expansive pyogranulomatous inflammation. Areas of heavy neutrophil influx also resulted in 
increased viral particles in those regions and the release of neutrophil extracellular traps, which 
are known to cause worsened disease in influenza pneumonia [55, 83]. Due to these findings, 
this swine model offers a consistent and effective model for influenza to test various novel 
combination therapies targeting the innate immune response and subsequent damage to the 
host. This project was aimed to test the therapeutic efficacy of SCH527123, a CXCR2 antagonist, 
which has been tested in murine models on combination with antiviral agent, oseltamivir. Due 
to constraints on availability of the space the project has been temporarily stalled. The present 
study demonstrates that influenza infection in piglets show widespread alveolar damage 
accompanied by massive neutrophil-influx and NETs accumulation in swine-influenza infected 
piglets. Small airways show occlusions with neutrophils and NETs and a strong CXCR2-staining. 
These findings confirm the results obtained in a murine-model and demonstrate pathogenic role 
of neutrophils and NETs in influenza infection in piglets.  
174 
 
CHAPTER VI 
 
 
PROJECT SUMMARY 
 
Influenza virus has long afflicted the human population and shaped the course of history 
over the last century. Arguably the deadliest outcome with influenza pneumonia is secondary 
bacterial infections. Throughout all pandemics, secondary bacterial infections complicate the 
disease with Streptococcus pneumoniae being the most common pathogen identified. 
 As the scientific community becomes increasingly aware of the importance of 
coinfection with influenza pneumonia, we have also become increasingly aware of the 
complexity of coinfection. No single factor can be claimed solely responsible for the lethal 
synergism seen with coinfection, but instead a complex network of viral, bacterial, host and 
environmental factors contribute to the pathogenesis of the disease. The host’s immune 
response is a significant contributor to pathology and clinical severity seen with influenza 
coinfections. An excessive neutrophil response beyond 12 hours post S. pneumoniae infection 
results in a greater bacterial burden and significant host damage due to factors such as the 
release of neutrophil extracellular traps. Chemokine receptors are critical to neutrophil function 
and innate recruitment and are potential targets for the treatment of various diseases and 
clinical conditions. The importance of controlling both the bacterial infections and host 
responses to those infection is clear. In a dual infection model, a clear link can be seen between
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severe pulmonary neutrophilia with resultant immunopathology and poor clinical outcome.  
Various animal models have been considered for further studying influenza virus 
vaccines, treatment, and the pathogenesis behind the disease. Mouse models are the most 
widely used due to their availability and affordability, but several downsides are present to using 
mice to model this disease. In contrast to many of the setbacks with other animal models, pigs 
are excellent models for influenza infection studies, and should be considered for future studies. 
What is clear from this brief summary is the need to better understand these pathogen 
and host interactions so that novel therapeutic options and pandemic planning can occur. Our 
goal was to identify and characterize a dual infection model the emulates a pandemic influenza 
outbreak resulting in lethal synergism and high rates of mortality. Upon characterization of the 
model, the availability of chemokine receptors as therapeutic targets in disease was assessed in 
order to best control the excessive innate response seen in dual infection. Finally, identifying 
and characterizing a swine model allows for many opportunities for studies related to viral 
pathogenesis, coinfection, therapeutics, and vaccine development. 
We first worked to characterize a murine model for influenza pneumonia with 
subsequent pneumococcal infection that mimicked a pandemic outbreak. Several models were 
tested and each evaluated for excessive innate response, pulmonary pathology and clinical 
effect. In addition, histones were evaluated for their role in the pathogenesis of the disease. 
Next, we characterized neutrophils for their phenotypic changes and functional responsiveness 
during primary influenza as well as secondary pneumococcal superinfection.  For 
characterization of neutrophils, we evaluated expression of chemokine receptors including CC 
(CCR1, CCR2, CCR3, CCR5) and CXC (CXCR1, CXR2, CXCR3 and CXCR4) and integrin molecules 
(CD16, CD62L and CD11b) during primary influenza and secondary pneumococcal infection in 
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circulating and lung-recruited neutrophils. Effects of chemokine receptors on functional changes 
– reactive oxygen species production and phagocytosis – were also evaluated. 
After establishing an influenza coinfection model with significant neutrophil influx and 
resultant immunopathology and identifying availability of chemokine receptor targets, we 
selected a combination therapy including oseltamivir, clarithromycin and Sch527123 to test in 
this model. We hypothesized that a CXCR2 antagonist would reduce neutrophil recruitment to 
the lungs, and when used in combination with antiviral and antibiotic therapy, reduce 
immunopathology and improve clinical outcome. Finally, a swine model for influenza 
pneumonia was characterized in order to assess innate immune response to infection and the 
potential of this model for future therapeutic studies. 
The proposed murine model for influenza coinfection is a good representation of 
pandemic influenza outbreaks resulting in secondary infection that is lethally synergistic. Mice 
infected with 100 TCID50 PR/8 H1N1 and 200 CFU S. pneumoniae 72 hours after initial viral 
infection have an exaggerated innate response, with predominantly pyogranulomatous 
inflammation. Significant protein leakage, pulmonary pathology, and barrier breakdown is noted 
on days 5 and 6 after influenza infection (48 hours after bacterial infection) and correlates with 
bacteremia in all dual infected mice. This murine model will serve as a good animal model to 
further assess the pathogenesis of the barrier breakdown and development of bacteremia and 
sepsis, as well as provide a consistent model for the testing of potential therapeutics for 
pandemic influenza coinfection.  
In the next aim, we found that neutrophils acquire new phenotypic characteristics after 
they recruit into the lungs during acute influenza infection and also S. pneumoniae 
superinfection. Expression of CC chemokine receptors (CCR1, CCR2, CCR3, and CCR5) and CXC 
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chemokine receptors (CXCR3, and CXCR4) were induced in lung-recruited neutrophils in primary 
influenza and S. pneumoniae superinfection compared to S. pneumoniae alone infected animal 
groups. Secondly, CXCR2 is the most predominant chemokine receptor expressed in both 
circulating as well as lung-recruited neutrophils compared to S. pneumoniae infected animals. 
Thirdly, these findings also demonstrate significant decrease in integrins expression on 
neutrophils during infection. Finally, our findings also demonstrate that induced chemokine 
receptors including CCR5 and CXCR2 significantly influence neutrophil functional responsiveness 
including phagocytic activities and respiratory burst.  
Overall, identifying induction of novel chemokine receptor expressions on neutrophils 
helps in not only understanding their pathogenic role in influenza as well as S. pneumoniae 
superinfection but also opens a new avenue to develop novel therapeutic strategies in 
alleviating lung pathogenesis during primary influenza as well as S. pneumoniae superinfection.  
Sch527123 monotherapy is ineffective at improving survival and clinical outcome in this model. 
Interestingly, even though we do not see survival with any Sch527123 monotherapy treatment 
group, we do see a delay in lethality when started early (12 hours prior to bacterial infection) as 
opposed to after bacterial infection. Our results also support the need for early antiviral 
intervention. These are both key findings in our influenza coinfection research which provide 
evidence for the importance of early intervention with combination therapy by healthcare 
professionals, and the need for patients who think they may have influenza to see a healthcare 
provider as soon as possible. Results from this study support exciting findings that these 
antagonists may offer some hope to improving clinical outcome in severe cases, especially 
during pandemic influenza outbreaks when mortality is higher and treatments often prove 
ineffective.  
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With the final aim, our goal was to identify a swine model for influenza that resulted in 
moderate clinical disease and an excessive innate immune response to infection, of which 
neutrophilia predominated. Results indicate that piglets infected with 1 x 106 TCID50 Influenza 
A/swine/Iowa/15/30 (H1N1) intranasally developed clinical signs from days 2-6, with fever and 
nasal discharge predominating as generally noted in swine influenza. The present study 
demonstrates that influenza infection in piglets show widespread alveolar damage accompanied 
by massive neutrophil-influx and NETs accumulation in swine-influenza infected piglets. Small 
airways shown occlusions with neutrophils and NETs and a strong CXCR2-staining. These 
findings confirm the results obtained in a murine-model and demonstrate pathogenic role of 
neutrophils and NETs in influenza infection in piglets. 
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